US20070293494A1 - 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines - Google Patents

2-Anilino-4-(Heterocyclic) Amino-Pyrimidines Download PDF

Info

Publication number
US20070293494A1
US20070293494A1 US11/762,394 US76239407A US2007293494A1 US 20070293494 A1 US20070293494 A1 US 20070293494A1 US 76239407 A US76239407 A US 76239407A US 2007293494 A1 US2007293494 A1 US 2007293494A1
Authority
US
United States
Prior art keywords
pyrimidine
diamine
propyl
phenyl
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/762,394
Inventor
Jane Djung
Adam Golebiowski
Jack Hunter
Gary Shrum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38608732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070293494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/762,394 priority Critical patent/US20070293494A1/en
Publication of US20070293494A1 publication Critical patent/US20070293494A1/en
Priority to US12/465,704 priority patent/US8354407B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines which are inhibitors of Protein Kinase C-alpha (PKC- ⁇ ).
  • PKC- ⁇ inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure.
  • the present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.
  • cAMP cyclic adenosine monophosphate
  • cGMP cyclic guanosine monophosphate
  • DAG diacylglycerol
  • PKC protein kinase C family of calcium and/or lipid-activated serine-threonine kinases function downstream of nearly all membrane-associated signal transduction pathways.
  • PKC ⁇ , ⁇ I, ⁇ II, and ⁇ are calcium- and lipid-activated, while the novel isozymes ( ⁇ , ⁇ , ⁇ , and ⁇ ) and atypical isozymes ( ⁇ , ⁇ , ⁇ , and ⁇ ) are calcium independent but activated by distinct lipids.
  • GPCR G ⁇ q-coupled G-protein coupled receptors
  • PLC phospholipase C
  • IP 3 and DAG can activate the different isoforms of PKC by mobilizing calcium (calcium sensitive enzymes) or by directly activating PKC, respectively.
  • RACKs Receptor for Activated C Kinases
  • Alterations in PKC activity has been suggested to contribute to human diseases, inter alia, diabetes, numerous forms of cancer, microalbinuria, endothelial dysfunction, cerebrovascular disease, stroke, coronary heart disease, cardiovascular disease and sequela (e.g. arrhythmia, sudden death, increased infarct size, congestive heart failure, angina), myocardial ischemic states, hypertension, lipid disorders, ischemia-reperfusion injury, atherosclerosis, peripheral artery/vascular disease, microvascular complications of diabetes (neuropathy, nephropathy, retinopathy), restenosis, renal disease, blood coagulation disorders, inflammatory diseases and heart failure and inhibition of PKC in these settings could be used to treat or prevent human disease. Lending support to the modulation of PKC in cardiac disease, PKC activation has been associated with cardiac hypertrophy, dilated cardiomyopathy, ischemic injury and mitogen stimulation.
  • Heart disease is the leading cause of death in industrialized countries. Historically heart failure (HF) has been a product of hypertension, coronary heart disease, genetic disorders, valvular deformities, diabetes or cardiomyopathy. While the root cause of heart failure is multifaceted, it uniformly is marked by impaired diastolic and/or systolic function and can be accompanied by chamber enlargement which ultimately manifest in symptomatic heart failure (fatigue, pulmonary edema, circulatory congestion, etc.)
  • the risk of death due to heart failure is 5-10% annually in patients with mild symptoms of heart failure, and increases to 30-40% annually in patients with advanced heart failure, with a 50% overall mortality rate at 5 years.
  • the current mainstays of heart failure therapy are drugs that act on the renin-angiotensin-aldosterone system (ACEI, ARB, aldosterone inhibitor), diuretics, digoxin and ⁇ -adrenergic receptor blockers.
  • ACEI renin-angiotensin-aldosterone system
  • diuretics diuretics
  • digoxin and ⁇ -adrenergic receptor blockers Despite the fact that multiple drug classes are used to treat heart failure patients, new cases of heart failure are growing at over 10% per year.
  • ADHF acute decompensated heart failure
  • the primary function of the heart is to generate and sustain an arterial blood pressure necessary to provide adequate perfusion of organs. It has, therefore, become an area of intense investigation to decipher the mechanism(s) which initiate and contribute to the development of heart failure rather than relying on a means for treating the symptoms of heart failure alone.
  • cardiomyocyte cardiac contractile cells
  • impaired calcium cycling is a hallmark of heart failure as is the basis of contractile abnormalities.
  • Calcium plays a key role in regulating kinases, phosphatases and transcription factors believed to influence the remodeling process indicating that both acute and sustained alterations in intracellular calcium levels may have profound effect on cardiac function and remodeling (i.e., changes in wall thickness or chamber volume). This theory would support the proposition that the development of new therapies addressing the slowing and preventing of the disease progression, would be perhaps more effective against heart failure than palliation of heart failure.
  • the present invention meets the aforementioned needs in that it has been found that certain 2-arylamino-4-(heterocyclic)aminopyrimidines are effective for inhibiting Protein Kinase C-alpha (PKC- ⁇ ) thereby improving myocardial contraction and relaxation performance and slowing the progression of heart failure.
  • PKC- ⁇ Protein Kinase C-alpha
  • the present invention encompasses four major aspects each of which have their own separate categories, aspects, iterations, and specific iterative examples.
  • the major aspects of the present invention include:
  • the first aspect of the present invention as a whole, relates to compounds, which include all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof said compounds having the formula:
  • compositions comprising:
  • the third major aspect of the present invention relates to methods of use.
  • the PKC- ⁇ inhibitors of the present invention are important for improving myocardial contraction and relaxation performance and thereby slowing the progression of heart failure and their administration to humans is, therefore, an effective treatment for humans suffering from acute heart failure.
  • the fourth major aspect of the present invention relates to a process for preparing the PKC- ⁇ inhibitors of the present invention.
  • the present invention addresses several unmet medical needs, inter alia:
  • PKC- ⁇ inhibitors of the present invention which are capable of blocking Protein Kinase C-alpha from impairing sarcoplasmic reticulum Ca 2+ uptake.
  • hydrocarbyl stands for any carbon atom-based unit (organic molecule), said units optionally containing one or more organic functional group, including inorganic atoms comprising salts, inter alia, carboxylate salts, quaternary ammonium salts.
  • organic hydrocarbyl Within the broad meaning of the term “hydrocarbyl” are the classes “acyclic hydrocarbyl” and “cyclic hydrocarbyl” which terms are used to divide hydrocarbyl units into cyclic and non-cyclic classes.
  • cyclic hydrocarbyl units may comprise only carbon atoms in the ring (hydrocarbyl and aryl rings) or may comprise one or more heteroatoms in the ring (heterocyclic and heteroaryl).
  • hydrocarbyl rings the lowest number of carbon atoms in a ring are 3 carbon atoms; cyclopropyl.
  • aryl the lowest number of carbon atoms in a ring are 6 carbon atoms; phenyl.
  • heterocyclic the lowest number of carbon atoms in a ring is 1 carbon atom; diazirinyl, epoxy.
  • heteroaryl the lowest number of carbon atoms in a ring is 1 carbon atom; 1,2,3,4-tetrazolyl.
  • fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring.
  • 1,2,3,4-tetrahydroquinoline having the formula: is, for the purposes of the present invention, considered a heterocyclic unit.
  • 6,7-Dihydro-5H-cyclopentapyrimidine having the formula: is, for the purposes of the present invention, considered a heteroaryl unit.
  • the aryl ring will predominate and determine the type of category to which the ring is assigned.
  • 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula: is, for the purposes of the present invention, considered a heteroaryl unit.
  • substituted is used throughout the specification.
  • substituted is defined herein as “a hydrocarbyl moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several substituents as defined herein below.”
  • the units, when substituting for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety at a time.
  • these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety, or unit.
  • a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like.
  • a two hydrogen atom replacement includes carbonyl, oximino, and the like.
  • a two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like.
  • Three hydrogen replacements includes cyano, and the like.
  • substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain; can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced.
  • 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”
  • N,N-dimethyl-5-amino)octanyl is a “substituted C 8 alkyl unit
  • 3-guanidinopropyl is a “substituted C 3 alkyl unit”
  • 2-carboxypyridinyl is a “substituted heteroaryl unit.”
  • R 5 units a cyclic or acyclic hydrocarbyl unit, described herein below as R 5 units, wherein in the non-limiting examples provided herein below, R 12 is hydrogen, C 1 -C 10 linear or branched alkyl, C 2 -C 10 linear or branched alkenyl, C 2 -C 10 linear or branched alkynyl, and C 6 or C 10 aryl.
  • R 5 units according to the present invention may include the following substitutions either comprising R 5 itself or when R 5 comprises an R 6 unit which is bonded to the core phenyl unit by a linking unit:
  • the compounds of the present invention are 2-arylamino-4-(heterocyclicalkylene)-aminopyrimidines having the core scaffold: which includes a core pyrimidine ring and a core phenyl ring wherein R 5 represents one or more (from 1 to 5) optionally present, and independently selected, substitutes for hydrogen as outlined herein above and described in the categories, aspects, iterations, examples, and tables herein below.
  • the unit R 1 which contains the core phenyl ring may be depicted throughout the specification and claims equally well by the following general formulae: wherein R, R 1 , R 5 , R 6 , L, L 1 and y are further described herein below.
  • R units are substituted or unsubstituted heterocyclic units containing from 3 to 7 atoms.
  • the first category of R units relates to heterocyclic units wherein the linking group L is bonded to a nitrogen atom, said units having the formula: wherein R 2 and R 3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents.
  • the first aspect of category one of R units relates to C 3 , C 4 and C 5 unsubstituted heterocycles.
  • Non-limiting examples of this aspect includes units chosen from pyrrolidin-1-yl, pyrrolin-1-yl, imidazolidin-1-yl, imidazolin-1-yl, pyrazolidin-1-yl, pyrazolin-1-yl, piperidin-1-yl, piperazin-1-yl, and morpholin-4-yl.
  • the second aspect of category one of R units relates to C 3 , C 4 and C 5 substituted heterocycles.
  • Non-limiting examples of this aspect includes units chosen from 5,5-di-methyl-imidazolin-1-yl, 4-methylpiperazin-1-yl, 4-acetylpiperazin-1-yl, and 4-methane-sulfonyl-piperazin-1-yl.
  • the second category of R units relates to heterocyclic units wherein the linking group L is bonded to a carbon atom, the first aspect of said units having the formula: wherein R 2 and R 3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R 10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
  • One iteration of the first aspect of category two of R units relates to C 3 , C 4 and C 5 substituted or unsubstituted heterocycles non-limiting examples of which include units chosen from pyrrolidin-2-yl, N-methyl-pyrrolidin-2-yl, N-methyl-pyrrolidin-2-one-5-yl, pyrrolin-2-yl, imidazolidin-2-yl, imidazolin-2-yl, pyrazolidin-2-yl, pyrazolin-2-yl, piperidin-2-yl, N-methylpiperidin-2-yl, morpholin-3-yl, and N-methylmorpholin-3-yl.
  • a further iteration of the first aspect of category two of R units relates to C 3 , C 4 and C 5 substituted or unsubstituted heterocycles having a chiral center in the R units and wherein a particular enantiomer is selected, for example, one of the two enantiomeric R units having the formula:
  • the second aspect of the second category of R units relates to heterocyclic units wherein the linking group L is bonded to a carbon atom, said units having the formula: wherein R 2 and R 3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R 10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
  • R 10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
  • Non-limiting examples of this aspect includes pyrrolidin-3-yl, N-methyl-pyrrolidin-3-yl, piperidin-3-yl, N-methylpiperidin-3-yl, morpholin-2-yl, and N-methylmorpholin-2-yl.
  • the third aspect of the second category of R units relates to heterocyclic units wherein the linking group L is bonded to a carbon atom, said units having the formula: wherein R 2 and R 3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R 10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
  • R 10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
  • Non-limiting examples of this aspect include piperidin-4-yl, N-methylpiperidin-4-yl, and 2,2,6,6-tetramethyl-piperidin-4-yl.
  • R 1 is substituted or unsubstituted phenyl having the formula:
  • R 5 is hydrogen or one or more independently chosen substitutes for hydrogen, R 5 has the formula: -(L 1 ) y -R 6 the index y has the value 0 when L 1 is absent, and the value 1 when L 1 is present;
  • R 6 is a unit chosen from:
  • the first category of R 1 relates to substituted phenyl units wherein L 1 is absent (the index y is equal to 0) and R 5 comprises one or more substitutes for hydrogen each of which is independently chosen from:
  • the first aspect of Category one of R 1 relates to units which are substituted by one or more units from groups (ii)-(vii).
  • Non-limiting examples of this aspect include 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 3,4-difluorophenyl, 3-trifluoromethylphenyl, 3-trifluoromethyl-4-chloro-phenyl, 3-methoxyphenyl, 3-methylphenyl, 3-ethylphenyl, and 3-isopropylphenyl.
  • the second aspect of Category one of R 1 relates to units which are substituted by one or more halogen atom, for example, —F, —Cl, —Br, and —I.
  • Non-limiting examples of this aspect include 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichloro-phenyl, 2,3,4-trichlorophenyl
  • the third aspect of Category one of R 1 relates to units which are substituted by one or more C 1 -C 4 linear or branched alkyl, for example, methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), iso-propyl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), and tert-butyl (C 4 ).
  • C 1 -C 4 linear or branched alkyl for example, methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), iso-propyl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), and tert-butyl (C 4 ).
  • Non-limiting examples of this aspect include 2-methylphenyl, 4-methylphenyl, 2,3-dimethyl-phenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethyl-phenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethyl-phenyl, 2,3,6-trimethylphenyl, 2,4,5-tri-methylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethyl-phenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, and 2,4,6-tri
  • the fourth aspect of Category one of R 1 relates to units which are substituted by one or more C 1 -C 4 linear or branched alkoxy, for example, methoxy (C 1 ), ethoxy (C 2 ), n-propoxy (C 3 ), iso-propoxy (C 3 ), n-butoxy (C 4 ), sec-butoxy (C 4 ), iso-butoxy (C 4 ), and tert-butoxy (C 4 ).
  • Non-limiting examples of this aspect include 2-methoxyphenyl, 4-methoxy-phenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-di-methoxyphenyl, 3,4-dimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6-trimethoxy-phenyl, 2,4,5-trimethoxyphenyl, and 2,4,6-trimethoxyphenyl.
  • the fifth aspect of Category one of R 1 relates to units which are substituted by one or more hydroxy units, non-limiting examples of this aspect include 2-hydroxy-phenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 2,5-dihydroxyphenyl, 2,6-dihydroxyphenyl, 3,4-dihydroxy-phenyl, 2,3,4-trihydroxyphenyl, 2,3,5-trihydroxy-phenyl, 2,3,6-trihydroxyphenyl, 2,4,5-trihydroxyphenyl, and 2,4,6-trihydroxyphenyl.
  • R 1 Other aspects of Category one of R 1 include combinations of R 1 substituents which comprise substitute classes (ii)-(vii) not specifically exemplified herein.
  • the second category of R 1 relates to substituted core phenyl units wherein the index y is equal to 0 or 1 and R 5 comprises one or more substitutes for hydrogen each of which is independently chosen from units which comprise:
  • Substituted or unsubstituted phenyl units are present in the second category of R 1 when linked to the core phenyl units by way of a linking unit L 1 .
  • the core C 3 -C 9 heteroaryl rings of the second category of R 1 encompass the following non-limiting examples of substituted and unsubstituted rings: triazinyl (C 3 ), thiazoyl (C 3 ), 1H-imidazoyl (C 3 ), furanyl (C 4 ), thiophenyl (C 4 ), pyrimidinyl (C 4 ), 2-phenylpyrimidinyl (C 4 ), pyridinyl (C 5 ), 3-methylpyridinyl (C 5 ), 4-dimethylamino-pyridinyl (C 5 ), 7H-purinyl (C 5 ), 9H-purinyl (C 5 ), 6-amino-9H-purinyl (C 5 ), 5H-pyrrolo[3,2-d]pyrimidinyl (C 6 ), 7H-pyrrolo[2,3-d]pyrimidinyl (C 6 ), pyrido[2,3-d]pyrimidiny
  • the first aspect of the second category of R 1 relates to units wherein the linking unit L 1 is absent (the index y is equal to 0), non-limiting examples of which include units chosen from: 2-(pyrimidin-2-yl)phenyl, 2-(pyrimidin-3-yl)phenyl, 2-(pyrimidin-4-yl)phenyl, 3-(pyrimidin-2-yl)phenyl, 3-(pyrimidin-3-yl)phenyl, 3-(pyrimidin-4-yl)phenyl, 4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-3-yl)phenyl, 4-(pyrimidin-4-yl)phenyl, 2-(pyridin-2-yl)phenyl, 2-(pyridin-3-yl)phenyl, 2-(pyridin-4-yl)phenyl, 3-(pyridin-2-yl)phenyl, 3-(pyridin-3-yl)phenyl, 3-(pyridin-4-yl)phenyl
  • the second aspect of the second category of R 1 relates to units wherein L 1 is a unit having the formula: —[CH 2 ] j — wherein the index j is equal to 1 or 2, non-limiting examples of which include units chosen from: 2-[(pyrimidin-2-yl)phenyl]methyl, 2-[(pyrimidin-3-yl)phenyl]methyl, 2-[(pyrimidin-4-yl)phenyl]methyl, 3-[(pyrimidin-2-yl)phenyl]methyl, 3-[(pyrimidin-3-yl)phenyl]methyl, 3-[(pyrimidin-4-yl)phenyl]methyl, 4-[(pyrimidin-2-yl)phenyl]methyl, 4-[(pyrimidin-3-yl)phenyl]methyl, 4-[(pyrimidin-4-yl)phenyl]methyl, 2-[(pyridin-2-yl)phenyl]methyl, 2-[(pyridin-3-yl)phenyl]methyl, 2-[(pyridin-4
  • the third aspect of the second category of R 1 relates to units wherein L 1 is a unit having the formula: —O[CH 2 ] k — wherein the index k is equal to 1 or 2, non-limiting examples of which include R 5 units chosen from: 2-(pyrimidin-2-yl)phenyl, 2-(pyrimidin-3-yl)phenyl, 2-(pyrimidin-4-yl)phenyl, 3-(pyrimidin-2-yl)phenyl, 3-(pyrimidin-3-yl)phenyl, 3-(pyrimidin-4-yl)phenyl, 4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-3-yl)phenyl, 4-(pyrimidin-4-yl)phenyl, 2-(pyridin-2-yl)phenyl, 2-(pyridin-3-yl)phenyl, 2-(pyridin-4-yl)phenyl, 3-(pyridin-2-yl)phenyl, 3-(pyridin-3-yl
  • the fourth aspect of the second category of R 1 relates to units wherein L 1 is a unit having the formula: —SO 2 NH— and R 5 is a unit chosen from:
  • R 5 units which are chosen from:
  • R 1 units encompassed within this iteration include: benzene-sulfonamide, N-methyl-benzenesulfonamide, N-ethyl-benzenesulfon-amide, N-(n-propyl)-benzenesulfonamide, N-(iso-propyl)-benzenesulfonamide, N-(n-butyl)-benzenesulfonamide, N-(sec-butyl)-benzenesulfonamide, N-(iso-butyl)-benzene-sulfonamide, and N-(tert-butyl)-benzenesulfonamide.
  • R 5 units which are chosen from:
  • R 1 units encompassed within this iteration include: N-phenyl-benzene-sulfonamide, N-(pyrimidin-2-yl)-benzenesulfonamide, N-(pyrimidin-4-yl)-benzenesulfonamide, N-(pyrimidin-5-yl)-benzenesulfonamide, N-(pyridin-2-yl)-benzenesulfonamide, N-(pyridin-3-yl)-benzenesulfonamide, and N-(pyridin-4-yl)-benzenesulfonamide.
  • the fifth aspect of the second category of R 1 relates to units wherein L 1 is a unit having the formula: —[C(R 7a R 7b )] j NR 9 C(O)[C(R 8a R 8b )] k —; or —[C(R 7a R 7b )] j C(O)NR 9 [C(R 8a R 8b )] k — wherein R 7a , R 7b , R 8a , R 8b , and R 9 are each independently hydrogen, methyl, or ethyl; the indices j and k are each independently from 0 to 3.
  • the first iteration of the fifth aspect of the second category of R 1 units relates to R 1 units wherein R 6 units are linked to the phenyl ring by way of a L 1 unit chosen from units having the formula.
  • Non-limiting examples of the first iteration of the fifth aspect of the second category of R 1 units includes substituted or unsubstituted phenyl units linked with amide bond linking units having the formula —C(O)NH— or —NH(CO)—.
  • R 1 relates to substituted phenyl units wherein L 1 is absent (the index y is equal to 0) and R 5 comprises one or more substitutes for hydrogen each of which is independently chosen from units which comprise:
  • the core C 2 -C 5 heterocyclic rings of the third category of R 1 encompass the following unsubstituted rings: aziridinyl (C 2 ), [1,2,3]triazolyl (C 2 ), [1,2,4]triazolyl (C 2 ), urazolyl (C 2 ), oxazolyl (C 3 ), azetidinyl (C 3 ), pyrazolidinyl (C 3 ), imidazolidinyl (C 3 ), oxazolidinyl (C 3 ), isoxazolinyl (C 3 ), oxazolyl (C 3 ) isoxazolyl (C 3 ), thiazolidinyl (C 3 ), thiazolyl (C 3 ), imidazolidinonyl (C 3 ), isothiazolyl (C 3 ), isothiazolinyl (C 3 ), oxathiazolidinonyl (C 3 ), oxazolid
  • L is a linking unit having the formula: —[C(R 4a R 4b )] n — wherein each R 4a and R 4b unit is independently chosen from:
  • the first category of L units relates to unsubstituted alkylene units chosen from:
  • the first aspect of the first category of L units encompasses linking groups which are —CH 2 CH 2 CH 2 —, propylene; as exemplified in the generic formula:
  • the second aspect of the first category of L units encompasses linking groups which are CH 2 CH 2 —, ethylene.
  • the second category of L units relates to alkyl substituted alkylene units chosen from:
  • the first aspect of the second category of L units encompasses linking groups which are —CH(CH 3 )Cl 2 CH 2 —, 1-methylpropylene; as exemplified in the generic formula: wherein the above formula encompasses both the R and the S enantiomers of the linking unit.
  • L 1 is a linking unit which when present provides R 5 units with the formula: -(L 1 ) y -R 6 wherein y is equal to 1 when L 1 is present.
  • L 1 is a linking unit chosen from:
  • L 1 The various categories, aspects, iterations, and examples of L 1 can be found in the definitions of R 1 and in the examples and tables described and listed herein below.
  • the compounds of the present invention can be prepared by the following general procedure, the formulator adjusting the reaction conditions as is necessary and which one skilled in the art will be able to accomplish without undo experimentation.
  • Step 1 Preparation of intermediate 2-(methylthio)pyrimidine-4(3H)-one. This compound can be used in the preparation of each analog encompassed by the present invention. The general procedure follows.
  • Step 2 Formation of 2-anilino intermediate.
  • 2-(Substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one To a 2-(methyl-thio)pyrimidine-4(3H)-one (14.2 g, 100 mmol) in diglyme (60 mL) is added the substituted or unsubstituted aniline of choice (200 mmol). The resulting mixture is heated to reflux and stirred for approximately 18 hours. The product which typically forms as a solid upon cooling the mixture to room temperature, is washed with solvent (pentane, hexane, or isopentane). However, solvent can be added to the reaction mixture to induce crystallization if necessary.
  • solvent penentane, hexane, or isopentane
  • 2-(Substituted or unsubstituted phenylamino)-4-chloro-pyrimidine To a 2-(Substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one (5.02 g, 22.6 mmol) and N,N-dimethyl-aniline (450 mL) is added of phosphorus oxychloride (450 mL). The resulting mixture is heated to reflux for 15 minutes, cooled to room temperature and concentrated in vacuo. The residue is neutralized to pH 7 with 1M NaOH (aqueous). The organic layer is extracted with EtOAc (3 ⁇ 250 mL). The combined organic layers are dried (MgSO 4 ) and concentrated in vacuo. The residue can be conveniently purified over silica (5% EtOAc in hexanes) to afford the desired compound.
  • 2-(Substituted or unsubstituted phenylamino)-4-chloro-pyrimidine To a 2-(substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one (3.00 g, 13.5 mmol) in toluene (30 mL) is added N,N-dimethyl-aniline (3.57 mL, 28.4 mmol) and phosphorus oxychloride (1.24 mL, 13.5 mmol). The resulting mixture is heated to retlux for 15 minutes, cooled to room temperature and neutralized to pH 7 with 1M NaOH (aqueous). The organic layer is extracted with EtOAc (3 ⁇ 250 mL). The combined organic layers are dried (MgSO 4 ) and concentrated in vacuo. The residue can be conveniently purified over silica (5% EtOAc in hexanes) to afford the desired compound.
  • Step 4 Formation of final compounds (analogs) of the present invention.
  • analogs (compounds) of the present invention are arranged into several categories to assist the formulator in applying a rational synthetic strategy for the preparation of analogs which are not expressly exampled herein.
  • the arrangement into categories does not imply increased or decreased efficacy for any of the compositions of matter described herein.
  • the compounds which comprise Category I of the present invention are 2,4-di-aminopyrimidines having the formula: wherein linking group L is a propylene (—CH 2 CH 2 CH 2 —) unit and R units are heterocyclic units attached to the core scaffold by way of a ring nitrogen atom.
  • the first aspect of Category I encompasses R 1 units which are phenyl units substituted by one or more R 5 units chosen from:
  • the compounds which comprise the second aspect of Category I of the present invention are 2,4-di-aminopyrimidines having the formula: wherein R 1 units are substituted by one or more R 5 units chosen from:
  • the product was diluted with 5 mL of aqueous saturated sodium bicarbonate solution and extracted with EtOAc (3 ⁇ 10 ml). The combined organics are washed with 20 ml water and saturated aqueous NaCl (2 ⁇ 10 ml), then dried over magnesium sulfate and concentrated in vacuo. The residue is purified over silica (5-8% MeOH in CH 2 Cl 2 ) to afford 61 mg (38% yield) of the desired compound.
  • N 2 -biphenyl-3-yl-N 4 -(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (10) To 4-chloro-N-(3-biphenyl)pyrimidin-2-amine (301.0 mg, 1.07 mmol) in 5 mL THF is added potassium carbonate (396 mg, 2.15 mmol) followed by 3-morpholinopropyl-amine (0.3 mL, 2.05 mmol). The resulting mixture is heated at reflux for 96 hours. The reaction is cooled to room temperature and concentrated in vacuo. The residue is diluted with 15 mL of water and extracted with EtOAc (3 ⁇ 20 mL).
  • the compounds which comprise Category II of the present invention are 2,4-di-aminopyrimidines having the formula: wherein R is a heterocyclic unit attached to the core scaffold by way of a nitrogen atom and R 1 is a phenyl unit substituted by different category of R 5 units having the formula: -L 1 -R 6
  • the intermediate, 3-amino-N-phenylbenzenesulfonamide (12), can be conveniently prepared by the following steps from aniline and 3-nitrobenzene-1-sulfonyl chloride.
  • Other sulfonamide intermediates can be prepared in a like manner, the formulator making adjustments to the reaction conditions which are well known to those skilled in the art.
  • the compounds which comprise Category III of the present invention are 2,4-di-aminopyrimidines having the formula: wherein R is a heterocyclic unit chosen from: wherein R 2 , R 3 , and R 10 are each defined herein above.
  • the first aspect of Category III relates to R 1 units which are phenyl units substituted by one or more R 5 units chosen from:
  • the second aspect of Category III relates to R units which comprise a chiral carbon atom.
  • Scheme VI herein below and the following examples illustrate this second aspect of Category III of the present invention.
  • the (2R) enantiomer can be prepared in the same manner as described herein above,
  • the compounds of the present invention are inhibitors of Protein Kinase C-alpha (PKC- ⁇ ), therefore, they are PKC- ⁇ inhibitors which are capable of improving myocardial contraction and relaxation performance and slow the progression of heart failure. Certain exemplified compounds may also potentially inhibit additional isoforms of conventional PKC, such as PKC- ⁇ or PKC- ⁇ . This is not undesirable and can lead to increased pharmacological effects.
  • PKC- ⁇ Protein Kinase C-alpha
  • the level of disease for example, the relative degree of heart failure due to PKC- ⁇ activity will vary from patient to patient and be predicated by other exacerbating circumstances, inter alia, presence of other disease conditions (diabetes, high blood pressure, and the like) or patients may suffer from other conditions such as obesity. Therefore, the formulator may be required to employ differing levels or amounts of the compounds described herein to obtain a therapeutic level. The formulator can determine this amount by any of the known testing procedures known to the artisan.
  • the present invention also relates to compositions or formulations which comprise the PKC- ⁇ inhibitors according to the present invention.
  • the compositions of the present invention comprise.
  • excipient and “carrier” are used interchangeably throughout the description of the present invention.
  • excipient and carrier relate to their definition in terms of a medicament, said terms are defined in that respect as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
  • excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient.
  • An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach.
  • the formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
  • compositions according to the present invention include:
  • an effective amount means “an amount of one or more PKC- ⁇ inhibitors, effective at dosages and for periods of time necessary to achieve the desired result.”
  • An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the human or animal being treated.
  • dosage regimes may be described in examples herein, a person skilled in the art would appreciated that the dosage regime may be altered to provide optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • the compositions of the present invention can be administered as frequently as necessary to achieve a therapeutic amount.
  • the present invention also relates to a method for improving cardiac contraction/relaxation parameters in heart failure patients and/or attenuating adverse cardiac remodeling and prevent or slow the progression of worsening heart failure.
  • the present method comprises the step of administering to a human or higher mammal an effective amount of a composition comprising one or more of the PKC- ⁇ inhibitors according to the present invention.
  • the present method comprised a method for treating or preventing a disease or medical condition selected from diabetes, numerous forms of cancer, microalbinuria, endothelial dysfunction, cerebrovascular disease, stroke, coronary heart disease, cardiovascular disease and sequela (e.g. arrhythmia, sudden death, increased infarct size, congestive heart failure, angina), myocardial ischemic states, hypertension, lipid disorders, ischemia-reperfusion injury, atherosclerosis, peripheral artery/vascular disease, microvascular complications of diabetes (neuropathy, nephropathy, retinopathy), restenosis, renal disease, blood coagulation disorders, inflammatory diseases, cardiac hypertrophy, dilated cardiomyopathy, ischemic injury and suboptimal mitogen stimulation said method comprised of the steps of administering to a patient in need thereof a therapeutic amount of a PKC- ⁇ inhibitor as disclosed herein.
  • a disease or medical condition selected from diabetes, numerous forms of cancer, microalbinuria, endothelial dysfunction, cerebrovascular disease
  • the present invention also relates to the use of the 2-arylamino-4-(heterocyclic)-amino-pyrimidines or salts thereof, according to the present invention in the manufacture of a medicament for the treatment of heart disease wherein inhibition of PKC- ⁇ provides a benefit.
  • BSA bovine serum albumin
  • EDTA ethylenediaminetetraacetic acid
  • the reaction is initiated by addition of adenosine triphosphate (ATP; final concentration 45 ⁇ M) and a peptide substrate consisting of amino acids 28-43 (Ala-Ala-Lys-Ile-Gln-Ala-Ser-Phe-Arg-Gly-His-Met-Ala-Arg-Lys-Lys) of neurogranin (Promega; final concentration 22 ⁇ M). After a 30 minute incubation at 24° C.
  • ATP adenosine triphosphate
  • a peptide substrate consisting of amino acids 28-43 (Ala-Ala-Lys-Ile-Gln-Ala-Ser-Phe-Arg-Gly-His-Met-Ala-Arg-Lys-Lys) of neurogranin (Promega; final concentration 22 ⁇ M).
  • the reaction is terminated by adding; 5 ⁇ L of the reaction mixture into 50 ⁇ L of MALDI matrix solution (5 mg/ml ⁇ -cyano-4-hydroxy-cinnamic acid in 50% Acetonitrile/H 2 O, 0.1% TFA, 5 mM ammonium phosphate). Two microliters of the stopped reaction mixture is transferred onto a MALDI-TOF mass spectrometer target plate.
  • MALDI matrix solution 5 mg/ml ⁇ -cyano-4-hydroxy-cinnamic acid in 50% Acetonitrile/H 2 O, 0.1% TFA, 5 mM ammonium phosphate.
  • spectra are collected on an Applied Biosystems 4700 Proteomics Analyzer MALDI-TOF MS equipped with a Nd:YAG laser (355 nm, 3 ns pulse width, 200 Hz repetition rate) in negative ion reflector mode.
  • the system is operated with 4700 Explorer software, version 3.0.
  • Automated acquisition parameters are adjusted to capture and average only those individual spectra within defined success criteria. Specifically, signal intensities for the substrate peptide are set to a minimum threshold of 3000 counts and a maximum intensity of 65,000 counts. This ensured that neither null spectra nor saturated spectra are averaged into the final readout. Between 1000 and 1500 laser shots are averaged for each sample. Data are collected in triplicate from 3 successive days to capture the maximum variability related to preparation of enzyme reaction, transfer of samples to MALDI target plates, data collection, and data extraction.
  • the isotope cluster areas for each peptide substrate and product peaks are extracted into a Microsoft Excel worksheet from the 10 ⁇ 10 array of spectral data simultaneously using the automated analysis function provided within the 4700 Explore software.
  • the isotope cluster area is defined by the software algorithm based on the molecular weight and the general elemental composition of the peptides.
  • % MA % Maximal Activity
  • PKC(X activity in cells is determined using murine HL-1 atrial cardiac muscle cells.
  • HL-1 cells are plated at 18,000 cells/well in a 96-well tissue culture plate
  • Cells are cultured in 0.1 ml Claycomb growth medium (without norepinephrine) supplemented with 10% fetal bovine serum, 200 mM glutamine and 1% antibiotic/antimycotic.
  • PBS phosphate buffered saline
  • the medium is removed and replaced with serum free Claycomb medium supplemented with 200 mM glutamine containing different concentrations of compound at a final volume of 50 ⁇ l.
  • Compounds are dissolved in 100% dimethylsulfoxide (DMSO) and final DMSO concentrations are maintained at 0.5%. Plates are then incubated for 30 minutes at 37° C. in a 5% CO 2 incubator. The medium is then removed and the plates are rinsed 1 ⁇ with ice-cold 100 ⁇ l PBS.
  • DMSO dimethylsulfoxide
  • the PBS is removed and replaced with 10 ⁇ l of ice-cold lysis buffer consisting of B-PERII detergent (Pierce) diluted 1:1 in distilled water and including a final concentration of 0.3% ⁇ -mercaptoethanol, 50 ⁇ g/ml phenylmethylsulfonylfluoride (PMSF) 10 mM benzamidine, 10 nM okadaic acid, 20 ⁇ g/ml leupeptin and 20 ⁇ g/ml soybean trypsin inhibitor.
  • PMSF phenylmethylsulfonylfluoride
  • coactivation buffer consisting of 0.1 mg/ml BSA, 250 ⁇ M EDTA, 400 ⁇ M CaCl 2 .
  • the reaction is terminated by adding 5 ⁇ L of the reaction mixture into 50 ⁇ L of MALDI matrix solution (5 mg/ml ⁇ -cyano-4-hydroxycinnamic acid in 50% Acetonitrile/H 2 O, 0.1% TFA, 5 mM ammonium phosphate). Two microliters of the stopped reaction mixture is transferred onto a MALDI-TOF mass spectrometer target plate. Dose-dependent inhibition is measured by mass spectrometry as % maximal activity as described above for the isolated PKC ⁇ inhibition assays.
  • Selected PKC ⁇ inhibitors are evaluated in rats with acute heart failure (HF) after myocardial infarction (MI) for effects on cardiac contractility and hemodynamics.
  • HF acute heart failure
  • MI myocardial infarction
  • Male, Sprague-Dawley rats are anesthetized with isoflurane, intubated, placed on ventilators and maintained at a surgical plane of anesthesia during the course of the experiment.
  • the animals are instrumented, for the measurement of left ventricular function (+dP/dt, LVDP), arterial blood pressure, and the ECG is monitored for the incidence of arrhythmias.
  • a thoracotomy is performed at the fourth intercostal space to visualize the heart, the pericardium is opened and a suture is placed around the left anterior descending (LAD) coronary artery approximately 3-4 mm from its origin.
  • LAD left anterior descending
  • the LAD is permanently ligated to induce a myocardial infarction.
  • Severe arrhythmia are treated with the administration of lidocaine.
  • cardiac function stabilized approximately 40-60 min after ligation and baseline hemodynamic values are measured.
  • the effects of treatment are normalized to pre-treatment baseline values and expressed as a percentage.
  • Statistical significance (p ⁇ 0.05) is evaluated using one-way ANOVA and Dunnett's multiple comparison test.
  • Selected PKC ⁇ inhibitors are evaluated in rats with myocardial infarction (MI) for effects on cardiac contractility and hemodynamics.
  • MI myocardial infarction
  • the effects of inhibitors on cardiac contractility and hemodynamics are evaluated in MI rats as follows.
  • the animals are anesthetized with isoflurane.
  • a femoral artery is isolated and cannulated for the measurement of systemic blood pressure.
  • a jugular vein is isolated and cannulated for the intravenous infusion of inhibitor.
  • the right carotid artery is isolated and a Millar conductance catheter is inserted to the left ventricle (LV) of the heart.
  • the LV systolic pressure, end-diastolic pressure, +dP/dt max , ⁇ dP/dt min , and heart rate are derived from the LV pressure waveform.
  • Mean arterial blood pressure is derived from the systemic blood pressure waveform. Data are recorded continuously and derived using computerized data acquisition software (Notocord or Powerlab).
  • PKC- ⁇ inhibitors are infused at the following infusion doses in MI rats: 10, 30, 100, 300 and 1000 nmol/kg/min. The infusion of each dose is allowed to run for at least five minutes. At the end of the test infusions, 5.0 ⁇ g/kg/min of dobutamine is infused. The effects of treatment are normalized to pretreatment baseline values and expressed as a percentage. Statistical significance (p ⁇ 0.05) is evaluated using a one-way ANOVA and Dunnett's multiple comparison test.
  • Table VI provides non-limiting examples of PKC- ⁇ IC 50 values for representative compounds of the present invention.
  • PKC- ⁇ Compound IC 50 (nM) N 2 -(3-Chlorophenyl)-N 4 -(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine 2 N 2 -(3-Chlorophenyl)-N 4 -[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine- 5 2,4-diamine 1- ⁇ 3-[2-(3-Chlorophenylamino)-pyrimidin-4-ylamino]-propyl ⁇ -pyrrolidin-2- 710 one N 2 -[3-Trifluoromethyl-phenyl]-N 4 -(3-pyrrolidin-1-yl-propyl)-pyrimidine- 0.5 2,4-diamine N 4 -(3-Pyrrolidin-1-yl-propyl)-N

Abstract

The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

Description

    RELATED APPLICATIONS
  • This application claims the benefit of U.S. provisional application No. 60/813,956, filed Jun. 15, 2006, the entirety of which is incorporated herewith by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines which are inhibitors of Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.
    • BACKGROUND OF THE INVENTION
  • Many biologically active substances, for example, hormones, neurotransmitters and peptides are known to exert functions via intracellular mediators such as, cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), diacylglycerol (DAG) and calcium. In many cases, these mediators activate or inactivate intracellular kinases or phosphatases that are important in protein phosphorylation/dephosphorylation, and thus play important roles in regulating cellular processes and functions. The protein kinase C (PKC) family of calcium and/or lipid-activated serine-threonine kinases function downstream of nearly all membrane-associated signal transduction pathways.1 Approximately 12 different isozymes comprise the PKC family, which are broadly classified by their activation characteristics. The conventional PKC isozymes (PKCα, βI, βII, and γ) are calcium- and lipid-activated, while the novel isozymes (ε, θ, η, and δ) and atypical isozymes (ζ, ι, υ, and μ) are calcium independent but activated by distinct lipids.2 For example, stimulation of Gαq-coupled G-protein coupled receptors (GPCR) can activate phospholipase C (PLC) which in turn mediates hydrolysis of inositol phospholipids resulting in the generation of inositol 1,4,5-triphosphate (IP3) and DAG. IP3 and DAG can activate the different isoforms of PKC by mobilizing calcium (calcium sensitive enzymes) or by directly activating PKC, respectively. Once activated, PKC isozymes translocate to discrete subcellular locations through direct interactions with docking proteins termed RACKs (Receptor for Activated C Kinases), which permit specific substrate recognition and subsequent signal transduction.3
  • Alterations in PKC activity has been suggested to contribute to human diseases, inter alia, diabetes, numerous forms of cancer, microalbinuria, endothelial dysfunction, cerebrovascular disease, stroke, coronary heart disease, cardiovascular disease and sequela (e.g. arrhythmia, sudden death, increased infarct size, congestive heart failure, angina), myocardial ischemic states, hypertension, lipid disorders, ischemia-reperfusion injury, atherosclerosis, peripheral artery/vascular disease, microvascular complications of diabetes (neuropathy, nephropathy, retinopathy), restenosis, renal disease, blood coagulation disorders, inflammatory diseases and heart failure and inhibition of PKC in these settings could be used to treat or prevent human disease. Lending support to the modulation of PKC in cardiac disease, PKC activation has been associated with cardiac hypertrophy, dilated cardiomyopathy, ischemic injury and mitogen stimulation.
  • Heart disease is the leading cause of death in industrialized nations. Historically heart failure (HF) has been a product of hypertension, coronary heart disease, genetic disorders, valvular deformities, diabetes or cardiomyopathy. While the root cause of heart failure is multifaceted, it uniformly is marked by impaired diastolic and/or systolic function and can be accompanied by chamber enlargement which ultimately manifest in symptomatic heart failure (fatigue, pulmonary edema, circulatory congestion, etc.)
  • The risk of death due to heart failure is 5-10% annually in patients with mild symptoms of heart failure, and increases to 30-40% annually in patients with advanced heart failure, with a 50% overall mortality rate at 5 years. The current mainstays of heart failure therapy are drugs that act on the renin-angiotensin-aldosterone system (ACEI, ARB, aldosterone inhibitor), diuretics, digoxin and β-adrenergic receptor blockers. Despite the fact that multiple drug classes are used to treat heart failure patients, new cases of heart failure are growing at over 10% per year.
  • Patients with acute decompensated heart failure (ADHF) are a treatment challenge to physicians and can present with volume overload and/or diminished cardiac output. Initial treatments for ADHF patients include intravenous diuretics, vasodilators, natriuretic peptides and inotropic agents. Despite the widespread use of these agents, long-term safety and benefit of these drugs have been questioned. In the case of inotropes, drugs that increase cardiac output and cardiac contractility without increasing myocardial oxygen consumption or heart rate are desirous. Despite the available treatments for patients with ADHF, hospital readmission rates are approximately 50% within 6 months and mortality is approximately 20-40% at 1 year.
  • The primary function of the heart is to generate and sustain an arterial blood pressure necessary to provide adequate perfusion of organs. It has, therefore, become an area of intense investigation to decipher the mechanism(s) which initiate and contribute to the development of heart failure rather than relying on a means for treating the symptoms of heart failure alone. At the cardiomyocyte (cardiac contractile cells) level, impaired calcium cycling is a hallmark of heart failure as is the basis of contractile abnormalities. Calcium plays a key role in regulating kinases, phosphatases and transcription factors believed to influence the remodeling process indicating that both acute and sustained alterations in intracellular calcium levels may have profound effect on cardiac function and remodeling (i.e., changes in wall thickness or chamber volume). This theory would support the proposition that the development of new therapies addressing the slowing and preventing of the disease progression, would be perhaps more effective against heart failure than palliation of heart failure.
  • Therefore, there is a limited means to treat patients with various forms and stages of heart failure and there is incentive to develop novel, safe and effective treatments to prevent or treat patients with symptoms of heart failure, acute exacerbation of heart failure and chronic heart failure and other cardiovascular diseases. An agent that has benefits in the treating acute exacerbations of heart failure as well as treating chronic heart failure is desirous.
    • 1. Molkentin et al. (2001) Annu. Rev. Physiol. 63:391-426.
    • 2. Dempsey et al. (2000) Am. J. Physiol. Lung Mol. Physiol. 279:247-251.
    • 3. Mochly-Rosen, D. (1995) Science 268:247-251.
    SUMMARY OF THE INVENTION
  • The present invention meets the aforementioned needs in that it has been found that certain 2-arylamino-4-(heterocyclic)aminopyrimidines are effective for inhibiting Protein Kinase C-alpha (PKC-α) thereby improving myocardial contraction and relaxation performance and slowing the progression of heart failure.
  • The present invention encompasses four major aspects each of which have their own separate categories, aspects, iterations, and specific iterative examples. The major aspects of the present invention include:
      • i) novel compositions of matter which are effective in inhibiting PKC-A;
      • ii) compositions or pharmaceutical compositions (matrices) comprising said compositions of matter;
      • iii) methods for treating, preventing, controlling, abating, or alleviating one or more of the causes of progressive heart failure which is affected by administration of a PKC-A antagonist, whether administered alone or in a composition or within a pharmaceutical composition (matrix); and
      • iv) a process for preparing the PKC-α inhibitors of the present invention.
  • The first aspect of the present invention as a whole, relates to compounds, which include all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof said compounds having the formula:
    Figure US20070293494A1-20071220-C00001
      • wherein R is a substituted or unsubstituted heterocyclic unit containing from 3 to 7 atoms;
      • L is a linking group having the formula:
        —[C(R4aR4b)]n—
      • each R4a and R4b is independently chosen from:
      • i) hydrogen; or
      • ii) C1-C4 linear, branched, or cyclic alkyl;
      • the index n is from 0 to 4; and
      • R1 is substituted or unsubstituted phenyl having the formula:
        Figure US20070293494A1-20071220-C00002
      • R5 is hydrogen or one or more independently chosen substitutes for hydrogen.
  • The second major aspect of the present invention relates to compositions comprising:
      • a) an effective amount of one or more compounds according to the present invention; and
      • b) one or more acceptable excipients.
  • The third major aspect of the present invention relates to methods of use. As described herein below, the PKC-α inhibitors of the present invention are important for improving myocardial contraction and relaxation performance and thereby slowing the progression of heart failure and their administration to humans is, therefore, an effective treatment for humans suffering from acute heart failure.
  • The fourth major aspect of the present invention relates to a process for preparing the PKC-α inhibitors of the present invention.
  • These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (° C.) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention addresses several unmet medical needs, inter alia:
      • 1) improving cardiac contraction/relaxation parameters in heart failure patients, leading to reduction of symptoms; and
      • 2) attenuating adverse cardiac remodeling in heart failure patients, ultimately providing prolonged patient survival.
  • These and other unmet medical needs are resolved by the PKC-α inhibitors of the present invention, which are capable of blocking Protein Kinase C-alpha from impairing sarcoplasmic reticulum Ca2+ uptake. By providing heart failure patients with a PKC-α inhibitor, it is believed the patients will derive an improvement in cardiac function, thus resulting in improved myocardial contraction and relaxation performance and could result in slowing the progression to heart failure.
  • The following chemical hierarchy is used throughout the specification to describe and enable the scope of the present invention and to particularly point out and distinctly claim the units which comprise the compounds of the present invention. The term “hydrocarbyl” stands for any carbon atom-based unit (organic molecule), said units optionally containing one or more organic functional group, including inorganic atoms comprising salts, inter alia, carboxylate salts, quaternary ammonium salts. Within the broad meaning of the term “hydrocarbyl” are the classes “acyclic hydrocarbyl” and “cyclic hydrocarbyl” which terms are used to divide hydrocarbyl units into cyclic and non-cyclic classes.
  • As it relates to the following definitions, “cyclic hydrocarbyl” units may comprise only carbon atoms in the ring (hydrocarbyl and aryl rings) or may comprise one or more heteroatoms in the ring (heterocyclic and heteroaryl). For “hydrocarbyl” rings the lowest number of carbon atoms in a ring are 3 carbon atoms; cyclopropyl. For “aryl” rings the lowest number of carbon atoms in a ring are 6 carbon atoms; phenyl. For “heterocyclic” rings the lowest number of carbon atoms in a ring is 1 carbon atom; diazirinyl, epoxy. For “heteroaryl” rings the lowest number of carbon atoms in a ring is 1 carbon atom; 1,2,3,4-tetrazolyl.
    • A. Substituted and unsubstituted C1-C20 acyclic hydrocarbyl:
      • For the purposes of the present invention the term “substituted and unsubstituted C1-C20 acyclic hydrocarbyl” encompasses 3 categories of units:
    • 1) C1-C20 linear or branched alkyl, non-limiting examples of which include, methyl (C1), ethyl (C2), n-propyl (C3), iso-propyl (C3), n-butyl (C4), sec-butyl (C4), iso-butyl (C4), tert-butyl (C4), and the like; substituted C1-C20 linear or branched alkyl, non-limiting examples of which includes, hydroxymethyl (C1), chloromethyl (C1), trifluoromethyl (C1), aminomethyl (C1), 1-chloroethyl (C2), 2-hydroxyethyl (C2), 1,2-difluoroethyl (C2), 3-carboxypropyl (C3), and the like.
    • 2) C2-C20 linear or branched alkenyl, non-limiting examples of which include, ethenyl (C2), 3-propenyl (C3), 1-propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), buten-4-yl (C4), and the like; substituted C2-C20 linear or branched alkenyl, non-limiting examples of which include, 2-chloroethenyl (also 2-chlorovinyl) (C2), 4-hydroxybuten-1-yl (C4), 7-hydroxy-7-methyloct-4-en-2-yl (C1), 7-hydroxy-7-methyloct-3,5-dien-2-yl (C9), and the like.
    • 3) C2-C20 linear or branched alkynyl, non-limiting examples of which include, ethynyl (C2), prop-2-ynyl (also propargyl) (C3), propyn-1-yl (C3), and 2-methyl-hex-4-yn-1-yl (C7); substituted C2-C20 linear or branched alkynyl, non-limiting examples of which include, 5-hydroxy-5-methylhex-3-ynyl (C7), 6-hydroxy-6-methylhept-3-yn-2-yl (C8), 5-hydroxy-5-ethylhept-3-ynyl (C9), and the like.
    • B. Substituted and unsubstituted C1-C20 cyclic hydrocarbyl:
      • For the purposes of the present invention the term “substituted and unsubstituted C1-C20 cyclic hydrocarbyl” encompasses 5 categories of units:
    • 1) The term “carbocyclic” is defined herein as “encompassing rings comprising from 3 to 20 carbon atoms, wherein the atoms which comprise said rings are limited to carbon atoms, and further each ring can be independently substituted with one or more moieties capable of replacing one or more hydrogen atoms.” The following are non-limiting examples of “substituted and unsubstituted C3-C20 carbocyclic rings” which encompass the following categories of units:
      • i) carbocyclic rings having a single substituted or unsubstituted hydrocarbon ring, non-limiting examples of which include, cyclopropyl (C3), 2-methyl-cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), 2,3-dihydroxycyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclopentadienyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cycloheptyl (C7), cyclooctanyl (C8), decalinyl (C10), 2,5-dimethylcyclopentyl (C5), 3,5-dichlorocyclohexyl (C6), 4-hydroxycyclohexyl (C6), and 3,3,5-trimethylcyclohex-1-yl (C6).
      • ii) carbocyclic rings having two or more substituted or unsubstituted fused hydrocarbon rings, non-limiting examples of which include, octahydropentalenyl (C8), octahydro-1H-indenyl (C9), 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl (C9), decahydroazulenyl (C10); bicyclo[6.2.0]decanyl (C10), decahydronaphthalenyl (C10), and dodecahydro-1H-fluorenyl (C13).
      • iii) carbocyclic rings which are substituted or unsubstituted bicyclic hydrocarbon rings, non-limiting examples of which include, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
    • 2) The term “aryl” is defined herein as “units encompassing at least one phenyl or naphthyl ring and wherein there are no heteroaryl or heterocyclic rings fused to the phenyl or naphthyl ring and further each ring can be independently substituted with one or more moieties capable of replacing one or more hydrogen atoms.” The following are non-limiting examples of “substituted and unsubstituted C6-C14 aryl rings” which encompass the following categories of units:
      • i) C6 or C10 substituted or unsubstituted aryl rings; phenyl and naphthyl rings whether substituted or unsubstituted, non-limiting examples of which include, phenyl (C6), naphthylen-1-yl (C10), naphthylen-2-yl (C10), 4-fluorophenyl (C6), 2-hydroxyphenyl (C6), 3-methylphenyl (C6), 2-amino-4-fluorophenyl (C6), 2-(N,N-diethylamino)phenyl (C6), 2-cyanophenyl (C6), 2,6-di-tert-butylphenyl (C6), 3-methoxyphenyl (C6), 8-hydroxynaphthylen-2-yl (C10), 4,5-dimethoxynaphthylen-1-yl (C10), and 6-cyano-naphthylen-1-yl (C10).
      • ii) C6 or C10 aryl rings fused with 1 or 2 saturated rings non-limiting examples of which include, bicyclo[4.2.0]octa-1,3,5-trienyl (C8), and indanyl (C9).
    • 3) The terms “heterocyclic” and/or “heterocycle” are defined herein as “units comprising one or more C1-C20 rings having from 3 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), or mixtures of N, O, and S, and wherein further the ring which comprises the heteroatom is also not an aromatic ring.” The following are non-limiting examples of “substituted and unsubstituted C1-C20 heterocyclic rings” which encompass the following categories of units:
      • i) heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl (C1), aziridinyl (C2), urazolyl (C2), azetidinyl (C3), pyrazolidinyl (C3), imidazolidinyl (C3), oxazolidinyl (C3), isoxazolinyl (C3), isoxazolyl (C3), thiazolidinyl (C3), isothiazolyl (C3), isothiazolinyl (C3), oxathiazolidinonyl (C3), oxazolidinonyl (C3), hydantoinyl (C3), tetrahydrofuranyl (C4), pyrrolidinyl (C4), 1-methylpyrrolidinyl (C4), morpholinyl (C4), 4-methylmorpholinyl (C4), piperazinyl (C4), 1-methylpiperazinyl (C4), 1-acetylpiperazinyl (C4), 1-methanesulfonyl-piperazinyl (C4), piperidinyl (C5), 1-methylpiperidinyl (C5), 2,2,6,6-tetramethyl-piperidinyl (C5), dihydropyranyl (C5), tetrahydropyranyl (C5), piperidin-2-onyl (valerolactam) (C5), 2,3,4,5-tetrahydro-1H-azepinyl (C6), 2,3-dihydro-1H-indole (C8), and 1,2,3,4-tetrahydro-quinoline (C9).
      • ii) heterocyclic units having 2 or more rings one of which is a heterocyclic ring, non-limiting examples of which include hexahydro-1H-pyrrolizinyl (C7), 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl (C7), 8-azabicyclo[3.2.1]octyl (C7), 3a,4,5,6,7,7a-hexahydro-1H-indolyl (C8), 1,2,3,4-tetrahydroquinolinyl (C9), and decahydro-1H-cycloocta[b]pyrrolyl (C10).
    • 4) The term “heteroaryl” is defined herein as “encompassing one or more C1-C20 rings comprising from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), or mixtures of N, O, and S, and wherein further at least one of the rings which comprises a heteroatom is an aromatic ring.” The following are non-limiting examples of “substituted and unsubstituted C1-C20 heterocyclic rings” which encompass the following categories of units:
      • i) heteroaryl rings containing a single ring, non-limiting examples of which include, 1,2,3,4-tetrazolyl (C1), [1,2,3]triazolyl (C2), [1,2,4]triazolyl (C2), triazinyl (C3), thiazolyl (C3), 1H-imidazolyl (C3), oxazolyl (C3), furanyl (C4), thiopheneyl (C4), pyrimidinyl (C4), 2-phenylpyrimidinyl (C4), pyridinyl (C5), 3-methylpyridinyl (C5), and 4-dimethylaminopyridinyl (C5)
      • ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, non-limiting examples of which include: 7H-purinyl (C5), 9H-purinyl (C5), 6-amino-9H-purinyl (C5), 5H-pyrrolo[3,2-d]pyrimidinyl (C6), 7H-pyrrolo[2,3-d]pyrimidinyl (C6), pyrido[2,3-d]pyrimidinyl (C7), 2-phenylbenzo[d]thiazolyl (C7), 1H-indolyl (C5), 4,5,6,7-tetrahydro-1-H-indolyl (C5), quinoxalinyl (C5), 5-methylquinoxalinyl (C5), quinazolinyl (C8), quinolinyl (C9), 8-hydroxy-quinolinyl (C9), and isoquinolinyl (C9).
    • 5) C1-C6 tethered cyclic hydrocarbyl units (whether C3-C10 carbocyclic units, C6 or C10 aryl units, C1-C10 heterocyclic units, or C1-C10 heteroaryl units) which connected to another moiety, unit, or core of the molecule by way of a C1-C6 alkylene unit. Non-limiting examples of tethered cyclic hydrocarbyl units include benzyl C1-(C6) having the formula:
      Figure US20070293494A1-20071220-C00003
      • wherein Ra is optionally one or more independently chosen substitutions for hydrogen. Further examples include other aryl units, inter alia, (2-hydroxyphenyl)hexyl C6-(C6); naphthalen-2-ylmethyl C1-(C10), 4-fluorobenzyl C1-(C6), 2-(3-hydroxy-phenyl)ethyl C2-(C6), as well as substituted and unsubstituted C3-C10 alkylenecarbocyclic units, for example, cyclopropylmethyl C1-(C3), cyclopentylethyl C2-(C5), cyclohexylmethyl C1-(C6). Included within this category are substituted and unsubstituted C1-C10 alkylene-heteroaryl units, for example a 2-picolyl C1-(C6) unit having the formula:
        Figure US20070293494A1-20071220-C00004
      • wherein Ra is the same as defined above. In addition, C1-C12 tethered cyclic hydrocarbyl units include C1-C10 alkyleneheterocyclic units and alkylene-heteroaryl units, non-limiting examples of which include, aziridinylmethyl C1-(C2) and oxazol-2-ylmethyl C1-(C3).
  • For the purpose of the present invention fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring. For example, 1,2,3,4-tetrahydroquinoline having the formula:
    Figure US20070293494A1-20071220-C00005
    is, for the purposes of the present invention, considered a heterocyclic unit. 6,7-Dihydro-5H-cyclopentapyrimidine having the formula:
    Figure US20070293494A1-20071220-C00006
    is, for the purposes of the present invention, considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both a saturated and an aryl ring, the aryl ring will predominate and determine the type of category to which the ring is assigned. For example, 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula:
    Figure US20070293494A1-20071220-C00007
    is, for the purposes of the present invention, considered a heteroaryl unit.
  • The term “substituted” is used throughout the specification. The term “substituted” is defined herein as “a hydrocarbyl moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several substituents as defined herein below.” The units, when substituting for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety, or unit. For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. Three hydrogen replacements includes cyano, and the like. The term substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain; can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced. For example, 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”, N,N-dimethyl-5-amino)octanyl is a “substituted C8 alkyl unit, 3-guanidinopropyl is a “substituted C3 alkyl unit,” and 2-carboxypyridinyl is a “substituted heteroaryl unit.”
  • The following are non-limiting examples of categories and examples herewith of units which can suitably substitute for hydrogen atoms on a cyclic or acyclic hydrocarbyl unit, described herein below as R5 units, wherein in the non-limiting examples provided herein below, R12 is hydrogen, C1-C10 linear or branched alkyl, C2-C10 linear or branched alkenyl, C2-C10 linear or branched alkynyl, and C6 or C10 aryl.
  • R5 units according to the present invention may include the following substitutions either comprising R5 itself or when R5 comprises an R6 unit which is bonded to the core phenyl unit by a linking unit:
      • i) —NHCOR12; for example, —NHCOCH3, —NHCOCH2CH3, —NHCOC6H5;
      • ii) COR12; for example, —COCH3, —COCH2CH3, —COCH2CH2CH3;
      • iii) —CO2R12; for example, —CO2CH3, —CO2CH2CH3, —CO2CH2CH2CH3;
      • iv) —OCOR12; for example, —OCOCH3, —OCOCH2CH3, —OCOCH2CH2CH3;
      • v) —C(═NH)NH2;
      • vi) —NHC(═NH)NH2;
      • vii) —N(R12)2; for example, —NH2, —NHCH3, —N(CH3)2, —NH(CH2CH3);
      • viii) —NHC6H5;
      • ix) C1-C4 linear, branched, or cyclic alkyl; for example, methyl, ethyl;
      • x) —CON(R12)2; for example, —CONH2, CONHCH3, —CON(CH3)2;
      • xi) —CONHNH2;
      • xii) —NHCN;
      • xiii) —CN;
      • xiv) halogen: —F, —Cl, —Br, and —I;
      • xv) —NHN(R12)2; for example, —NHNH2, —NHNHCH3, —NHN(CH3)2;
      • xvi) —OR12; for example, —OH, —OCH3, —OCH2CH3, —OCH2CH2CH3;
      • xvii) —NO2;
      • xviii) —CHmX3-m; wherein X is halogen, m is from 0 to 2; for example, CH2F, —CHF2,  CF3, —CCl3, or —CBr3; and
      • xix) —SO2N(R12)2; for example, —SO2NH2; —SO2NHCH3; —SO2NHC6H5.
  • For the purposes of the present invention the terms “compound” and “analog” stand equally well for the novel compositions of matter described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms “compound” and “analog” are used interchangeably throughout the present specification.
  • The compounds of the present invention are 2-arylamino-4-(heterocyclicalkylene)-aminopyrimidines having the core scaffold:
    Figure US20070293494A1-20071220-C00008
    which includes a core pyrimidine ring and a core phenyl ring wherein R5 represents one or more (from 1 to 5) optionally present, and independently selected, substitutes for hydrogen as outlined herein above and described in the categories, aspects, iterations, examples, and tables herein below. As it relates to particularly pointing out the subject matter of the present invention, the unit R1 which contains the core phenyl ring, may be depicted throughout the specification and claims equally well by the following general formulae:
    Figure US20070293494A1-20071220-C00009
    wherein R, R1, R5, R6, L, L1 and y are further described herein below.
  • R units are substituted or unsubstituted heterocyclic units containing from 3 to 7 atoms.
  • The first category of R units relates to heterocyclic units wherein the linking group L is bonded to a nitrogen atom, said units having the formula:
    Figure US20070293494A1-20071220-C00010
    wherein R2 and R3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents.
  • The first aspect of category one of R units relates to C3, C4 and C5 unsubstituted heterocycles. Non-limiting examples of this aspect includes units chosen from pyrrolidin-1-yl, pyrrolin-1-yl, imidazolidin-1-yl, imidazolin-1-yl, pyrazolidin-1-yl, pyrazolin-1-yl, piperidin-1-yl, piperazin-1-yl, and morpholin-4-yl.
  • The second aspect of category one of R units relates to C3, C4 and C5 substituted heterocycles. Non-limiting examples of this aspect includes units chosen from 5,5-di-methyl-imidazolin-1-yl, 4-methylpiperazin-1-yl, 4-acetylpiperazin-1-yl, and 4-methane-sulfonyl-piperazin-1-yl.
  • The second category of R units relates to heterocyclic units wherein the linking group L is bonded to a carbon atom, the first aspect of said units having the formula:
    Figure US20070293494A1-20071220-C00011
    wherein R2 and R3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
  • One iteration of the first aspect of category two of R units relates to C3, C4 and C5 substituted or unsubstituted heterocycles non-limiting examples of which include units chosen from pyrrolidin-2-yl, N-methyl-pyrrolidin-2-yl, N-methyl-pyrrolidin-2-one-5-yl, pyrrolin-2-yl, imidazolidin-2-yl, imidazolin-2-yl, pyrazolidin-2-yl, pyrazolin-2-yl, piperidin-2-yl, N-methylpiperidin-2-yl, morpholin-3-yl, and N-methylmorpholin-3-yl.
  • A further iteration of the first aspect of category two of R units relates to C3, C4 and C5 substituted or unsubstituted heterocycles having a chiral center in the R units and wherein a particular enantiomer is selected, for example, one of the two enantiomeric R units having the formula:
    Figure US20070293494A1-20071220-C00012
  • The second aspect of the second category of R units relates to heterocyclic units wherein the linking group L is bonded to a carbon atom, said units having the formula:
    Figure US20070293494A1-20071220-C00013
    wherein R2 and R3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl. Non-limiting examples of this aspect includes pyrrolidin-3-yl, N-methyl-pyrrolidin-3-yl, piperidin-3-yl, N-methylpiperidin-3-yl, morpholin-2-yl, and N-methylmorpholin-2-yl.
  • The third aspect of the second category of R units relates to heterocyclic units wherein the linking group L is bonded to a carbon atom, said units having the formula:
    Figure US20070293494A1-20071220-C00014
    wherein R2 and R3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl. Non-limiting examples of this aspect include piperidin-4-yl, N-methylpiperidin-4-yl, and 2,2,6,6-tetramethyl-piperidin-4-yl.
  • R1 is substituted or unsubstituted phenyl having the formula:
    Figure US20070293494A1-20071220-C00015
    R5 is hydrogen or one or more independently chosen substitutes for hydrogen, R5 has the formula:
    -(L1)y-R6
    the index y has the value 0 when L1 is absent, and the value 1 when L1 is present; R6 is a unit chosen from:
      • i) hydrogen;
      • ii) halogen;
      • iii) nitro;
      • iv) hydroxy;
      • v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino;
      • vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
      • vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
      • viii) substituted or unsubstituted phenyl;
      • ix) substituted or unsubstituted C2-C5 heterocyclic;
      • x) substituted or unsubstituted C3-C9 heteroaryl;
      • xi) cyano; or
      • xii) CHmX3-m wherein X is halogen and m is from 0 to 2.
  • The first category of R1 relates to substituted phenyl units wherein L1 is absent (the index y is equal to 0) and R5 comprises one or more substitutes for hydrogen each of which is independently chosen from:
      • ii) halogen; —F, —Cl, —Br, and —I;
      • iii) nitro; —NO2;
      • iv) hydroxy; —OH;
      • v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino; inter alia, —NH2, —NH(CH3), and —N(CH3)2;
      • vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
      • vii) substituted or unsubstituted C1-C4 linear or branched alkoxy.
  • The first aspect of Category one of R1 relates to units which are substituted by one or more units from groups (ii)-(vii). Non-limiting examples of this aspect include 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 3,4-difluorophenyl, 3-trifluoromethylphenyl, 3-trifluoromethyl-4-chloro-phenyl, 3-methoxyphenyl, 3-methylphenyl, 3-ethylphenyl, and 3-isopropylphenyl.
  • The second aspect of Category one of R1 relates to units which are substituted by one or more halogen atom, for example, —F, —Cl, —Br, and —I. Non-limiting examples of this aspect include 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichloro-phenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-tri-chlorophenyl, and 2,4,6-trichlorophenyl.
  • The third aspect of Category one of R1 relates to units which are substituted by one or more C1-C4 linear or branched alkyl, for example, methyl (C1), ethyl (C2), n-propyl (C3), iso-propyl (C3), n-butyl (C4), sec-butyl (C4), iso-butyl (C4), and tert-butyl (C4). Non-limiting examples of this aspect include 2-methylphenyl, 4-methylphenyl, 2,3-dimethyl-phenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethyl-phenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethyl-phenyl, 2,3,6-trimethylphenyl, 2,4,5-tri-methylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethyl-phenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, and 2,4,6-triethyl-phenyl.
  • The fourth aspect of Category one of R1 relates to units which are substituted by one or more C1-C4 linear or branched alkoxy, for example, methoxy (C1), ethoxy (C2), n-propoxy (C3), iso-propoxy (C3), n-butoxy (C4), sec-butoxy (C4), iso-butoxy (C4), and tert-butoxy (C4). Non-limiting examples of this aspect include 2-methoxyphenyl, 4-methoxy-phenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-di-methoxyphenyl, 3,4-dimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6-trimethoxy-phenyl, 2,4,5-trimethoxyphenyl, and 2,4,6-trimethoxyphenyl.
  • The fifth aspect of Category one of R1 relates to units which are substituted by one or more hydroxy units, non-limiting examples of this aspect include 2-hydroxy-phenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 2,5-dihydroxyphenyl, 2,6-dihydroxyphenyl, 3,4-dihydroxy-phenyl, 2,3,4-trihydroxyphenyl, 2,3,5-trihydroxy-phenyl, 2,3,6-trihydroxyphenyl, 2,4,5-trihydroxyphenyl, and 2,4,6-trihydroxyphenyl.
  • Other aspects of Category one of R1 include combinations of R1 substituents which comprise substitute classes (ii)-(vii) not specifically exemplified herein.
  • The second category of R1 relates to substituted core phenyl units wherein the index y is equal to 0 or 1 and R5 comprises one or more substitutes for hydrogen each of which is independently chosen from units which comprise:
      • viii) substituted or unsubstituted phenyl; or
      • ix) substituted or unsubstituted C3-C9 heteroaryl units.
  • Substituted or unsubstituted phenyl units are present in the second category of R1 when linked to the core phenyl units by way of a linking unit L1.
  • The core C3-C9 heteroaryl rings of the second category of R1 encompass the following non-limiting examples of substituted and unsubstituted rings: triazinyl (C3), thiazoyl (C3), 1H-imidazoyl (C3), furanyl (C4), thiophenyl (C4), pyrimidinyl (C4), 2-phenylpyrimidinyl (C4), pyridinyl (C5), 3-methylpyridinyl (C5), 4-dimethylamino-pyridinyl (C5), 7H-purinyl (C5), 9H-purinyl (C5), 6-amino-9H-purinyl (C5), 5H-pyrrolo[3,2-d]pyrimidinyl (C6), 7H-pyrrolo[2,3-d]pyrimidinyl (C6), pyrido[2,3-d]pyrimidinyl (C7), 2-phenylbenzo[d]thiazolyl (C7), 4,5,6,7-tetrahydro-1-H-indolyl (C8), quinoxalinyl (C8), 5-methylquinoxalinyl (C8), quinazolinyl (C8), 6,7-dihydro-5H-[1]pyridine (C8), quinolinyl (C9), 8-hydroxy-quinolinyl (C9), and isoquinolinyl (C9).
  • The first aspect of the second category of R1 relates to units wherein the linking unit L1 is absent (the index y is equal to 0), non-limiting examples of which include units chosen from: 2-(pyrimidin-2-yl)phenyl, 2-(pyrimidin-3-yl)phenyl, 2-(pyrimidin-4-yl)phenyl, 3-(pyrimidin-2-yl)phenyl, 3-(pyrimidin-3-yl)phenyl, 3-(pyrimidin-4-yl)phenyl, 4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-3-yl)phenyl, 4-(pyrimidin-4-yl)phenyl, 2-(pyridin-2-yl)phenyl, 2-(pyridin-3-yl)phenyl, 2-(pyridin-4-yl)phenyl, 3-(pyridin-2-yl)phenyl, 3-(pyridin-3-yl)phenyl, 3-(pyridin-4-yl)phenyl, 4-(pyridin-2-yl)phenyl, 4-(pyridin-3-yl)phenyl, and 4-(pyridin-4-yl)phenyl.
  • The second aspect of the second category of R1 relates to units wherein L1 is a unit having the formula:
    —[CH2]j—
    wherein the index j is equal to 1 or 2, non-limiting examples of which include units chosen from: 2-[(pyrimidin-2-yl)phenyl]methyl, 2-[(pyrimidin-3-yl)phenyl]methyl, 2-[(pyrimidin-4-yl)phenyl]methyl, 3-[(pyrimidin-2-yl)phenyl]methyl, 3-[(pyrimidin-3-yl)phenyl]methyl, 3-[(pyrimidin-4-yl)phenyl]methyl, 4-[(pyrimidin-2-yl)phenyl]methyl, 4-[(pyrimidin-3-yl)phenyl]methyl, 4-[(pyrimidin-4-yl)phenyl]methyl, 2-[(pyridin-2-yl)phenyl]methyl, 2-[(pyridin-3-yl)phenyl]methyl, 2-[(pyridin-4-yl)phenyl]methyl, 3-[(pyridin-2-yl)phenyl]methyl, 3-[(pyridin-3-yl)phenyl]methyl, 3-[(pyridin-4-yl)phenyl]-methyl, 4-[(pyridin-2-yl)phenyl]methyl, 4-[(pyridin-3-yl)phenyl]methyl, and 4-[(pyridin-4-yl)phenyl]methyl.
  • The third aspect of the second category of R1 relates to units wherein L1 is a unit having the formula:
    —O[CH2]k—
    wherein the index k is equal to 1 or 2, non-limiting examples of which include R5 units chosen from: 2-(pyrimidin-2-yl)phenyl, 2-(pyrimidin-3-yl)phenyl, 2-(pyrimidin-4-yl)phenyl, 3-(pyrimidin-2-yl)phenyl, 3-(pyrimidin-3-yl)phenyl, 3-(pyrimidin-4-yl)phenyl, 4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-3-yl)phenyl, 4-(pyrimidin-4-yl)phenyl, 2-(pyridin-2-yl)phenyl, 2-(pyridin-3-yl)phenyl, 2-(pyridin-4-yl)phenyl, 3-(pyridin-2-yl)phenyl, 3-(pyridin-3-yl)phenyl, 3-(pyridin-4-yl)phenyl, 4-(pyridin-2-yl)phenyl, 4-(pyridin-3-yl)phenyl, and 4-(pyridin-4-yl)phenyl.
  • The fourth aspect of the second category of R1 relates to units wherein L1 is a unit having the formula:
    —SO2NH—
    and R5 is a unit chosen from:
      • i) hydrogen;
      • ii) C1-C4 linear or branched alkyl;
      • iii) substituted or unsubstituted phenyl; and
      • iv) substituted or unsubstituted heteroaryl.
  • The first iteration of the fourth aspect of category two of R1 units encompasses R5 units which are chosen from:
      • i) hydrogen; or
      • ii) C1-C4 linear or branched alkyl.
  • Non-limiting examples of R1 units encompassed within this iteration include: benzene-sulfonamide, N-methyl-benzenesulfonamide, N-ethyl-benzenesulfon-amide, N-(n-propyl)-benzenesulfonamide, N-(iso-propyl)-benzenesulfonamide, N-(n-butyl)-benzenesulfonamide, N-(sec-butyl)-benzenesulfonamide, N-(iso-butyl)-benzene-sulfonamide, and N-(tert-butyl)-benzenesulfonamide.
  • The second iteration of the fourth aspect of category two of R1 units encompasses R5 units which are chosen from:
      • iii) substituted or unsubstituted phenyl; or
      • iv) substituted or unsubstituted heteroaryl.
  • Non-limiting examples of R1 units encompassed within this iteration include: N-phenyl-benzene-sulfonamide, N-(pyrimidin-2-yl)-benzenesulfonamide, N-(pyrimidin-4-yl)-benzenesulfonamide, N-(pyrimidin-5-yl)-benzenesulfonamide, N-(pyridin-2-yl)-benzenesulfonamide, N-(pyridin-3-yl)-benzenesulfonamide, and N-(pyridin-4-yl)-benzenesulfonamide.
  • The fifth aspect of the second category of R1 relates to units wherein L1 is a unit having the formula:
    —[C(R7aR7b)]jNR9C(O)[C(R8aR8b)]k—; or
    —[C(R7aR7b)]jC(O)NR9[C(R8aR8b)]k—
    wherein R7a, R7b, R8a, R8b, and R9 are each independently hydrogen, methyl, or ethyl; the indices j and k are each independently from 0 to 3.
  • The first iteration of the fifth aspect of the second category of R1 units relates to R1 units wherein R6 units are linked to the phenyl ring by way of a L1 unit chosen from units having the formula.
      • i) —NH(CO)—;
      • ii) —NH(CO)CH2—; and
      • iii) —C(O)NH—;
        and R6 comprises a unit chosen from:
      • viii) substituted or unsubstituted phenyl; or
      • x) substituted or unsubstituted C3-C9 heteroaryl.
  • Non-limiting examples of the first iteration of the fifth aspect of the second category of R1 units includes substituted or unsubstituted phenyl units linked with amide bond linking units having the formula —C(O)NH— or —NH(CO)—. The following are examples of R5 units which are amide bond-linked substituted or unsubstituted phenyl units substituted at the 3-position of the core phenyl ring:
    Figure US20070293494A1-20071220-C00016
    wherein R11 comprises one or more of the R12 substitutions for hydrogen as defined and exemplified herein above.
  • The third category of R1 relates to substituted phenyl units wherein L1 is absent (the index y is equal to 0) and R5 comprises one or more substitutes for hydrogen each of which is independently chosen from units which comprise:
      • viii) substituted or unsubstituted C2-C5 heterocyclic units.
  • The core C2-C5 heterocyclic rings of the third category of R1 encompass the following unsubstituted rings: aziridinyl (C2), [1,2,3]triazolyl (C2), [1,2,4]triazolyl (C2), urazolyl (C2), oxazolyl (C3), azetidinyl (C3), pyrazolidinyl (C3), imidazolidinyl (C3), oxazolidinyl (C3), isoxazolinyl (C3), oxazolyl (C3) isoxazolyl (C3), thiazolidinyl (C3), thiazolyl (C3), imidazolidinonyl (C3), isothiazolyl (C3), isothiazolinyl (C3), oxathiazolidinonyl (C3), oxazolidinonyl (C3), hydantoinyl (C3), tetrahydrofuranyl (C4), pyrrolidinyl (C4), tetrahydrothiopenyl (C4), morpholinyl (C4), piperazinyl (C4), piperidinyl (C4), dihydropyranyl (C5), tetrahydropyranyl (C5), and piperidin-2-onyl (valerolactam) (C5). However, the C2-C5 heterocyclic rings described herein can be substituted with one or more units chosen from:
      • i) C1-C4 linear or branched alkyl, for example, methyl (C1), ethyl (C2), n-propyl (C3), iso-propyl (C3), n-butyl (C4), sec-butyl (C4), iso-butyl (C4), and tert-butyl (C4); or
      • ii) amino —NH2, or mono- or di-[C1-C4 linear or branched alkyl]substituted amino, for example, —NH12; —NHCH3; —N(CH3)2; —NH(CH2CH3); —N(CH2CH3)2; —N(CH3)(CH2CH3); —NH(CH2CH2CH3); —N[CH(CH3)2]2; —N(CH2CH2CH3)2; —NH[CH(CH3)2]; —N(CH2CH2CH3)[CH(CH3)2]; —N(CH3)(CH2CH2CH3); —N(CH2CH3)(CH2CH2CH3); —N[C(CH3)3]2; —N(CH3)[CH(CH3)2]; —N(CH2CH3)[CH(CH3)2]2; —NH[C(CH3)3]; —NH(CH2CH2CH2CH3); —N(CH2CH2CH2CH3)2; —NH[CH2CH(CH3)2]; —N[CH2CH(CH3)2]2; —NH[CH(CH3)CH2CH3]; —N[CH(CH3)CH2CH3]2; —N(CH2CH2CH3)[CH2CH(CH3)2]; —N(CH2CH2CH2CH3)[C(CH3)3]; and —N(CH2CH2CH2CH3)[CH(CH3)CH2CH3].
  • L is a linking unit having the formula:
    —[C(R4aR4b)]n—
    wherein each R4a and R4b unit is independently chosen from:
      • i) hydrogen; or
      • ii) C1-C4 linear, branched, or cyclic alkyl; for example, methyl (C1), ethyl (C2), n-propyl(C3), iso-propyl (C3), cyclopropyl (C3), n-butyl (C4), iso-butyl (C4), sec-butyl (C4), and tert-butyl (C4);
        the index n is from 1 to 4. The index n indicates the number of units which comprise L linking units, for example, a linking unit having the formula CH2— (methylene) would have an index n equal to 1. A linking unit having the formula —CH2CH2 (ethylene) or the unit having the formula —CH(CH3)CH2— (1-methylethylene) each have an index n equal to 2.
  • The first category of L units relates to unsubstituted alkylene units chosen from:
      • i) CH2—, methylene;
      • ii) —CH2CH2—, ethylene;
      • iii) —CH12CH2CH2—, propylene; and
      • iv) —CH2CH2CH2CH2—, butylene.
  • The first aspect of the first category of L units encompasses linking groups which are —CH2CH2CH2—, propylene; as exemplified in the generic formula:
    Figure US20070293494A1-20071220-C00017
  • The second aspect of the first category of L units encompasses linking groups which are CH2CH2—, ethylene.
  • The second category of L units relates to alkyl substituted alkylene units chosen from:
      • i) —CH(CH3)CH2—, 1-methylethylene;
      • ii) —CH2CH(CH3)—, 2-methylethylene;
      • iii) —CH(CH3)CH2CH2—, 1-methylpropylene;
      • iv) —CH2CH(CH3)CH2—, 2-methylpropylene; and
      • v) CH2C(CH3)2CH2—, 2,2-dimethylpropylene.
  • The first aspect of the second category of L units encompasses linking groups which are —CH(CH3)Cl2CH2—, 1-methylpropylene; as exemplified in the generic formula:
    Figure US20070293494A1-20071220-C00018
    wherein the above formula encompasses both the R and the S enantiomers of the linking unit.
  • L1 is a linking unit which when present provides R5 units with the formula:
    -(L1)y-R6
    wherein y is equal to 1 when L1 is present.
  • L1 is a linking unit chosen from:
      • i) —[C(R7aR7b)]j—;
      • ii) —[C(R7aR7b)]jO[C(R8aR8b)]k—;
      • iii) —[C(R7aR7b)]jNR9SO2[C(R8aR8b)]k—;
      • iv) —[C(R7aR7b)]jSO2NR9[C(R8aR8b)]k—;
      • v) [C(R7aR7b)]jNR9C(O)[C(R8aR8b)]k—;
      • vi) [C(R7aR7b)]jC(O)NR9[C(R8aR8b)]k—; or
      • vii) —[C(R7aR7b)]jSO2NR9[C(R8aR8b)]k—;
        R7a, R7b, R8a, R8b, and R9 are each independently hydrogen, methyl, or ethyl; the indices j and k are each independently from 0 to 3; the index y is 0 or 1.
  • The various categories, aspects, iterations, and examples of L1 can be found in the definitions of R1 and in the examples and tables described and listed herein below.
    • Synthesis Procedure
  • The compounds of the present invention can be prepared by the following general procedure, the formulator adjusting the reaction conditions as is necessary and which one skilled in the art will be able to accomplish without undo experimentation.
  • Step 1: Preparation of intermediate 2-(methylthio)pyrimidine-4(3H)-one. This compound can be used in the preparation of each analog encompassed by the present invention. The general procedure follows.
    Figure US20070293494A1-20071220-C00019
  • To a solution of sodium hydroxide (8 g, 200 mmol) in H2O (75 mL) at room temperature is added thiouridine (14.2 g, 100 mmol). The resulting mixture is stirred at room temperature for 20 minutes. Methyl iodide (6.86 mL, 110 mmol) in THF (10 mL) is added dropwise slowly and the mixture is stirred at room temperature for 18 hours. A white solid forms upon acidifying the mixture to pH 5 with glacial acetic acid. At this point the mixture is cooled in an ice bath and allowed to stand for approximately 2 hours after which the final product separates as a white solid and can be collected by filtration. First crop of crystals typically yields the desired product in an excess of 60% yield. 1H NMR (DMSO-d6, 300 MHz): δ 2.45 (s, 3H), 6.07 (d, J=6.6 Hz, 1H), 7.85 (d, J=6.6 Hz, 1H).
  • Step 2: Formation of 2-anilino intermediate.
    Figure US20070293494A1-20071220-C00020
  • 2-(Substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one: To a 2-(methyl-thio)pyrimidine-4(3H)-one (14.2 g, 100 mmol) in diglyme (60 mL) is added the substituted or unsubstituted aniline of choice (200 mmol). The resulting mixture is heated to reflux and stirred for approximately 18 hours. The product which typically forms as a solid upon cooling the mixture to room temperature, is washed with solvent (pentane, hexane, or isopentane). However, solvent can be added to the reaction mixture to induce crystallization if necessary.
  • Step 3. Formation of 4-chloro-2-anilino intermediate.
    Figure US20070293494A1-20071220-C00021
  • 2-(Substituted or unsubstituted phenylamino)-4-chloro-pyrimidine: To a 2-(Substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one (5.02 g, 22.6 mmol) and N,N-dimethyl-aniline (450 mL) is added of phosphorus oxychloride (450 mL). The resulting mixture is heated to reflux for 15 minutes, cooled to room temperature and concentrated in vacuo. The residue is neutralized to pH 7 with 1M NaOH (aqueous). The organic layer is extracted with EtOAc (3×250 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue can be conveniently purified over silica (5% EtOAc in hexanes) to afford the desired compound.
  • Alternatively, the 4-chloro-2-anilino intermediate can be synthesized the following way:
  • 2-(Substituted or unsubstituted phenylamino)-4-chloro-pyrimidine: To a 2-(substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one (3.00 g, 13.5 mmol) in toluene (30 mL) is added N,N-dimethyl-aniline (3.57 mL, 28.4 mmol) and phosphorus oxychloride (1.24 mL, 13.5 mmol). The resulting mixture is heated to retlux for 15 minutes, cooled to room temperature and neutralized to pH 7 with 1M NaOH (aqueous). The organic layer is extracted with EtOAc (3×250 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue can be conveniently purified over silica (5% EtOAc in hexanes) to afford the desired compound.
  • Step 4. Formation of final compounds (analogs) of the present invention.
    Figure US20070293494A1-20071220-C00022
  • To the 2-(Substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one formed in Step (2) (100 mmol) in THF (500 mL) is added diisopropylethylamine (200 mmol) followed by the desired diamine (200 mmol). The resulting mixture is heated to reflux for approximately 18 hours. The reaction is cooled to room temperature and concentrated in vacuo. The residue which forms is diluted with water and extracted with solvent. The combined organic layers are dried (MgSO4) and concentrated in vacuo. This residue can be crystallized or purified over silica to afford the final compound.
  • Schemes I-IV herein below provide illustrative examples of the preparation of compounds encompassed by the various categories of the present invention.
  • The analogs (compounds) of the present invention are arranged into several categories to assist the formulator in applying a rational synthetic strategy for the preparation of analogs which are not expressly exampled herein. The arrangement into categories does not imply increased or decreased efficacy for any of the compositions of matter described herein.
    • Analog Categories
  • The compounds which comprise Category I of the present invention are 2,4-di-aminopyrimidines having the formula:
    Figure US20070293494A1-20071220-C00023
    wherein linking group L is a propylene (—CH2CH2CH2—) unit and R units are heterocyclic units attached to the core scaffold by way of a ring nitrogen atom. The first aspect of Category I encompasses R1 units which are phenyl units substituted by one or more R5 units chosen from:
      • i) halogen; —F, —Cl, —Br, and —I;
      • ii) nitro; —NO2;
      • iii) hydroxy; —OH;
      • iv) amino or mono- or di-(substituted C1-C4 alkyl)amino; inter alia, —NH2, —NH(CH3), and —N(CH3)2,
      • v) substituted or unsubstituted C1-C4 linear or branched alkyl;
      • vi) substituted or unsubstituted C1-C4 linear or branched alkoxy;
  • which are further exemplified herein below in Table I.
    TABLE I
    No R R1
    1 pyrrolidin-1-yl 3-chlorophenyl
    2 pyrrolin-1-yl 3-chlorophenyl
    3 imidazolidin-1-yl 3-chlorophenyl
    4 imidazolin-1-yl 3-chlorophenyl
    5 pyrazolidin-1-yl 3-chlorophenyl
    6 pyrazolin-1-yl 3-chlorophenyl
    7 piperidin-1-yl 3-chlorophenyl
    8 piperazin-1-yl 3-chlorophenyl
    9 4-methylpiperazin-1-yl 3-chlorophenyl
    10 morpholin-4-yl 3-chlorophenyl
    11 pyrrolidin-1-yl 4-chlorophenyl
    12 pyrrolin-1-yl 4-chlorophenyl
    13 imidazolidin-1-yl 4-chlorophenyl
    14 imidazolin-1-yl 4-chlorophenyl
    15 pyrazolidin-1-yl 4-chlorophenyl
    16 pyrazolin-1-yl 4-chlorophenyl
    17 piperidin-1-yl 4-chlorophenyl
    18 piperazin-1-yl 4-chlorophenyl
    19 4-methylpiperazin-1-yl 4-chlorophenyl
    20 morpholin-4-yl 4-chlorophenyl
    21 pyrrolidin-1-yl 3,4-dichlorophenyl
    22 pyrrolin-1-yl 3,4-dichlorophenyl
    23 imidazolidin-1-yl 3,4-dichlorophenyl
    24 imidazolin-1-yl 3,4-dichlorophenyl
    25 pyrazolidin-1-yl 3,4-dichlorophenyl
    26 pyrazolin-1-yl 3,4-dichlorophenyl
    27 piperidin-1-yl 3,4-dichlorophenyl
    28 piperazin-1-yl 3,4-dichlorophenyl
    29 4-methylpiperazin-1-yl 3,4-dichlorophenyl
    30 morpholin-4-yl 3,4-dichlorophenyl
    31 pyrrolidin-1-yl 3-chloro-4-methylphenyl
    32 pyrrolin-1-yl 3-chloro-4-methylphenyl
    33 imidazolidin-1-yl 3-chloro-4-methylphenyl
    34 imidazolin-1-yl 3-chloro-4-methylphenyl
    35 pyrazolidin-1-yl 3-chloro-4-methylphenyl
    36 pyrazolin-1-yl 3-chloro-4-methylphenyl
    37 piperidin-1-yl 3-chloro-4-methylphenyl
    38 piperazin-1-yl 3-chloro-4-methylphenyl
    39 4-methylpiperazin-1-yl 3-chloro-4-methylphenyl
    40 morpholin-4-yl 3-chloro-4-methylphenyl
    41 pyrrolidin-1-yl 3-chloro-4-fluorophenyl
    42 pyrrolin-1-yl 3-chloro-4-fluorophenyl
    43 imidazolidin-1-yl 3-chloro-4-fluorophenyl
    44 imidazolin-1-yl 3-chloro-4-fluorophenyl
    45 pyrazolidin-1-yl 3-chloro-4-fluorophenyl
    46 pyrazolin-1-yl 3-chloro-4-fluorophenyl
    47 piperidin-1-yl 3-chloro-4-fluorophenyl
    48 piperazin-1-yl 3-chloro-4-fluorophenyl
    49 4-methylpiperazin-1-yl 3-chloro-4-fluorophenyl
    50 morpholin-4-yl 3-chloro-4-fluorophenyl
    51 pyrrolidin-1-yl 3,4-difluorophenyl
    52 pyrrolin-1-yl 3,4-difluorophenyl
    53 imidazolidin-1-yl 3,4-difluorophenyl
    54 imidazolin-1-yl 3,4-difluorophenyl
    55 pyrazolidin-1-yl 3,4-difluorophenyl
    56 pyrazolin-1-yl 3,4-difluorophenyl
    57 piperidin-1-yl 3,4-difluorophenyl
    58 piperazin-1-yl 3,4-difluorophenyl
    59 4-methylpiperazin-1-yl 3,4-difluorophenyl
    60 morpholin-4-yl 3,4-difluorophenyl
    61 pyrrolidin-1-yl 3-CF3-phenyl
    62 pyrrolin-1-yl 3-CF3-phenyl
    63 imidazolidin-1-yl 3-CF3-phenyl
    64 imidazolin-1-yl 3-CF3-phenyl
    65 pyrazolidin-1-yl 3-CF3-phenyl
    66 pyrazolin-1-yl 3-CF3-phenyl
    67 piperidin-1-yl 3-CF3-phenyl
    68 piperazin-1-yl 3-CF3-phenyl
    69 4-methylpiperazin-1-yl 3-CF3-phenyl
    70 morpholin-4-yl 3-CF3-phenyl
    71 pyrrolidin-1-yl 3-CF3-4-Cl-phenyl
    72 pyrrolin-1-yl 3-CF3-4-Cl-phenyl
    73 imidazolidin-1-yl 3-CF3-4-Cl-phenyl
    74 imidazolin-1-yl 3-CF3-4-Cl-phenyl
    75 pyrazolidin-1-yl 3-CF3-4-Cl-phenyl
    76 pyrazolin-1-yl 3-CF3-4-Cl-phenyl
    77 piperidin-1-yl 3-CF3-4-Cl-phenyl
    78 piperazin-1-yl 3-CF3-4-Cl-phenyl
    79 4-methylpiperazin-1-yl 3-CF3-4-Cl-phenyl
    80 morpholin-4-yl 3-CF3-4-Cl-phenyl
    81 pyrrolidin-1-yl 3-methylphenyl
    82 pyrrolin-1-yl 3-methylphenyl
    83 imidazolidin-1-yl 3-methylphenyl
    84 imidazolin-1-yl 3-methylphenyl
    85 pyrazolidin-1-yl 3-methylphenyl
    86 pyrazolin-1-yl 3-methylphenyl
    87 piperidin-1-yl 3-methylphenyl
    88 piperazin-1-yl 3-methylphenyl
    89 4-methylpiperazin-1-yl 3-methylphenyl
    90 morpholin-4-yl 3-methylphenyl
    91 pyrrolidin-1-yl 3-methoxyphenyl
    92 pyrrolin-1-yl 3-methoxyphenyl
    93 imidazolidin-1-yl 3-methoxyphenyl
    94 imidazolin-1-yl 3-methoxyphenyl
    95 pyrazolidin-1-yl 3-methoxyphenyl
    96 pyrazolin-1-yl 3-methoxyphenyl
    97 piperidin-1-yl 3-methoxyphenyl
    98 piperazin-1-yl 3-methoxyphenyl
    99 4-methylpiperazin-1-yl 3-methoxyphenyl
    100 morpholin-4-yl 3-methoxyphenyl
    101 pyrrolidin-1-yl 3-ethylphenyl
    102 pyrrolin-1-yl 3-ethylphenyl
    103 imidazolidin-1-yl 3-ethylphenyl
    104 imidazolin-1-yl 3-ethylphenyl
    105 pyrazolidin-1-yl 3-ethylphenyl
    106 pyrazolin-1-yl 3-ethylphenyl
    107 piperidin-1-yl 3-ethylphenyl
    108 piperazin-1-yl 3-ethylphenyl
    109 4-methylpiperazin-1-yl 3-ethylphenyl
    110 morpholin-4-yl 3-ethylphenyl
    111 pyrrolidin-1-yl 3-isopropylphenyl
    112 pyrrolin-1-yl 3-isopropylphenyl
    113 imidazolidin-1-yl 3-isopropylphenyl
    114 imidazolin-1-yl 3-isopropylphenyl
    115 pyrazolidin-1-yl 3-isopropylphenyl
    116 pyrazolin-1-yl 3-isopropylphenyl
    117 piperidin-1-yl 3-isopropylphenyl
    118 piperazin-1-yl 3-isopropylphenyl
    119 4-methylpiperazin-1-yl 3-isopropylphenyl
    120 morpholin-4-yl 3-isopropylphenyl
  • The compounds which comprise Category I of the present invention can be prepared by the procedure outlined herein below in Scheme I.
    Figure US20070293494A1-20071220-C00024
    Figure US20070293494A1-20071220-C00025
    • EXAMPLE 1 N2-(3-chlorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (4)
  • Preparation of 2-(methylthio)pyrimidine-4(3H-one (1): To a solution of sodium hydroxide (6.24 g, 156.07 mmol) in H2O (55 mL) at room temperature is added thiouridine (10 g, 78.03 mmol). The resulting mixture is stirred at room temperature for 20 min. Methyl iodide (5.45 mL, 87.40 mmol) in THF (10 mL) is added dropwise slowly and the mixture is stirred at room temperature for 18 hours. A white solid forms upon acidifying the mixture to pH 5 with glacial acetic acid. The mixture is allowed to stand at 0° C. (ice bath) for 2 hours and filtered to afford 7.4 g (67% yield) of the desired compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 2.45 (s, 3H), 6.07 (d, J=6.6 Hz, 1H), 7.85 (d, J=6.6 Hz, 1H).
  • Preparation of 2-(3-chlorophenylamino)pyrimidin-4(3H)-one (2): To 2-(methyl-thio)pyrimidine-4(3H)-one, 1, (4.88 g, 34.37 mmol) in diglyme (20 mL) is added 3-chloroaniline (4.3 mL, 68.74 mmol). The resulting mixture is heated to reflux and stirred for 18 hours. A solid forms upon cooling the mixture to room temperature. The solid is washed with hexanes to afford 5.0 g (66% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 5.91 (d, J=5.7 Hz, 2H), 7.05 (d, J=7.5 Hz, 1H), 7.11 (br s, 1H), 7.32 (t, J=7.8, 15.9 Hz, 1H), 7.45 (d, J=7.8 Hz, 1H), 7.86 (d, J=4.5 Hz, 1H), 7.94 (s, 1H).
  • Preparation of 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine (3): To a 2-(substituted or unsubstituted phenylamino)pyrimidin-4(3H)-one (3.00 g, 13.5 mmol) in toluene (30 mL) is added N,N-dimethyl-aniline (3.57 mL, 28.4 mmol) and phosphorus oxychloride (1.24 mL, 13.5 mmol). The resulting mixture is heated to reflux for 15 minutes, cooled to room temperature and neutralized to pH 7 with 1M NaOH (aqueous). The organic layer is extracted with EtOAc (3×250 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue is purified over silica (5% EtOAc in hexanes) to afford 2.0 g (61% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 7.06-7.04 (m, 2H), 7.34 (t, J=8.1, 1H), 7.65-7.61 (m, 1H), 7.93 (m, 1H), 8.50 (d, J=5.1 Hz, 1H), 10.26 (s, 1H).
  • Preparation of N2-(3-chlorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (4): To 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine, 3, (0.2 g, 0.84 mmol) in THF (4 mL) is added diisopropylethylamine (0.29 mL, 1.67 mmol) followed by 3-morpholino-propylamine (0.245 mL, 1.67 mmol). The resulting mixture was heated to reflux for 6 hours. Another 2 equivalents of 3-morpholinopropylamine (0.245 mL, 1.67 mmol) is added and the reaction heated to reflux and stirred for 18 hours. The resulting mixture is heated to reflux for 18 hours. The reaction is cooled to room temperature and concentrated in vacuo. The residue is diluted with 5 mL water and extracted with EtOAc (3×25 ml). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue is diluted with 5 mL water and extracted with EtOAc (3×25 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. This residue is purified over silica (6% MeOH in CH2Cl2 with 0.7% Et3N) to afford 0.120 g (41% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 1.68-1.75 (m, 2H), 2.34-2.40 (m, 6H), 3.30-3.35 (m, 2H), 3.55-3.58 (m, 4H), 5.97 (d, J=5.7 Hz, 1H), 6.88 (d, J=7.2 Hz, 1H), 7.19-7.28 (m, 2H), 7.59 (d, J=7.2 Hz, 1H), 7.80 (br s, 1H), 8.13 (br s, 1H), 9.19 (br s, 1H). MS (ESI, pos. ion) m/z: 348 (M+1).
  • The following are non-limiting examples of compounds which comprise first aspect of Category I of the present invention, the characterization of which will assist the formulator in establishing the chemical formulae of compounds which are not specifically exemplified herein. Alternatively, these compounds may also be synthesized by the synthetic route or methods described later in Scheme II.
  • N2-(3-Fluorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: 1H NMR (CDCl3, 300 MHz) δ 1.83 (q, J=6.3 Hz, 2H), 2.47-2.57 (m, 6H), 3.47 (bs, 2H), 3.78 (t, J=4.8 Hz, 1H), 5.88 (d, J=6.0 Hz, 1H), 6.68 (tt, J=3.3, 1.0 Hz, 1H), 7.12 (d, J=8.1 Hz, 1H), 7.20 (t, J=6.3 Hz, 1H), 7.70 (bs, 1H), 7.81 (dt, J=12.0, 2.4 Hz, 1H), 7.96 (d, J=5.4 Hz, 1H); HRMS calcd for C17H22FN5O, 332.1887 nm z (M+H)+; observed 332.1887 m/z.
  • N2-(3-Nitrophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine. Yield 96 mg (66%) 1H NMR (CDCl3, 300 MHz): δ 1.87 (m, 2H), 2.54 (m, 6H), 3.59 (s, 2H), 3.77 (t, J=4.5 Hz, 4H), 5.94 (d, J=6.0 Hz, 1H), 6.37 (m, 1H), 7.42 (t, J=8.1 Hz, 1H), 7.67 (m, 1H), 7.81 (m, 1H), 7.91 (s, 1H), 7.97 (d, J=5.1 Hz, 1H). HRMS calcd for C17H22N6O3, 343.1882 m/z (M+H)+; observed 343.1895 m/z.
  • N2-(3-Bromophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine. 1H NMR (CDCl3, 300 MHz): δ 1.84 (m, 2H), 2.53 (m, 6H), 3.49 (bs, 2H), 3.78 (t, J=4.8 Hz, 4H), 5.88 (d, J=6.0 Hz, 1H), 6.318 (bs, 1H), 7.13 (m, 3H), 7.38 (d, J=7.2 Hz, 1H), 7.94 (d, J=4.8 Hz, 1H), 8.12 (s, 1H). HRMS calcd for C17H22N5OBr, 392.1086 m/z (M+H)+; observed 392.1090 m/z.
  • N2-(3-Aminophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine. 1H NMR (CDCl3, 300 MHz): δ 1.83 (m, 2H), 2.52 (m, 6H), 3.45 (m, 2H), 3.71 (bs, 2H), 3.79 (t, J=4.5 Hz, 4H), 5.83 (d, J=6.0 Hz, 1H), 6.12 (bs, 1H), 6.35 (m, 1H), 6.87 (s, 1H), 6.94 (m, 1H), 7.09 (t, J=8.1 Hz, 1H), 7.19 (t J=2.4 Hz, 1H), 7.93 (d, J=6.0 Hz, 1H). HRMS calcd for C17H24N6O, 329.2090 m/z (M+H)+; observed 329.2085 m/z.
  • {3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-methanol: 1H NMR (CDCl3, 300 MHz) δ 1.72 (q, J=7.2 Hz, 2H), 2.30-2.41 (m, 6H), 3.30-3.38 (m, 2H), 3.58 (t, J=4.5 Hz, 4H), 4.45 (d, J=4.8 Hz, 2H), 5.10 (t, J=5.7 Hz, 1H), 5.92 (d, J=5.7 Hz, 1H), 6.83 (d, J=7.5 Hz, 1H), 7.16 (t, J=7.8 Hz, 2H), 762 (d, J=7.2 Hz, 1H), 7.80 (bs, 2H), 8.90 (s, 1H); HRMS calcd for C18H25N5O2, 344.2087 m/z (M+H)+; observed 344.2084 m/z.
  • N2-(3-Phenoxyphenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine. 1H NMR (DMSO-d6, 300 MHz): δ 1.62 (m, 2H), 2.31 (m, 6H), 2.52 (s, 2H), 3.56 (m, 4H), 5.92 (d, J=5.7 Hz, 1H), 6.51 (d, J=8.1 Hz, 1H), 6.99 (d, J=8.1 Hz, 2H), 7.10 (t, J=8.1 Hz, 1H), 7.21 (m, 2H), 7.37 (m, 2H), 7.80 (m, 1H), 9.10 (bs, 1H). HRMS calcd for C23H27N5O2, 406.2243 m/z (M+H)+; observed 406.2252 m/z.
  • N2-(3-Chlorophenyl)-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine: 1H NMR (DMSO-d6, 300 MHz): δ 1.65-1.74 (m, 2H), 2.14 (s, 3H), 2.30-2.38 (m, 10H), 3.32-3.34 (m, 2H), 5.97 (d, J=5.7 Hz, 1H), 6.88 (d, J=7.8 Hz, 1H), 7.2 (t J=8.1 Hz, 1H), 7.28 (hr s, 1H), 7.69 (d, J=8.1 Hz, 1H), 7.80 (hr s, 1H), 8.12 (br S, 1H), 9.19 (s, 1H). MS (ESI, pos. ion) m/z: 361 (M+1).
  • N2-(4-(Benzyloxy)-3-chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine. Yield 118 mg (46%) 1H NMR (CDCl3, 300 MHz): δ 189 (m, 6H), 2.64 (m, 4H), 2.70 (t, J=6.6 Hz, 2H), 3.49 (m, 2H), 5.15 (s, 2H), 5.84 (d, J=5.7 Hz, 1H), 6.20 (s, 1H), 7.25 (m, 1H), 7.41 (m, 3H), 7.49 (m, 2H), 7.90 (m, 2H). HRS calcd for C24H28N5OCl, 438.2061 m/z (M+H)+; observed 438.2077 m/z.
  • N2-(3-Nitrophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine. 1H NMR (DMSO-d6, 300 MHz): δ 1.87 (m, 2H), 2.01 (m, 4H), 3.00 (m, 2H), 3.22 (m, 2H), 3.55 (m, 4H), 6.29 (d, J=6.6 Hz, 1H), 7.68 (t, J=8.4 Hz, 1H), 7.86 (d, J=7.2 Hz, 1H), 7.968 (m, 2H), 8.98 (s, 1H). HRMS calcd for C17H22N6O2, 343.1882 m/z (M+H)+; observed 343.1895 #/Z.
  • N2-(3-Chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine. 1H NMR (DMSO-d6, 300 MHz): δ 1.71 (m, 6H), 2.50 (m, 6H), 3.37 (m, 3H), 5.98 (d, J=5.7 Hz, 1H), 6.90 (d, J=9.0 Hz, 1H), 7.22 (t, J=8.1 Hz, 1H), 7.30 (s, 1H), 7.61 (d, J=8.1 Hz, 1H), 8.15 (s, 1H), 9.2 (s, 1H). HRMS calcd for C17H22N5Cl, 332.1642 m/z (M+H)+; observed 332.1655 m/z.
  • N2-(3-Methylphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine: 1H NMR (DMSO-d6, 300 MHz) δ 1.78-2.06 (m, 6H), 2.35 (s, 3H), 2.85-3.00 (m, 2H), 3.10-3.18 (m, 2H), 3.40-3.55 (m, 4H), 6.27 (d, J=7.5 Hz, 1H), 7.02 (d, J=7.2 Hz, 1H), 7.32 (t, J=7.5 Hz, 1H), 7.37-7.42 (m, 2H), 7.84 (d, J=7.2 Hz, 1H), 9.34 (bs, 1H), 10.59 (s, 1H), 10.77 (bs, 1H); HRMS calcd for C18H27N5Cl, 312.2188 m/z (M+H)+; observed 312.2191 m/z.
  • N2-[3-Methoxyphenyl]-NJ-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine: 1H NMR (DMSO-d6, 300 MHz) δ 1.80-2.10 (m, 6H), 2.87-3.02 (m, 2H), 3.10-3.20 (m, 2H), 3.40-3.55 (m, 4H), 3.79 (s, 3H), 6.27 (d, J=7.2 Hz, 1H), 6.76 (d, J=8.1 Hz, 1H), 7.12 (d, J=8.4 Hz, 1H), 7.28-7.34 (m, 2H), 7.85 (d, J=7.2 Hz, 1H), 9.29 (bs, 1H), 10.60 (s, 1H), 10.78 (bs, 1H); HRMS calcd for C18H25N5O, 328.2137 m/z (M+H)+; observed 328.2149 m/z.
  • N2-[3-Trifluoromethyl-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine 1H NMR (DMSO-d6, 300 MHz) δ 1.77-2.04 (m, 6H), 2.83-3.00 (m, 2H), 3.03-3.20 (m, 2H), 3.31-3.70 (m, 4H), 6.32 (d, J=6.3 Hz, 1H), 7.50 (d, J=7.2 Hz, 1H), 7.65 (t, J=6.6 Hz, 1H), 7.8 (d, J=7.0 Hz, 1H), 7.89 (d, J=7.0 Hz, 1H), 8.15 (s, 1H), 9.40 (bs, 1H), 10.73 (bs, 1H), 11.00 (s, 1H); HRMS calcd for C18H24N5F3Cl, 366.1906 m/z (M+H)+; observed 366.1906 m/z.
  • N2-(3-Chlorophenyl)-N4-[3-(1-methylpiperidin-4-yl)-methyl]-pyrimidine-2,4-diamine hydrochloride. 1H NMR (CD3OD, 300 MHz): δ 1.53-1.58 (m, 2H), 2.04-2.09 (m, 3H), 2.87 (s, 3H), 2.98-3.05 (m, 2H), 3.46-3.59 (m, 4H), 6.31 (d, 1H, J=7.2 Hz), 7.27-7.48 (m, 3H), 7.25 (d, 1H, J=7.2 Hz), 7.83 (s, 1H). MS (ESI, pos. ion) m/z: 332 (M+1).
  • N2-(3-Isopropylphenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: 1H NMR (CDCl3, 300 MHz): δ (ppm) 1.20 (d, J=2.1 Hz, 3H), 1.22 (d, J=2.1 Hz, 3H), 1.69-1.77 (m, 2H), 2.34-2.37 (m, 6H), 2.78-2.85 (m, 1H), 3.34 (m, 2H), 3.55-3.58 (m, 4H), 5.91 (d, J=6.0 Hz, 1H), 6.75 (d, J=7.8 Hz, 1H), 7.09-7.15 (m, 2H), 7.53 (bs, 1H), 7.77 (bs, 2H), 8.84 (s, 1H). HRMS calcd for C20H29N5O, 356.2450, m/z (M+H)+; observed 356.2463 m/z.
  • N2-(3,5-Bis-trifluoromethyl-phenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: 1H NMR (CD3OD, 300 MHz) δ 2.12-2.22 (m, 2H), 3.13-3.27 (m, 4H), 3.49 (d, J=12.3 Hz, 2H), 3.65 (t, J=6.3 Hz, 2H), 3.83 (t, J=12.3 Hz, 2H), 4.07 (d, J=12.3 Hz, 2H), 6.43 (d, J=7.2 Hz, 1H), 7.83 (d, J=7.2 Hz, 1H), 7.85 (s, 1H), 8.32 (s, 2H); HRMS calcd for C19H21F6N5O, 450.1729 m/z (M+H)+; observed 450.1743 m/z.
  • N4-(3-Morpholin-4-yl-propyl)-N2-(3-trifluoromethoxy-phenyl)-pyrimidine-2,4-diamine: MS (ESI, pos. ion) m/z: 398 (M+1).
  • N4-(3-Morpholin-4-yl-propyl)-N2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-pyrimidine-2,4-diamine: MS (ESI, pos. ion) m/z: 430 (M+1).
  • Further compounds which are encompassed within the first aspect of Category I of the present invention but which are not fully exemplified include:
    • N2-(3-Chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Chlorophenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Chlorophenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Chlorophenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Chlorophenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Fluorophenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methylphenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Methoxyphenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Trifluoromethylphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Trifluoromethylphenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Trifluoromethylphenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Trifluoromethylphenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Trifluoromethylphenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3-Trifluoromethylphenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine; and
    • N2-(3-Trifluoromethylphenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine.
  • The compounds which comprise the second aspect of Category I of the present invention are 2,4-di-aminopyrimidines having the formula:
    Figure US20070293494A1-20071220-C00026
    wherein R1 units are substituted by one or more R5 units chosen from:
      • x) substituted or unsubstituted C3-C9 heteroaryl units;
  • which are further exemplified herein below in Table II.
    TABLE II
    No R R1
    121 pyrrolidin-1-yl 2-(pyridin-2-yl)phenyl
    122 pyrrolin-1-yl 2-(pyridin-2-yl)phenyl
    123 imidazolin-1-yl 2-(pyridin-2-yl)phenyl
    124 imidazolin-1-yl 2-(pyridin-2-yl)phenyl
    125 pyrazolidin-1-yl 2-(pyridin-2-yl)phenyl
    126 pyrazolin-1-yl 2-(pyridin-2-yl)phenyl
    127 piperidin-1-yl 2-(pyridin-2-yl)phenyl
    128 piperazin-1-yl 2-(pyridin-2-yl)phenyl
    129 4-methylpiperazin-1-yl 2-(pyridin-2-yl)phenyl
    130 morpholin-4-yl 2-(pyridin-2-yl)phenyl
    131 pyrrolidin-1-yl 2-(pyridin-3-yl)phenyl
    132 pyrrolin-1-yl 2-(pyridin-3-yl)phenyl
    133 imidazolidin-1-yl 2-(pyridin-3-yl)phenyl
    134 imidazolin-1-yl 2-(pyridin-3-yl)phenyl
    135 pyrazolidin-1-yl 2-(pyridin-3-yl)phenyl
    136 pyrazolin-1-yl 2-(pyridin-3-yl)phenyl
    137 piperidin-1-yl 2-(pyridin-3-yl)phenyl
    138 piperazin-1-yl 2-(pyridin-3-yl)phenyl
    139 4-methylpiperazin-1-yl 2-(pyridin-3-yl)phenyl
    140 morpholin-4-yl 2-(pyridin-4-yl)phenyl
    141 pyrrolidin-1-yl 2-(pyridin-4-yl)phenyl
    142 pyrrolin-1-yl 2-(pyridin-4-yl)phenyl
    143 imidazolidin-1-yl 2-(pyridin-4-yl)phenyl
    144 imidazolin-1-yl 2-(pyridin-4-yl)phenyl
    145 pyrazolidin-1-yl 2-(pyridin-4-yl)phenyl
    146 pyrazolin-1-yl 2-(pyridin-4-yl)phenyl
    147 piperidin-1-yl 2-(pyridin-4-yl)phenyl
    148 piperazin-1-yl 2-(pyridin-4-yl)phenyl
    149 4-methylpiperazin-1-yl 2-(pyridin-4-yl)phenyl
    150 morpholin-4-yl 2-(pyridin-4-yl)phenyl
    151 pyrrolidin-1-yl 3-(pyridin-2-yl)phenyl
    152 pyrrolin-1-yl 3-(pyridin-2-yl)phenyl
    153 imidazolidin-1-yl 3-(pyridin-2-yl)phenyl
    154 imidazolin-1-yl 3-(pyridin-2-yl)phenyl
    155 pyrazolidin-1-yl 3-(pyridin-2-yl)phenyl
    156 pyrazolin-1-yl 3-(pyridin-2-yl)phenyl
    157 piperidin-1-yl 3-(pyridin-2-yl)phenyl
    158 piperazin-1-yl 3-(pyridin-2-yl)phenyl
    159 4-methylpiperazin-1-yl 3-(pyridin-2-yl)phenyl
    160 morpholin-4-yl 3-(pyridin-2-yl)phenyl
    161 pyrrolidin-1-yl 3-(pyridin-3-yl)phenyl
    162 pyrrolin-1-yl 3-(pyridin-3-yl)phenyl
    163 imidazolidin-1-yl 3-(pyridin-3-yl)phenyl
    164 imidazolin-1-yl 3-(pyridin-3-yl)phenyl
    165 pyrazolidin-1-yl 3-(pyridin-3-yl)phenyl
    166 pyrazolin-1-yl 3-(pyridin-3-yl)phenyl
    167 piperidin-1-yl 3-(pyridin-3-yl)phenyl
    168 piperazin-1-yl 3-(pyridin-3-yl)phenyl
    169 4-methylpiperazin-1-yl 3-(pyridin-3-yl)phenyl
    170 morpholin-4-yl 3-(pyridin-4-yl)phenyl
    171 pyrrolidin-1-yl 3-(pyridin-4-yl)phenyl
    172 pyrrolin-1-yl 3-(pyridin-4-yl)phenyl
    173 imidazolidin-1-yl 3-(pyridin-4-yl)phenyl
    174 imidazolin-1-yl 3-(pyridin-4-yl)phenyl
    175 pyrazolidin-1-yl 3-(pyridin-4-yl)phenyl
    176 pyrazolin-1-yl 3-(pyridin-4-yl)phenyl
    177 piperidin-1-yl 3-(pyridin-4-yl)phenyl
    178 piperazin-1-yl 3-(pyridin-4-yl)phenyl
    179 4-methylpiperazin-1-yl 3-(pyridin-4-yl)phenyl
    180 morpholin-4-yl 3-(pyridin-4-yl)phenyl
    181 pyrrolidin-1-yl 4-(pyridin-2-yl)phenyl
    182 pyrrolin-1-yl 4-(pyridin-2-yl)phenyl
    183 imidazolidin-1-yl 4-(pyridin-2-yl)phenyl
    184 imidazolin-1-yl 4-(pyridin-2-yl)phenyl
    185 pyrazolidin-1-yl 4-(pyridin-2-yl)phenyl
    186 pyrazolin-1-yl 4-(pyridin-2-yl)phenyl
    187 piperidin-1-yl 4-(pyridin-2-yl)phenyl
    188 piperazin-1-yl 4-(pyridin-2-yl)phenyl
    189 4-methylpiperazin-1-yl 4-(pyridin-2-yl)phenyl
    190 morpholin-4-yl 4-(pyridin-2-yl)phenyl
    191 pyrrolidin-1-yl 4-(pyridin-3-yl)phenyl
    192 pyrrolin-1-yl 4-(pyridin-3-yl)phenyl
    193 imidazolidin-1-yl 4-(pyridin-3-yl)phenyl
    194 imidazolin-1-yl 4-(pyridin-3-yl)phenyl
    195 pyrazolidin-1-yl 4-(pyridin-3-yl)phenyl
    196 pyrazolin-1-yl 4-(pyridin-3-yl)phenyl
    197 piperidin-1-yl 4-(pyridin-3-yl)phenyl
    198 piperazin-1-yl 4-(pyridin-3-yl)phenyl
    199 4-methylpiperazin-1-yl 4-(pyridin-3-yl)phenyl
    200 morpholin-4-yl 4-(pyridin-4-yl)phenyl
    201 pyrrolidin-1-yl 4-(pyridin-4-yl)phenyl
    202 pyrrolin-1-yl 4-(pyridin-4-yl)phenyl
    203 imidazolidin-1-yl 4-(pyridin-4-yl)phenyl
    204 imidazolin-1-yl 4-(pyridin-4-yl)phenyl
    205 pyrazolidin-1-yl 4-(pyridin-4-yl)phenyl
    206 pyrazolin-1-yl 4-(pyridin-4-yl)phenyl
    207 piperidin-1-yl 4-(pyridin-4-yl)phenyl
    208 piperazin-1-yl 4-(pyridin-4-yl)phenyl
    209 4-methylpiperazin-1-yl 4-(pyridin-4-yl)phenyl
    210 morpholin-4-yl 4-(pyridin-4-yl)phenyl
    211 pyrrolidin-1-yl 3-(pyrimidin-2-yl)phenyl
    212 pyrrolin-1-yl 3-(pyrimidin-2-yl)phenyl
    213 imidazolidin-1-yl 3-(pyrimidin-2-yl)phenyl
    214 imidazolin-1-yl 3-(pyrimidin-2-yl)phenyl
    215 pyrazolidin-1-yl 3-(pyrimidin-2-yl)phenyl
    216 pyrazolin-1-yl 3-(pyrimidin-2-yl)phenyl
    217 piperidin-1-yl 3-(pyrimidin-2-yl)phenyl
    218 piperazin-1-yl 3-(pyrimidin-2-yl)phenyl
    219 4-methylpiperazin-1-yl 3-(pyrimidin-2-yl)phenyl
    220 morpholin-4-yl 3-(pyrimidin-2-yl)phenyl
    221 pyrrolidin-1-yl 3-(pyrimidin-3-yl)phenyl
    222 pyrrolin-1-yl 3-(pyrimidin-3-yl)phenyl
    223 imidazolidin-1-yl 3-(pyrimidin-3-yl)phenyl
    224 imidazolin-1-yl 3-(pyrimidin-3-yl)phenyl
    225 pyrazolidin-1-yl 3-(pyrimidin-3-yl)phenyl
    226 pyrazolin-1-yl 3-(pyrimidin-3-yl)phenyl
    227 piperidin-1-yl 3-(pyrimidin-3-yl)phenyl
    228 piperazin-1-yl 3-(pyrimidin-3-yl)phenyl
    229 4-methylpiperazin-1-yl 3-(pyrimidin-3-yl)phenyl
    230 morpholin-4-yl 3-(pyrimidin-4-yl)phenyl
    231 pyrrolidin-1-yl 3-(pyrimidin-4-yl)phenyl
    232 pyrrolin-1-yl 3-(pyrimidin-4-yl)phenyl
    233 imidazolidin-1-yl 3-(pyrimidin-4-yl)phenyl
    234 imidazolin-1-yl 3-(pyrimidin-4-yl)phenyl
    235 pyrazolidin-1-yl 3-(pyrimidin-4-yl)phenyl
    236 pyrazolin-1-yl 3-(pyrimidin-4-yl)phenyl
    237 piperidin-1-yl 3-(pyrimidin-4-yl)phenyl
    238 piperazin-1-yl 3-(pyrimidin-4-yl)phenyl
    239 4-methylpiperazin-1-yl 3-(pyrimidin-4-yl)phenyl
    240 morpholin-4-yl 3-(pyrimidin-4-yl)phenyl
  • The compounds which comprise the second aspect of Category I of the present invention can be prepared by the procedure outlined herein below in Scheme II and Example 2.
    Figure US20070293494A1-20071220-C00027
    Figure US20070293494A1-20071220-C00028
    • EXAMPLE 2 N2-[3-(Pyridin-3-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (7)
  • Preparation of 2-chloro-N-(3-morpholinopropyl)pyrimidin-4-amine (5): To 2,4-dichloropyrimidine (5.0 g, 33.5 mmol), diisoproylethylamine (5.85 ml, 33.5 mmol) in 50 ml of a 1:1 mixture of n-butanol and water is added 3-morpholinopropan-1-amine (4.90 ml, 33.5 mmol). The resulting mixture was stirred for 18 hours at room temperature. The mixture is then concentrated in vacuo, diluted with 30 mL water and extracted with EtOAc (3×50 ml). Combined organic layers are washed with saturated NaHCO3 (2×20 ml) and saturated NaCl (2×20 ml), then dried over magnesium sulfate. The residue is purified over silica (25% EtOAc in Hexanes) to afford 4.5 g (51% yield) of the desired product. 1H NMR (CDCl3, 300 MHz): δ (ppm) 1.83 (q, J=2.0 Hz, 2H), 2.54 (m, 6H), 3.53 (bs, 2H), 3.79 (t J=4.7 Hz, 4H), 6.24 (d, J=5.67 Hz, 1H), 6.92 (bs, 1H), 7.99 (bs, 1H). MS (ESI, pos. ion) m/z: 257 (M+1).
  • Preparation of 3-(pyridin-3-yl)benzenamine (6): To 3-bromoaniline (513.1 mg, 2.983 mmol) was added ethanol/toluene (1:1, 20 mL), 3-pyridinylboronic acid (397.3 mg, 3.232 mmol), sodium carbonate (1.85 g, 17.45 mmol) in 9 mL water, and tetrakis(triphenylphosphine)palladium (504.3 mg, 0.439 mmol). The resulting mixture is heated to 80° C. and stirred for 16 h. The reaction mixture is cooled, diluted with 10 mL of water and extracted with EtOAc (3×25 ml). The organics were combined and, washed with 10 mL of water and saturated aqueous NaCl (2×10 mL), then dried over magnesium sulfate and concentrated in vacuo to a brown oil. The oil is purified over silica (0-5% MeOH in CH2Cl2) to afford 345 mg (68% yield) of the desired compound. MS (ESI, pos. ion) m/z: 171 (M+1).
  • Preparation of N2-(3-(pyridin-3-yl)-phenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2, 4-diamine(7): To 2-chloro-N-(3-morpholinopropyl)pyrimidin-4-amine,5, (105.7 mg, 0.4117 mmol) in 3 mL of EtOH/water (1:1) is added 3-(pyridin-3-yl)benzenamine (84.0 mg, 0.4941 mmol) and 2 drops concentrated HCl. The resulting mixture is heated to 80° C. with stirring for 3 days. The reaction mixture is cooled to room temperature and concentrated in vacuo. The product was diluted with 5 mL of aqueous saturated sodium bicarbonate solution and extracted with EtOAc (3×10 ml). The combined organics are washed with 20 ml water and saturated aqueous NaCl (2×10 ml), then dried over magnesium sulfate and concentrated in vacuo. The residue is purified over silica (5-8% MeOH in CH2Cl2) to afford 61 mg (38% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 1.63-1.77 (m, 2H), 2.20-2.40 (m, 6H), 3.30-3.47 (m, 2H), 3.54 (t, J=4.2 Hz, 4H), 5.96 (d, J=5.4 Hz, 1H), 7.12-7.28 (m, 2H), 7.36 (t, J=7.8 Hz, 1H), 7.50 (dd, J=4.8, 7.8 Hz, 1H), 7.78 (bs, 1H), 7.82 (d, J=7.8 Hz, 1H), 8.01 (d, J=7.8 Hz, 1H), 8.29 (bs, 1H), 8.58 (d, J=4.8 Hz, 1H), 8.85 (s, 1H), 9.10 (s, 1H). HRMS calcd for C22H2(N6O, 391.2246 m/z (M+H)+; observed 391.2242 m/z.
  • The following are non-limiting examples of compounds which comprise the second aspect of Category I of the present invention, the characterization of which will assist the formulator in establishing the chemical formulae of compounds which are not specifically exemplified herein. Alternatively, these compounds may also be synthesized by the synthetic route or methods described earlier in Scheme I.
  • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2, 4-diamine. 1H NMR (DMSO-d6, 300 MHz): δ 1.71-1.76 (m, 2H), 2.25-2.34 (m, 6H), 2.52 (s, 2H), 3.51 (m, 4H), 6.00 (d, J=6.0 Hz, 1H), 7.29 (bs, 1H), 7.45 (m, 2H), 7.54 (m, 2H), 7.84 (m, 1H), 8.06 (d, J=8.1 Hz, 1H), 8.15 (d, J=7.5 Hz, 1H), 8.86 (bs, 1H), 9.28 (s, 1H). HRMS calcd for C24H26N6OS, 447.1967 m/z (M+H)+; observed 447.1976 m/z.
  • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: HRMS calcd for C25H28N6O, 429.2397 m/z (M−H)+; observed 429.2395 m/z.
  • N2-[3-(1H-Indol-4-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: HRMS calcd for C25H29N6O, 429.2397 m/z (M+1)+; observed 429.2406 m/z.
  • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: HRMS calcd for C22H27N6O, 391.2246 m/z (M+H)+; observed 391.2255 m/z.
  • N2-[3-(1H-Indol-6-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: HRMS calcd for C25H29N6O, 429.2403 m/z (M+H)+; observed 429.2412 m/z.
  • Further compounds which are encompassed within the second aspect of Category II of the present invention but which are not fully exemplified include:
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl)]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(H-Indol-3-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[3-(Pyridin-2-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2, 4-diamine;
    • N2-[3-(Pyridin-4-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2, 4-diamine;
    • N2-[3-(1H-Indol-2-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2, 4-diamine;
    • N2-[3-(1H-Indol-3-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2, 4-diamine; and
    • N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine.
  • The third aspect of Category I of the present invention are 2,4-di-amino-pyrimidines having the formula:
    Figure US20070293494A1-20071220-C00029
    wherein R1 phenyl units are substituted by one or more R5 units chosen from:
  • viii) substituted or unsubstituted phenyl;
  • which are exemplified herein below in Table III.
    TABLE III
    No R R1
    241 pyrrolidin-1-yl biphenyl-3-yl
    242 pyrrolin-1-yl biphenyl-3-yl
    243 imidazolidin-1-yl biphenyl-3-yl
    244 imidazolin-1-yl biphenyl-3-yl
    245 pyrazolidin-1-yl biphenyl-3-yl
    246 pyrazolin-1-yl biphenyl-3-yl
    247 piperidin-1-yl biphenyl-3-yl
    248 piperazin-1-yl biphenyl-3-yl
    249 4-methylpiperazin-1-yl biphenyl-3-yl
    250 morpholin-4-yl biphenyl-3-yl
    251 pyrrolidin-1-yl biphenyl-4-yl
    252 pyrrolin-1-yl biphenyl-4-yl
    253 imidazolidin-1-yl biphenyl-4-yl
    254 imidazolin-1-yl biphenyl-4-yl
    255 pyrazolidin-1-yl biphenyl-4-yl
    256 pyrazolin-1-yl biphenyl-4-yl
    257 piperidin-1-yl biphenyl-4-yl
    258 piperazin-1-yl biphenyl-4-yl
    259 4-methylpiperazin-1-yl biphenyl-4-yl
    260 morpholin-4-yl biphenyl-4-yl
    261 pyrrolidin-1-yl 4′-fluoro-biphenyl-3-yl
    262 pyrrolin-1-yl 4′-fluoro-biphenyl-3-yl
    263 imidazolidin-1-yl 4′-fluoro-biphenyl-3-yl
    264 imidazolin-1-yl 4′-fluoro-biphenyl-3-yl
    265 pyrazolidin-1-yl 4′-fluoro-biphenyl-3-yl
    266 pyrazolin-1-yl 4′-fluoro-biphenyl-3-yl
    267 piperidin-1-yl 4′-fluoro-biphenyl-3-yl
    268 piperazin-1-yl 4′-fluoro-biphenyl-3-yl
    269 4-methylpiperazin-1-yl 4′-fluoro-biphenyl-3-yl
    270 morpholin-4-yl 4′-fluoro-biphenyl-3-yl
    271 pyrrolidin-1-yl 4′-chloro-biphenyl-3-yl
    272 pyrrolin-1-yl 4′-chloro-biphenyl-3-yl
    273 imidazolidin-1-yl 4′-chloro-biphenyl-3-yl
    274 imidazolin-1-yl 4′-chloro-biphenyl-3-yl
    275 pyrazolidin-1-yl 4′-chloro-biphenyl-3-yl
    276 pyrazolin-1-yl 4′-chloro-biphenyl-3-yl
    277 piperidin-1-yl 4′-chloro-biphenyl-3-yl
    278 piperazin-1-yl 4′-chloro-biphenyl-3-yl
    279 4-methylpiperazin-1-yl 4′-chloro-biphenyl-3-yl
    280 morpholin-4-yl 4′-chloro-biphenyl-3-yl
  • Figure US20070293494A1-20071220-C00030
    Figure US20070293494A1-20071220-C00031
    • EXAMPLE 3 N2-Biphenyl-3-yl-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (10)
  • Preparation of 2-(3-biphenylamino)pyrimidin-4(3H)-one (8): To 2-(methylthio)-pyrimidine-4(3H)-one (790 mg, 5.5 mmol) in 5 mL of diglyme is added 3-amino-biphenyl (1.91 g, 11.2 mmol). The resulting mixture is stirred at reflux for 18 hours. The mixture is cooled to room temperature and hexanes are added to form a precipitate which is collected by filtration to afford 1.34 g (92% yield) of the desired compound which is used without purification. MS (ESI, pos. ion) m/z: 264 (M+1).
  • Preparation of 4-chloro-N-(3-biphenyl)pyrimidin-2-amine (9): To 2-(3-biphenyl-amino)pyrimidin-4(3H)-one (1.34 g, 5.0 mmol), and N,N-dimethylaniline (1.5 mL) is added 10 mL of phosphorus oxychloride. The resulting mixture is heated at reflux for 1 hour, cooled to room temperature and concentrated in vacuo. The residue is neutralized with 1M NaOH (aqueous). The organics are extracted t portions of EtOAc (2×50 mL). The combined organic layers are washed with brine, dried (MgSO4), and concentrated in vacuo. The residue is purified over silica (5% EtOAc in hexanes) to afford 780 mg (54% yield) of the desired compound. MS (ESI, pos. ion) m/z: 282 (M+1).
  • Preparation of N2-biphenyl-3-yl-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (10): To 4-chloro-N-(3-biphenyl)pyrimidin-2-amine (301.0 mg, 1.07 mmol) in 5 mL THF is added potassium carbonate (396 mg, 2.15 mmol) followed by 3-morpholinopropyl-amine (0.3 mL, 2.05 mmol). The resulting mixture is heated at reflux for 96 hours. The reaction is cooled to room temperature and concentrated in vacuo. The residue is diluted with 15 mL of water and extracted with EtOAc (3×20 mL). The combined organic layers are washed with water and brine, dried (MgSO4) and concentrated in vacuo. The crude product is purified over silica (5% MeOH in CH2Cl2) to afford 362 mg (87% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 1.69 (m, 2H), 2.26-2.32 (m, 6H), 3.38 (m, 2H), 3.54 (t, J=4.2 Hz, 4H), 5.95 (d, J=6.0 Hz, 1H), 7.15 (d, J=7.5 Hz, 1H), 7.21 (bs, 1H), 7.29-7.39 (m, 2H), 7.47 (t, J=8.1 Hz, 2H), 7.62 (d, J=8.1 Hz, 2H), 7.73 (bs, 1H), 7.81 (d, J=6.0 Hz, 1H), 8.23 (bs, 1H), 9.05 (s, 1H). MS (ESI, pos. ion) m/z: 390 (M+1).
  • The following are non-limiting examples of compounds which comprise the third aspect of Category I of the present invention, the characterization of which will assist the formulator in establishing the chemical formulae of compounds which are not specifically exemplified herein. Alternatively, these compounds may also be synthesized by the synthetic route or methods described earlier in Scheme 11.
  • N2-(3′-Nitrobiphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine. 1H NMR (CDCl3, 300 MHz) δ 1.80-1.88 (m, 2H), 2.52 (t, J=4.5 Hz, 4H), 2.55 (t, J=6.3 Hz, 2H), 3.56 (bs, 2H), 3.76 (t, J=45 Hz, 4H), 5.90 (d, J=6.0 Hz, 1H), 7.28 (d, J=7.8 Hz, 1H), 7.29 (s, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.47 (bs, 1H), 7.58 (bs, 1H), 7.64 (t, J=57.5 Hz, 1H), 7.93 (d, J=6.0 Hz, 1H), 7.97 (d, J=7.5 Hz, 1H), 8.15 (bs, 1H), 8.23 (d, J=7.5 Hz, 1H), 8.52 (bs, 1H); HRMS calcd for C23H26N6O3, 435.2145 m/z (M+H)+; observed 435.2125 m/z.
  • Further compounds which are encompassed within the third aspect of Category II of the present invention but which are not fully exemplified include:
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-3′-Nitro-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-dimethylamino-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-[(-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine; and
    • N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine.
  • The compounds which comprise Category II of the present invention are 2,4-di-aminopyrimidines having the formula:
    Figure US20070293494A1-20071220-C00032
    wherein R is a heterocyclic unit attached to the core scaffold by way of a nitrogen atom and R1 is a phenyl unit substituted by different category of R5 units having the formula:
    -L1-R6
  • and L1 and R6 are further defined herein below in Table IV.
    TABLE IV
    No R L1 R6
    281 pyrrolidin-1-yl —SO2NH— —H
    282 pyrrolin-1-yl —SO2NH— —H
    283 imidazolidin-1-yl —SO2NH— —H
    284 imidazolin-1-yl —SO2NH— —H
    285 pyrazolidin-1-yl —SO2NH— —H
    286 pyrazolin-1-yl —SO2NH— —H
    287 piperidin-1-yl —SO2NH— —H
    288 piperazin-1-yl —SO2NH— —H
    289 4-methylpiperazin-1-yl —SO2NH— —H
    290 morpholin-4-yl —SO2NH— —H
    291 pyrrolidin-1-yl —SO2NH— —CH3
    292 pyrrolin-1-yl —SO2NH— —CH3
    293 imidazolidin-1-yl —SO2NH— —CH3
    294 imidazolin-1-yl —SO2NH— —CH3
    295 pyrazolidin-1-yl —SO2NH— —CH3
    296 pyrazolin-1-yl —SO2NH— —CH3
    297 piperidin-1-yl —SO2NH— —CH3
    298 piperazin-1-yl —SO2NH— —CH3
    299 4-methylpiperazin-1-yl —SO2NH— —CH3
    300 morpholin-4-yl —SO2NH— —CH3
    301 pyrrolidin-1-yl —SO2NH— phenyl
    302 pyrrolin-1-yl —SO2NH— phenyl
    303 imidazolidin-1-yl —SO2NH— phenyl
    304 imidazolin-1-yl —SO2NH— phenyl
    305 pyrazolidin-1-yl —SO2NH— phenyl
    306 pyrazolin-1-yl —SO2NH— phenyl
    307 piperidin-1-yl —SO2NH— phenyl
    308 piperazin-1-yl —SO2NH— phenyl
    309 4-methylpiperazin-1-yl —SO2NH— phenyl
    310 morpholin-4-yl —SO2NH— phenyl
    311 pyrrolidin-1-yl —SO2NH— pyridin-3-yl
    312 pyrrolin-1-yl —SO2NH— pyridin-3-yl
    313 imidazolidin-1-yl —SO2NH— pyridin-3-yl
    314 imidazolin-1-yl —SO2NH— pyridin-3-yl
    315 pyrazolidin-1-yl —SO2NH— pyridin-3-yl
    316 pyrazolin-1-yl —SO2NH— pyridin-3-yl
    317 piperidin-1-yl —SO2NH— pyridin-3-yl
    318 piperazin-1-yl —SO2NH— pyridin-3-yl
    319 4-methylpiperazin-1-yl —SO2NH— pyridin-3-yl
    320 morpholin-4-yl —SO2NH— pyridin-3-yl
    321 pyrrolidin-1-yl —NHC(O)— phenyl
    322 pyrrolin-1-yl —NHC(O)— phenyl
    323 imidazolidin-1-yl —NHC(O)— phenyl
    324 imidazolin-1-yl —NHC(O)— phenyl
    325 pyrazolidin-1-yl —NHC(O)— phenyl
    326 pyrazolin-1-yl —NHC(O)— phenyl
    327 piperidin-1-yl —NHC(O)— phenyl
    328 piperazin-1-yl —NHC(O)— phenyl
    329 4-methylpiperazin-1-yl —NHC(O)— phenyl
    330 morpholin-4-yl —NHC(O)— phenyl
    331 pyrrolidin-1-yl —NHC(O)— pyridin-3-yl
    332 pyrrolin-1-yl —NHC(O)— pyridin-3-yl
    333 imidazolidin-1-yl —NHC(O)— pyridin-3-yl
    334 imidazolin-1-yl —NHC(O)— pyridin-3-yl
    335 pyrazolidin-1-yl —NHC(O)— pyridin-3-yl
    336 pyrazolin-1-yl —NHC(O)— pyridin-3-yl
    337 piperidin-1-yl —NHC(O)— pyridin-3-yl
    338 piperazin-1-yl —NHC(O)— pyridin-3-yl
    339 4-methylpiperazin-1-yl —NHC(O)— pyridin-3-yl
    340 morpholin-4-yl —NHC(O)— pyridin-3-yl
    341 pyrrolidin-1-yl —C(O)NH— pyridin-3-yl
    342 pyrrolin-1-yl —C(O)NH— pyridin-3-yl
    343 imidazolidin-1-yl —C(O)NH— pyridin-3-yl
    344 imidazolin-1-yl —C(O)NH— pyridin-3-yl
    345 pyrazolidin-1-yl —C(O)NH— pyridin-3-yl
    346 pyrazolin-1-yl —C(O)NH— pyridin-3-yl
    347 piperidin-1-yl —C(O)NH— pyridin-3-yl
    348 piperazin-1-yl —C(O)NH— pyridin-3-yl
    349 4-methylpiperazin-1-yl —C(O)NH— pyridin-3-yl
    350 morpholin-4-yl —C(O)NH— pyridin-3-yl
    351 pyrrolidin-1-yl —CH2CH2— pyridin-3-yl
    352 pyrrolin-1-yl —CH2CH2— pyridin-3-yl
    353 imidazolidin-1-yl —CH2CH2— pyridin-3-yl
    354 imidazolin-1-yl —CH2CH2— pyridin-3-yl
    355 pyrazolidin-1-yl —CH2CH2— pyridin-3-yl
    356 pyrazolin-1-yl —CH2CH2— pyridin-3-yl
    357 piperidin-1-yl —CH2CH2— pyridin-3-yl
    358 piperazin-1-yl —CH2CH2— pyridin-3-yl
    359 4-methylpiperazin-1-yl —CH2CH2— pyridin-3-yl
    360 morpholin-4-yl —CH2CH2— pyridin-3-yl
  • The compounds which comprise Category II of the present invention can be prepared by the procedure outlined herein below in Scheme IV and Example 4.
    Figure US20070293494A1-20071220-C00033
    Figure US20070293494A1-20071220-C00034
    • EXAMPLE 4 N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-benzenesulfonamide (14)
  • The intermediate, 3-amino-N-phenylbenzenesulfonamide (12), can be conveniently prepared by the following steps from aniline and 3-nitrobenzene-1-sulfonyl chloride. Other sulfonamide intermediates can be prepared in a like manner, the formulator making adjustments to the reaction conditions which are well known to those skilled in the art.
  • Preparation of 3-nitro-N-phenylbenzenesulfonamide (11): To 3-nitrobenzene-1-sulfonyl chloride (296.9 mg, 1.340 mmol) is added THF (20 mL), aniline (134.8 mg, 1.447 mmol) and potassium carbonate (408.5 mg, 2.955 mmol). The resulting mixture is heated at 50° C. for 16 hours. The reaction mixture is subsequently cooled and concentrated in vacuo after which the residue is treated with 10 ml of H2O and extracted with EtOAc (75 mL). The organic layer is washed with saturated aqueous NaCl (2×75 mL), dried (MgSO4), and concentrated in vacuo. The residue is purified over silica (CH2Cl2) to afford 257 mg (69% yield) of the desired compound. MS (ESI, pos. ion) m/z: 279 (M+1).
  • Preparation of 3-amino-N-phenylbenzenesulfonamide (12); To 3-nitro-N-phenylbenzenesulfonamide (255.5 mg, 0.919 mmol) in 4 mL of THF is added SnCl2 dihydrate (1.015 g, 4.486 mmol). The resulting mixture is heated in a microwave reactor at a power of 75 Watts and 135° C. for 1 min then at 15 Watts and 135° C. for 14 min. The reaction is cooled to room temperature, diluted with EtOAc (20 mL), washed with saturated aqueous NaHCO3 (10 ml) and allowed to stir for about 12 hours. The reaction mixture is then extracted with EtOAc (75 mL). The organic layer is washed with H2O (75 mL), saturated aqueous NaCl (2×75 mL), dried (MgSO4) and concentrated in vacuo to yield a yellow residue. This residue is purified over silica (0-4% MeOH in CH2Cl2) to afford 178 mg (78% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 5.57 (s, 2H), 6.69 (d, J=8.1 Hz, 1H), 6.84 (d, J=7.5 Hz, 1H), 6.95 (s, 1H), 6.99 (t, J=7.5 Hz, 1H), 7.07 (d, J=8.1 Hz, 2H), 7.12 (t, J=8.1 Hz, 1H), 7.21 (t, J=8.1 Hz, 2H), 10.12 (s, 1H). MS (ESI, pos. ion) m/z: 249 (M+1).
  • Preparation of 2-chloro-N-(3-morpholinopropyl)pyrimidin-4-amine (13): To 2,4-dichloropyrimidine (5.0 g, 33.5 mmol), diisopropylethylamine (5.85 ml, 33.5 mmol) in 50 mL of a 1:1 mixture of n-BuOH—H2O (1:1) is added 3-morpholinopropan-1-amine (4.90 mL, 33.5 mmol). The resulting mixture is stirred for 18 hours at room temperature. The mixture is then concentrated in vacuo, diluted with 30 mL H2O and extracted with EtOAc (3×75 mL). Combined organic layers are washed with saturated aqueous NaHCO3 (2×75 mL), saturated aqueous NaCl (2×75 mL), and dried (MgSO4). The residue is purified over silica (25% EtOAc in hexanes) to afford 4.5 g (53% yield) of the desired compound. 1H NMR (CDCl3, 300 MHz): δ 1.81 (m, 2H), 2.43-2.62 (m, 6H), 3.30 (m, 2H), 3.79-3.94 (m, 4H), 6.23 (d, J=5.4 Hz, 1H), 6.92 (bs, 1H), 7.99 (bs, 1H). MS (ESI, pos. ion) m/z: 257 (M+1).
  • Preparation of N-{3-[4-(3-morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-benzenesulfonamide (14): To 2-chloro-N-(3-morpholinopropylpyrimidin-4-amine, 13, (103.1 mg, 0.4016 mmol) in 30 mL of EtOH—H2O (1:1) is added 3-amino-N-phenylbenzenesulfonamide, 12, (116.5 mg, 0.4697 mmol) and 4 drops concentrated HCl. The resulting mixture is heated at 70° C. with sufficient stirring for 16 hours. The reaction mixture is then cooled to room temperature and concentrated in vacuo. The product is extracted with EtOAc (100 mL). The combined organic layers are washed with H2O (2×75 mL) and saturated aqueous NaCl (2×75 mL), dried (MgSO4), and concentrated in vacuo. The resulting residue is purified over silica (5-10% MeOH in CH2Cl2) to afford 157 mg (83% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz): δ 1.72 (m, 2H), 2.34-2.39, (m, 6H), 3.30-3.41 (m, 2H), 3.55-59 (m, 4H), 5.99 (d, J=5.7 Hz, 1H), 7.00 (t, J=7.5 Hz, 1H), 7.11 (d, J=7.5 Hz, 2H), 7.18-7.28 (m, 4H), 7.36 (t, J=7.8 Hz, 1H), 7.81 (bs, 2H), 8.56 (s, 1H), 9.33 (s, 1H), 10.24 (bs, 1H). HRMS calcd for C23H28N6O3, 469.2022 m/z (M+H)+; observed 469.2020 m/z.
  • The following are non-limiting examples of compounds which comprise Category II of the present invention, the characterization of which will assist the formulator in establishing the chemical formulae of compounds which are not specifically exemplified herein. Alternatively, these compounds may also be synthesized by the synthetic route or methods described earlier in Scheme 1.
  • N2-[3-(1H-Imidazol-1-ylmethyl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: 1H NMR (CDCl3, 30 MHz) δ 1.84 (q, J=6.3 Hz, 2H), 2.27-2.37 (m, 2H), 2.48-2.56 (m, 4H), 3.36-3.44 (m, 2H), 3.77 (t, J=4.5 Hz, 4H), 5.14 (s, 2H), 5.86 (d, J=6.0 Hz, 1H), 6.27 (bs, 1H), 6.80 (d, J=7.5 Hz, 1H), 6.96 (s, 1H), 7.11 (s, 1H), 7.24-7.31 (m, 2H), 7.45 (d, J=7.8 Hz, 1H), 7.60 (d, J=5.4 Hz, 2H), 7.90 (d, J=5.7 Hz, 1H); HRMS calcd for C21H27N7O, 394.2355 m/z (M+H)+; observed 394.2371 m/z.
  • 3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-N-(pyridin-3-ylmethyl)-benzenesulfonamide. 1H NMR (DMSO-d6, 300 MHz): δ 1.62-1.77 (m, 2H), 2.28-2.40 (m, 6H), 3.35-3.42 (m, 2H), 3.52-3.57 (m, 4H), 4.05 (d, J=5.4 Hz, 2H), 6.00 (d, J=5.4 Hz, 1H), 7.28-7.34 (m, 3H), 7.42 (t, J=7.8 Hz, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.75-7.95 (m, 2H), 8.15 (t, J=6.0 Hz, 1H), 8.44 (d, J=6.0 Hz, 1H), 8.45 (s, 1H), 8.59 (s, 1H), 9.33 (s, 1H). HRMS calcd for C23H29N7O3S, 484.2131 m/z (M+H)+; observed 484.2148 m/z.
  • N2-[3-(1H-Indol-2-ylmethyl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine.
  • 3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-benzenesulfonamide 1H NMR (DMSO-d6, 300 MHz) δ 2.01-2.12 (m, 2H), 2.96-3.12 (m, 2H), 3.14-3.19 (m, 2H), 3.36-3.43 (m, 2H), 3.48-3.56 (m, 2H), 3.79-4.10 (m, 4H), 6.32 (d, J=7.2 Hz, 1H), 7.49 (s, 2H), 7.58-7.65 (m, 3H), 7.92 (d, J=7.2 Hz, 1H), 8.49 (s, 1H), 9.34 (bs, 1H), 1.01 (s, 1H); HRMS calcd for C17H24N6O3S, 393.1709 m/z (M+n)+; observed 393.1719 m/z.
  • N-(3-Chlorophenyl)-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide: HRMS calcd for C24H27N6OCl, 451.2013 m/z (M+H)+; observed 451.2016 m/z.
  • N-(3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl)-benzamide 1H NMR (DMSO-d6, 300 MHz): 1.67 (m, 2H), 2.18-2.34 (m, 6H), 3.29-3.42 (m, 2H), 3.53 (t, J=4.5 Hz, 4H), 5.93 (d, J=5.7 Hz, 1H), 7.08-7.25 (m, 3H), 7.45 (bs, 1H), 7.50-7.59 (m, 3H), 7.74-7.85 (m, 1H), 7.96 (d, J=6.9 Hz, 2H), 8.29 (bs, 1H), 8.96 (s, 1H), 10.15 (s, 1H). HRMS calcd for C24H28N6O2, 433.2352 m/z (M+H)+; observed 433.2357 m/z.
  • N-Isopropyl-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide: HRMS calcd for C21H30N6O, 383.2559 m/z (M+H)+; observed 383.2564 m/z.
  • N2-[3-(4-Methyl-piperazine-1-sulfonyl)phenyl]-4-(3-morpholin-4-ylpropyl)-pyrimidine-2, 4-diamine. 1H NMR (DMSO-d6, 300 MHz): δ 1.67-1.78 (m, 2H), 2.15 (s, 3H), 2.28-2.45 (m, 10H), 2.85-2.98 (m, 4H), 3.32-3.47 (m, 2H), 3.58 (t, J=4.5 Hz, 4H), 6.08 (d, J=5.7 Hz, 1H), 7.19 (d, J=8.1 Hz, 1H), 7.30 (s, 1H), 7.49 (t, J=8.1 Hz, 1H), 7.83 (d, J=5.7 Hz, 1H), 7.92 (bs, 1H), 8.53 (s, 1H), 9.40 (s, 1H). HRMS calcd for, C22H33N7O3S 476.2444 m/z (M+H)+; observed 476.2449 m/z.
  • N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-nicotinamide. 1H NMR (DMSO-d6, 300 MHz): δ 1.62-1.73 (m, 2H), 2.20-2.33 (m, 6H), 3.29-3.40 (m, 2H), 3.53 (t, J=4.5 Hz, 4H), 5.93 (d, J=6.0 Hz, 1H), 7.08-7.24 (m, 3H), 7.46 (bs, 1H), 7.56 (dd, J=4.8, 8.1 Hz, 1H), 7.80 (d, J=6.0 Hz, 1H), 8.29 (d, J=8.1 Hz, 2H), 8.76 (d, J=4.8 Hz, 1H), 8.99 (s, 1H), 9.10 (s, 1H), 10.35 (s, 1H). HRMS calcd for C23H27N7O2, 434.2304 m/z (M+H)+; observed 434.2300 m/z.
  • N-(3-Chloro-phenyl)-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide: HRMS calcd for C24H28N6OCl, 451.2013 m/z (M+H)+; observed 451.2016 m/z.
  • N-Benzyl-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide: HRMS calcd for C25H13N6O, 431.2559 m/z (M+H)+; observed 431.2561 m/z.
  • 4-Dimethylamino-N-{3-[4-(3-morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-benzamide: HRMS calcd for C26H34N7O2, 476.2774 m/z (M+H)+; observed 476.2787 m/z.
  • 3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-N-phenyl-benzenesulfonamide: HRMS calcd for C23H29N6O3S, 469.2022 m/z (M+H)+; observed 469.2020 m/z.
  • 3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-N-(2-pyridin-3-yl-ethyl)-benzenesulfonamide: HRMS calcd for C24H32N7O3S, 498.2287 m/z (M+H)+; observed 498.2300 m/z.
  • N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-isonicotinamide: HRMS calcd for C23H28N7O2, 434.2304 m/z (M+H)+; observed 434.2317 m/z.
  • N2-[3-(Morpholine-4-sulfonyl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine: HRMS calcd for C21H31N6O4S, 463.2128 m/z (M+H)+; observed 463.2135 m/z.
  • The compounds which comprise Category III of the present invention are 2,4-di-aminopyrimidines having the formula:
    Figure US20070293494A1-20071220-C00035
    wherein R is a heterocyclic unit chosen from:
    Figure US20070293494A1-20071220-C00036
    wherein R2, R3, and R10 are each defined herein above. The first aspect of Category III relates to R1 units which are phenyl units substituted by one or more R5 units chosen from:
      • ii) halogen; —F, —CI, —Br, and —I;
      • iii) nitro; —NO2;
      • iv) hydroxy; —OH;
      • v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino; inter alia, —NH2, —NH(CH3), and —N(CH3)2,
      • vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
      • vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
  • which are further exemplified herein below in Table V and in the following examples.
    TABLE V
    No. L R R5
    361 —CH2— piperidine-2-yl 3-chloro
    362 —CH2— N-methylpiperidine-2-yl 3-chloro
    363 —CH2— piperidine-3-yl 3-chloro
    364 —CH2— N-methylpiperidine-3-yl 3-chloro
    365 —CH2— piperidine-4-yl 3-chloro
    366 —CH2— N-methylpiperidine-4-yl 3-chloro
    367 —CH2— pyrrolidin-2-yl 3-chloro
    368 —CH2— N-methylpyrrolidin-2-yl 3-chloro
    369 —CH2— pyrrolidin-3-yl 3-chloro
    370 —CH2— N-methylpyrrolidin-3-yl 3-chloro
    371 —CH2— morpholin-2-yl 3-chloro
    372 —CH2— morpholin-3-yl 3-chloro
    373 —CH2CH2— piperidine-2-yl 3-chloro
    374 —CH2CH2— N-methylpiperidine-2-yl 3-chloro
    375 —CH2CH2— piperidine-3-yl 3-chloro
    376 —CH2CH2— N-methylpiperidine-3-yl 3-chloro
    377 —CH2CH2— piperidine-4-yl 3-chloro
    378 —CH2CH2— N-methylpiperidine-4-yl 3-chloro
    379 —CH2CH2— pyrrolidin-2-yl 3-chloro
    380 —CH2CH2— N-methylpyrrolidin-2-yl 3-chloro
    381 —CH2CH2— pyrrolidin-3-yl 3-chloro
    382 —CH2CH2— N-methylpyrrolidin-3-yl 3-chloro
    383 —CH2CH2— morpholin-2-yl 3-chloro
    384 —CH2CH2— morpholin-3-yl 3-chloro
    385 —CH2— piperidine-2-yl 3-fluoro
    386 —CH2— N-methylpiperidine-2-yl 3-fluoro
    387 —CH2— piperidine-3-yl 3-fluoro
    388 —CH2— N-methylpiperidine-3-yl 3-fluoro
    389 —CH2— piperidine-4-yl 3-fluoro
    390 —CH2— N-methylpiperidine-4-yl 3-fluoro
    391 —CH2— pyrrolidin-2-yl 3-fluoro
    392 —CH2— N-methylpyrrolidin-2-yl 3-fluoro
    393 —CH2— pyrrolidin-3-yl 3-fluoro
    394 —CH2— N-methylpyrrolidin-3-yl 3-fluoro
    395 —CH2— morpholin-2-yl 3-fluoro
    396 —CH2— morpholin-3-yl 3-fluoro
    397 —CH2CH2— piperidine-2-yl 3-fluoro
    398 —CH2CH2— N-methylpiperidine-2-yl 3-fluoro
    399 —CH2CH2— piperidine-3-yl 3-fluoro
    400 —CH2CH2— N-methylpiperidine-3-yl 3-fluoro
    401 —CH2CH2— piperidine-4-yl 3-fluoro
    402 —CH2CH2— N-methylpiperidine-4-yl 3-fluoro
    403 —CH2CH2— pyrrolidin-2-yl 3-fluoro
    404 —CH2CH2— N-methylpyrrolidin-2-yl 3-fluoro
    405 —CH2CH2— pyrrolidin-3-yl 3-fluoro
    406 —CH2CH2— N-methylpyrrolidin-3-yl 3-fluoro
    407 —CH2CH2— morpholin-2-yl 3-fluoro
    408 —CH2CH2— morpholin-3-yl 3-fluoro
    409 —CH2— piperidine-2-yl 3-methyl
    410 —CH2— N-methylpiperidine-2-yl 3-methyl
    411 —CH2— piperidine-3-yl 3-methyl
    412 —CH2— N-methylpiperidine-3-yl 3-methyl
    413 —CH2— piperidine-4-yl 3-methyl
    414 —CH2— N-methylpiperidine-4-yl 3-methyl
    415 —CH2— pyrrolidin-2-yl 3-methyl
    416 —CH2— N-methylpyrrolidin-2-yl 3-methyl
    417 —CH2— pyrrolidin-3-yl 3-methyl
    418 —CH2— N-methylpyrrolidin-3-yl 3-methyl
    419 —CH2— morpholin-2-yl 3-methyl
    420 —CH2— morpholin-3-yl 3-methyl
    421 —CH2CH2— piperidine-2-yl 3-methyl
    422 —CH2CH2— N-methylpiperidine-2-yl 3-methyl
    423 —CH2CH2— piperidine-3-yl 3-methyl
    424 —CH2CH2— N-methylpiperidine-3-yl 3-methyl
    425 —CH2CH2— piperidine-4-yl 3-methyl
    426 —CH2CH2— N-methylpiperidine-4-yl 3-methyl
    427 —CH2CH2— pyrrolidin-2-yl 3-methyl
    428 —CH2CH2— N-methylpyrrolidin-2-yl 3-methyl
    429 —CH2CH2— pyrrolidin-3-yl 3-methyl
    430 —CH2CH2— N-methylpyrrolidin-3-yl 3-methyl
    431 —CH2CH2— morpholin-2-yl 3-methyl
    432 —CH2CH2— morpholin-3-yl 3-methyl
    433 —CH2— piperidine-2-yl 3-methoxy
    434 —CH2— N-methylpiperidine-2-yl 3-methoxy
    435 —CH2— piperidine-3-yl 3-methoxy
    436 —CH2— N-methylpiperidine-3-yl 3-methoxy
    437 —CH2— piperidine-4-yl 3-methoxy
    438 —CH2— N-methylpiperidine-4-yl 3-methoxy
    439 —CH2— pyrrolidin-2-yl 3-methoxy
    440 —CH2— N-methylpyrrolidin-2-yl 3-methoxy
    441 —CH2— pyrrolidin-3-yl 3-methoxy
    442 —CH2— N-methylpyrrolidin-3-yl 3-methoxy
    443 —CH2— morpholin-2-yl 3-methoxy
    444 —CH2— morpholin-3-yl 3-methoxy
    445 —CH2CH2— piperidine-2-yl 3-methoxy
    446 —CH2CH2— N-methylpiperidine-2-yl 3-methoxy
    447 —CH2CH2— piperidine-3-yl 3-methoxy
    448 —CH2CH2— N-methylpiperidine-3-yl 3-methoxy
    449 —CH2CH2— piperidine-4-yl 3-methoxy
    450 —CH2CH2— N-methylpiperidine-4-yl 3-methoxy
    451 —CH2CH2— pyrrolidin-2-yl 3-methoxy
    452 —CH2CH2— N-methylpyrrolidin-2-yl 3-methoxy
    453 —CH2CH2— pyrrolidin-3-yl 3-methoxy
    454 —CH2CH2— N-methylpyrrolidin-3-yl 3-methoxy
    455 —CH2CH2— morpholin-2-yl 3-methoxy
    456 —CH2CH2— morpholin-3-yl 3-methoxy
  • The compounds which comprise the first aspect of Category III of the present invention can be prepared by the procedure outlined herein below in Scheme V and Example 5.
    Figure US20070293494A1-20071220-C00037
    • EXAMPLE 5 N2-(3-Chlorophenyl)-N4-piperidin-2-ylmethyl-pyrimidine-2,4-diamine (16)
  • Preparation of 2-{[2-(3-chlorophenylamino)pyrimidin-4-ylamino]methyl}-piperidine-1-carboxylic acid tert-butyl ester (15): To a solution of 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine (300 mg, 1.25 mmol) and tert-butyl 2-(aminomethyl)-piperidine-1-carboxylate (540 mg, 2.50 mmol) in THF (10 mL) is added diisopropylethyl-amine (0.43 mL, 2.50 mmol). The reaction is heated at reflux for 18 hours and then cooled to room temperature. The crude reaction is partitioned between EtOAc and sat. NaHCO3. The organic layer is dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 268 mg (51% yield) of the desired compound: MS (ESI, pos. ion) m/z: 418 (M+1).
  • Preparation of N2-(3-chlorophenyl)-N4-piperidin-2-ylmethyl-pyrimidine-2,4-diamine (16): 2-{[2-(3-chlorophenylamino)pyrimidin-4-ylamino]methyl}-piperidine-1-carboxylic acid tert-butyl ester, 15, is dissolved in neat trifluoroacetic acid (3 mL) and stirred at room temperature for 3 hours. The reaction is concentrated in vacuo and the residue partitioned between EtOAc and sat. NaHCO3. The organic layer is dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 7 mg (7% yield) of the desired compound: 1H NMR (CDCl3, 300 MHz) δ 1.50-1.63 (m, 1H), 1.70-1.92 (m, 4H), 1.95-2.10 (m, 2H), 2.88 (dt, J=12.0, 3.6 Hz, 1H), 3.30-3.40 (m, 1H), 3.52 (d, J=12.0 Hz, 1H), 3.61-3.70 (m, 1H), 3.87 (d, J=15.3 Hz, 1H) 6.01 (d, J=6.6 Hz, 1H), 7.02 (dt, J=7.5, 1.8 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H), 7.25 (t, J=1.8 Hz, 1H), 7.75 (d, J=6.6 Hz, 1H), 7.96 (t, J=1.8 Hz, 1H); HRMS calcd for C16H20ClN5, 318.1485 m/z (M+H)+; observed 318.1481 m/z.
  • The following are non-limiting examples of compounds which comprise first aspect of Category III of the present invention, the characterization of which will assist the formulator in establishing the chemical formulae of compounds which are not specifically exemplified herein. Alternatively, these compounds may also be synthesized by the synthetic route or methods described earlier in Scheme II.
  • N2-(3-Chlorophenyl)-N-(1-methylpiperidin-2-ylmethyl)-pyrimidine-2,4-diamine: 1H NMR (CD3OD, 300 MHz) δ 1.31-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.75-1.88 (m, 2H), 2.28-2.40 (m, 2H), 2.47 (s, 3H), 2.96 (dt, J=11.7, 2.7 Hz, 1H), 3.42-3.49 (m, 1H), 3.79 (d, J=12.6 Hz, 1H), 6.03 (d, J=6.3 Hz, 1H), 6.95 (ddd, J=8.1, 1.8, 0.9 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H), 7.47 (d, J=8.1 Hz, 1H), 7.80 (d, J=5.7 Hz, 1H), 7.88 (t, J=1.8 Hz, 1H); HRMS calcd for C17H22ClN5, 332.1642 m/z (M+H)+; observed 332.1631 m/z.
  • N2-(3-Chlorophenyl)-N4-piperidin-3-ylmethyl-pyrimidine-2,4-diamine 1H NMR (CDCl3, 300 MHz) δ 1.26-1.44 (m, 2H), 1.66-1.80 (m, 1H), 1.95-2.04 (m, 2H), 2.14-2.28 (m, 1H), 2.76 (t, J=12.0 Hz, 1H), 2.90 (dt, J=12.9, 3.3 Hz, 1H), 3.36-3.45 (m, 2H), 3.51 (dd, J=13.8, 6.0 Hz, 7$), 6.14 (d, J=16.6 Hz, 1H), 7.10 (d, J=7.2 Hz, 1H), 7.33 (t, J=7.8 Hz, 1H), 7.38 (d, J=7.2 Hz, 1H), 7.77 (d, J=6.6 Hz, 1H), 7.98 (s, 1H); HRMS calcd for C16H20ClN5, 318.1485 m/z (M+H)+; observed 318.1483 m/z.
  • N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-3-ylmethyl)-pyrimidine-2,4-diamine: 1H NMR (CD3OD, 300 MHz) δ 1.00-1.17 (m, 1H), 1.58-1.73 (m, 1H), 1.78-1.85 (m, 1H), 1.85-2.20 (m, 5H), 2.38 (s, 3H), 2.95 (d, J=11.1 Hz, 1H), 3.08 (d, J=9.9 Hz, 1H), 3.30-3.39 (m, 1H), 6.00 (d, J=5.7 Hz, 1H), 6.95 (ddd, J=7.8, 1.8, 0.9 Hz, 1H), 7.24 (t, J=8.1 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.77 (d, J=6.0 Hz, 1H), 8.09 (s, 1H); HRMS calcd for C17H22ClN5, 332.1642 m/z (M+9)+; observed 332.1637 m/z.
  • N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-4-yl-methyl)-pyrimidine-2,4-diamine hydrochloride salt. 1H NMR (CD3OD, 300 MHz): δ 1.53-1.58 (m, 2H), 2.04-2.09 (m, 3H), 2.87 (s, 3H), 2.98-3.05 (m, 2H), 3.46-3.59 (m, 4H), 6.31 (d, 1H, J=7.2 Hz), 7.27-7.48 (m, 3H), 7.25 (d, 1H, J=7.2 Hz), 7.83 (s, 1H). MS (ESI, pos. ion) m/z: 332 (M+1).
  • N2-(3-Chlorophenyl)-N4-[2-(1-methylpyrrolidin-2-yl)-ethyl]-pyrimidine-2,4-diamine: HRMS calcd for C17H22N5Cl, 332.1642 m/z (M+H)+; observed 332.1638 m/z.
  • N2-(3-Chlorophenyl)-N4-morpholin-2-ylmethyl-pyrimidine-2,4-diamine trifluoroacetate salt: 1H NMR (DMSO-d6, 300 MHz) δ 2.82-2.88 (m, 1H), 2.98-3.03 (m, 1H), 3.14-3.30 (m, 4H), 3.71 (t, J=12.0 Hz, 2H), 3.87-3.93 (m, 1H), 4.01 (d, J=12.3 Hz, 1H), 7.11 (d, J=8.1 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.53 (d, J=8.1 Hz, 1H), 7.90 (d, J=6.0 Hz, 1H), 9.33 (s, 3H), 8.58 (bs, 1H), 9.07 (bs, 2H), 10.30 (bs, 1H); HRMS calcd for C15H18N5ClO, 320.1278 m/z (M+H)+; observed 320.1277 nm z.
  • N2-(3-Chlorophenyl)-N4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-pyrimidine-2,4-diamine 1H NMR (CDCl3, 300 MHz) δ 1.63-1.70 (m, 2H), 1.78-1.90 (m, 2H), 1.95-2.08 (m, 2H), 2.11-2.20 (m, 2H), 3.27-3.33 (m, 2H), 4.56-4.63 (m, 1H), 5.85 (d, J=5.7 Hz, 1H), 6.95 (bs, 1H), 6.98 (dd, J=7.5, 0.6 Hz, 1H), 7.23 (t, J=7.8 Hz, 1H), 7.35 (dd, J=8.1, 1.2 Hz, 1H), 7.86 (t, J=1.8 Hz, 1H), 7.90 (d, J=5.1 Hz, 1H); HRMS calcd for C18H22N5Cl, 344.1642 m/z (M+H)+; observed 344.1644 m/z.
  • N2-(3-Chloro-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine: (ESI, neg. ion) m/z: 395 (M−1).
  • N2-(3-Chloro-phenyl)-N4-piperidin-4-ylmethyl-pyrimidine-2,4-diamine.
  • N2-(3-Chloro-phenyl)-N4-(1-isopropyl-piperidin-3-ylmethyl)-pyrimidine-2,4-diamine: (ESI, pos. ion) m/z: 360 (M+1).
  • The second aspect of Category III relates to R units which comprise a chiral carbon atom. Scheme VI herein below and the following examples illustrate this second aspect of Category III of the present invention.
    Figure US20070293494A1-20071220-C00038
    • EXAMPLE 6 N2-(3-Chlorophenyl)-N4-{[(2S)-1-methylpyrrolidin-2-yl]methyl}pyrimidine-2,4-diamine (17)
  • Preparation of tert-butyl (2S)-2-[({2-[(3-chlorophenyl)amino]pyrimidin-4-yl}amino)methyl]pyrrolidine-1-carboxylate (16): To a solution of 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine, 3, (300 mg, 1.25 mmol) and tert-butyl (2S)-2-(aminomethyl)pyrrolidine-1-carboxylate (500 mg, 2.50 mmol) in THF (10 mL) is added diisopropylethylamine (0.43 mL, 2.50 mmol). The reaction was heated at reflux for 18 hours and then cooled to room temperature. The crude reaction is then partitioned between EtOAc and sat. NaHCO3. The organic layer is dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 160 mg (32% yield) of the desired product: MS (ESI, pos. ion) m/z: 404 (M+1).
  • Preparation of N2-(3-chlorophenyl)-N4-{[(2S)-1-methylpyrrolidin-2-yl]methyl}pyrimidine-2,4-diamine (17): To a solution of tert-butyl (28)-2-[({2-[(3-chlorophenyl)amino]pyrimidin-4-yl}amino)methyl]pyrrolidine-1-carboxylate (160 mg, 0.40 mmol) in THF (3 mL) is added lithium aluminum hydride (2 M in THF, 0.6 mL, 1.19 mmol). The reaction is stirred at room temperature for 24 hours and then quenched with NaOH (1 N, 2 mL) and stirred for an additional hour. The reaction solution is partitioned between EtOAc and sat. NaHCO3. The organic layer is dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 22 mg (17% yield) of the desired compound: 1H NMR (CDCl3, 300 MHz) δ 1.58-1.68 (m, 1H), 1.70-1.83 (m, 2H), 1.99-2.11 (m, 1H), 2.29 (q, J=8.7 Hz, 1H), 2.43 (s, 3H), 2.48-2.58 (m, 1H), 3.04-3.12 (m, 1H), 3.29 (t, J=6.3 Hz, 1H), 3.77 (d, J=11.7 Hz, 1H), 6.01 (d, J=6.0 Hz, 1H), 6.94 (ddd, J=8.1, 2.4, 0.9 Hz, 1H), 7.23 (t, J=7.8 Hz, 1H), 7.49 (ddd, J=8.4, 2.1, 0.9 Hz, 1H), 7.78 (d, J=6.0 Hz, 1H), 7.89 (t J=2.1 Hz, 1H); HRMS calcd for C16H20ClN5, 318.1485 nm z (M+H)+; observed 318.1491 m/z.
  • The (2R) enantiomer can be prepared in the same manner as described herein above,
    Figure US20070293494A1-20071220-C00039
    • EXAMPLE 7 N2-(3-Chlorophenyl)-N4-[(2S)-pyrrolidin-2-ylmethyl]pyrimidine-2,4-diamine (18)
  • Preparation of N2-(3-chlorophenyl)-N4-[(2S)-pyrrolidin-2-ylmethyl]pyrimidine-2, 4-diamine (18): To a solution of tert-butyl (2S)-2-[({2-[(3-chlorophenyl)amino]-pyrimidin-4-yl}amino)methyl]pyrrolidine-1-carboxylate, 15, (150 mg, 0.37 mmol) in CH2Cl2 (5 mL) is added trifluoroacetic acid (3 mL). The reaction is stirred at room temperature for 24 hours then partitioned between EtOAc and sat. NaHCO3. The organic layer is dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 36 mg (32% yield) of the desired material: 1H NMR (CD)Cl3, 300 MHz) δ 1.43-1.56 (m, 1H), 1.70-1.91 (m, 2H), 1.93-2.06 (m, 1H), 2.97 (t, J=6.9 Hz, 2H), 3.16-3.29 (m, 1H), 3.41-3.52 (m, 1H), 3.54-3.66 (m, 1H), 5.71 (t, J=5.1 Hz, 1H), 5.91 (d, J=6.0 Hz, 1H), 6.96 (ddd, J=7.8, 5.7, 0.9 Hz, 1H), 7.20 (t, J=8.1 Hz, 1H), 7.26-7.32 (m, 1H), 7.57 (bs, 1H), 7.91 (d, J=5.7 Hz, 1H), 7.99 (s, 1H); HRMS calcd for C15H18ClN5, 304.1329 m/z (M+H)+; observed 304.1319 m/z.
    Figure US20070293494A1-20071220-C00040
    • EXAMPLE 8 N2-(3-Chlorophenyl)-N4-{[(3S)-1-methylpyrrolidin-3-yl]methyl}pyrimidine-2,4-diamine (20)
  • Preparation of tert-butyl (3S)-3-[({2-[(3-chlorophenyl)amino]pyrimidin-4-yl}amino)methyl]pyrrolidine-1-carboxylate (19): To a solution of 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine (500 mg, 2.08 mmol) and tert-butyl (3S)-3-(amino-methyl)pyrrolidine-1-carboxylate (625 mg, 3.12 mmol) in THF (10 mL) is added diisopropylethylamine (0.73 mL, 4.16 mmol). The reaction is heated at reflux for 18 hours and then cooled to room temperature. The crude reaction is partitioned between EtOAc and sat. NaHCO3. The organic layer is dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 356 mg (42% yield) of the desired compound: MS (ESI, pos. ion) m/z: 404 (M+1).
  • Preparation of N2-(3-chlorophenyl)-N4-{[(38)-1-methylpyrrolidin-3-yl]methyl}pyrimidine-2,4-diamine (20): To a solution of tert-butyl (3S)-3-[({2-[(3-chlorophenyl)-amino]pyrimidin-4-yl}amino)methyl]pyrrolidine-1-carboxylate, 19, (356 mg, 0.88 mmol) in THF (2 mL) is added lithium aluminum hydride (2 M in THF, 1.32 mL, 2.64 mmol). The reaction is heated to 50° C. for 3 days, cooled to room temperature, quenched with NaOH (1 N, 2 mL) and stirred for an additional hour. The reaction mixture is extracted with EtOAc (2×25 mL) and the combined organic layers are dried (MgSO4), concentrated in vacuo, and purified over silica (MeOH/CH2Cl2) to afford 190 mg (68% yield) of the desired product: 1H NMR (DMSO, 300 MHz) δ 1.40-1.50 (m, 1H), 1.86-1.96 (m, 1H), 2.23 (s, 3H), 2.25-2.33 (m, 1H), 2.34-2.41 (m, 1H), 2.42-2.54 (m, 5H), 5.96 (d, J=5.7 Hz, 1H), 6.89 (dt, J=7.5, 0.9 Hz, 1H)>7.22 (t, J=8.4 Hz, 1H), 7.39 (bs, 1H), 7.57 (d, J=7.8 Hz, 1H), 7.74-7.85 (m, 2H), 8.15 (bs, 1H), 9.21 (s, 1H); HRMS calcd for C16H20ClN5, 318.1485 m/z (M+H)+; observed 318.1485 m/z.
  • In some instances the formulator will find it necessary to synthesize various R units encompassed within the scope of the present invention. Schemes 1× and X and Examples 9 and 10 herein below disclose examples of compounds having substituted heterocyclic units for R.
    Figure US20070293494A1-20071220-C00041
    • EXAMPLE 9 1-(4-{3-[2-(3-Chloro-phenylamino)-pyrimidin-4-ylamino]-propyl}-piperazin-1-yl)-ethanone (23)
  • Preparation of 3-(4-acetylpiperazin-1-yl)propanenitrile (21): To 1-(piperazin-1-yl)ethanone (5 g, 39 mmol) in MeOH (50 mL) at 0° C. is added acrylonitrile (2.57 mL, 39 mmol) in one portion. The resulting reaction is stirred for 12 hours while allowing the reaction to warm to room temperature. The reaction mixture is concentrated in vacuo and the resulting residue diluted with 5 mL of water and extracted with EtOAc (3×25 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue is purified over silica (2% MeOH in CH2Cl2) to afford 6.4 g (91% yield) of the desired compound. 1H NMR (CDCl3, 300 MHz) δ2.08 (s, 3H), 2.46 (t, J=5.1 Hz, 2H), 2.51-2.53 (m, 4H), 2.71 (t, J=6.9 Hz, 2H), 3.48 (t, J=5.1 Hz, 2H), 3.26 (t, J=5.1 Hz, 2H). MS (ESL, pos. ion) m/z: 182 (M+1).
  • Preparation of 1-(4-(3-aminopropyl)piperazin-1-yl)ethanone (22): A Parr hydrogenation vessel is charged with ethanol (200 mL) and purged with nitrogen for 10 minutes. Raney nickel catalyst (20 g), 3-(4-acetylpiperazin-1-yl)propanenitrile, 21, (4.12 g, 22.64 mmol) dissolved in ethanol (138 mL), and NH4OH (98 mL) are added. The flask is then cooled to 0° C. and purged with ammonia gas for 15 minutes. Hydrogen gas is then introduced and the reaction vessel shaken for 18 hours at 40 psi of hydrogen, Once complete, the reaction solution is filtered through celite, and the solute concentrated in vacuo and used without further purification. MS (ESI, pos. ion) m/z: 186 (M+1).
  • Preparation of 1-(4-{3-[2-(3-chloro-phenylamino)-pyrimidin-4-ylamino]-propyl}-piperazin-1-yl)-ethanone (23): To 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine (0.5 g, 2.09 mmol) in THF (13 mL) is added DIPEA (0.73 mL, 4.18 mmol) followed by 1-(4-(3-aminopropyl)-piperazin-1-yl)ethanone, 22, (0.77 g, 4.18 mmol). The resulting mixture is refluxed for 12 hours after which the reaction mixture is cooled to room temperature and the solvent removed in vacuo. To the resulting residue is added water (50 mL) and the solution is washed with EtOAc (3×100 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue which is obtained is purified over silica (10% MeOH in CH2Cl2) to afford 0.173 g (10% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz) δ1.67-1.75 (m, 2H), 1.97 (s, 3H), 2.27-2.40 (m, 6H), 3.37-3.42 (m, 6H), 5.96 (d, J=6.0 Hz, 1H), 6.87 (d, J=8.1 Hz, 1H), 7.21 (t, J=8.1 Hz, 1H), 7.28 (bs, 1H), 7.58 (d, J=7.2 Hz, 1H), 7.80 (bs, 1H), 8.13 (bs, 1H), 9.19 (s, 1H). MS (ESI, pos. ion) m/z: 389 (M+1). HRMS calcd for C19H25ClN6O, 389.1857 m/z (M+H)+; observed 389.1851 m/z.
    Figure US20070293494A1-20071220-C00042
    • EXAMPLE 10 N2-(3-Chloro-phenyl)-N4-[3-(4-methanesulfonyl-piperazin-1-yl)-propyl]-pyrimidine-2,4-diamine (26)
  • Preparation of 3-(4-(methylsulfonyl)piperazin-1-yl)propanenitrile (24); To 1-(methylsulfonyl)piperazine (1 g, 6.09 mmol) in MeOH (11 mL) at 0° C. is added acrylonitrile (0.402 mL, 6.09 mmol). The reaction mixture is concentrated in vacuo and the resulting residue diluted with 5 mL of water and extracted with EtOAc (3×25 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue is purified over silica (2% MeOH in CH2Cl2) to afford 1.1 g (99% yield) of the desired compound. 1H NMR (CDCl3, 300 MHz) δ2.56 (t, J=6.9 Hz, 2H), 2.66 (t, J=4.8 Hz, 4H), 2.76 (t, J=6.9 Hz, 2H), 2.81 (s, 3H), 3.30 (t, J=4.8 Hz, 4H). MS (ESI, pos. ion) t/z: 218 (M+1).
  • Preparation of 3-(4-(methylsulfonyl)piperazin-1-yl)propan-1-amine (25): A Parr hydrogenation vessel is charged with ethanol (200 mL) and purged with nitrogen for 10 minutes. Raney nickel catalyst (4.5 g), 3-(4-(methylsulfonyl)piperazin-1-yl)propanenitrile, 24, (1.1 g, 5.07 mmol) dissolved in ethanol (50 mL), and NH4OH (98 mL) are added. The flask is then cooled to 0° C. and purged with ammonia gas for 15 minutes. Hydrogen gas is then introduced and the reaction vessel shaken for 18 hours at 40 psi of hydrogen. Once complete, the reaction solution is filtered through celite, and the solute concentrated in vacuo and used without further purification. 1H NMR (MeOD, 300 MHz) δ 1.70 (m, 2H), 2.48 (t, J=7.2 Hz, 2H), 2.59 (t, J=4.2 Hz, 4H), 2.71 (t, J=6.6 Hz, 2H), 2.86 (s, 3H), 3.25 (t, J=4.8, 4H).
  • Preparation of N2-(3-Chloro-phenyl)-N4-[3-(4-methanesulfonyl-piperazin-1-yl)-propyl]-pyrimidine-2,4-diamine (26): To 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine (0.2 g, 0.837 mmol) in THF (10 mL) is added DIPEA (0.29 ml, 1.67 mmol) followed by 3-(4-(methylsulfonyl)piperazin-1-yl)propan-1-amine, 25, (0.0.369 g, 1.67 mmol). The resulting mixture is refluxed for 12 hours after which the reaction mixture is cooled to room temperature and the solvent removed in vacuo. To the resulting residue is added water (50 mL) and the solution is washed with EtOAc (3×100 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. The residue which is obtained is purified over silica (10% MeOH in CH2Cl2) to afford 0.129 g (50% yield) of the desired compound. 1H NMR (DMSO-d6, 300 MHz) δ1.71 (m, 2H), 2.39-2.45 (m, 6H), 2.84 (s, 3H), 3.08 (m, 4H), 3.38 (m, 2H), 5.96 (d, J=5.7 Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 7.18-7.27 (m, 2H), 7.58 (d, J=7.5 Hz, 1H), 7.81 (bs, 1H), 8.12 (bs, 1H), 9.18 (s, 1H). MS (ESI, pos. ion) m/z: 425 (M+1). HRMS calcd for C18H25ClN6O2S, 425.1526 m/z (M+H)+; observed 425.1512 m/z.
  • The compounds of the present invention are inhibitors of Protein Kinase C-alpha (PKC-α), therefore, they are PKC-α inhibitors which are capable of improving myocardial contraction and relaxation performance and slow the progression of heart failure. Certain exemplified compounds may also potentially inhibit additional isoforms of conventional PKC, such as PKC-β or PKC-γ. This is not undesirable and can lead to increased pharmacological effects.
  • The level of disease, for example, the relative degree of heart failure due to PKC-α activity will vary from patient to patient and be predicated by other exacerbating circumstances, inter alia, presence of other disease conditions (diabetes, high blood pressure, and the like) or patients may suffer from other conditions such as obesity. Therefore, the formulator may be required to employ differing levels or amounts of the compounds described herein to obtain a therapeutic level. The formulator can determine this amount by any of the known testing procedures known to the artisan.
    • Formulations
  • The present invention also relates to compositions or formulations which comprise the PKC-α inhibitors according to the present invention. In general, the compositions of the present invention comprise.
      • a) an effective amount of one or more 2-arylamino-4-(heterocyclic)amino-pyrimidines or salts thereof according to the present invention which are effective for inhibiting PKC-α; and
      • b) one or more excipients.
  • For the purposes of the present invention the term “excipient” and “carrier” are used interchangeably throughout the description of the present invention. One aspect of excipient and carrier relate to their definition in terms of a medicament, said terms are defined in that respect as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
  • The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
  • Non-limiting examples of compositions according to the present invention include:
      • a) from about 0.001 mg to about 1000 mg of one or more PKC-α inhibitors according to the present invention; and
      • b) one or more excipient.
  • Another embodiment according to the present invention relates to the following compositions:
      • a) from about 0.01 mg to about 100 mg of one or more PKC-α inhibitors according to the present invention; and
      • b) one or more excipient.
  • A further embodiment according to the present invention relates to the following compositions:
      • a) from about 0.1 mg to about 10 mg of one or more PKC-α inhibitors according to the present invention; and
      • b) one or more excipient.
  • The term “effective amount” as used herein means “an amount of one or more PKC-α inhibitors, effective at dosages and for periods of time necessary to achieve the desired result.” An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the human or animal being treated. Although particular dosage regimes may be described in examples herein, a person skilled in the art would appreciated that the dosage regime may be altered to provide optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In addition, the compositions of the present invention can be administered as frequently as necessary to achieve a therapeutic amount.
    • Method of Use
  • The present invention also relates to a method for improving cardiac contraction/relaxation parameters in heart failure patients and/or attenuating adverse cardiac remodeling and prevent or slow the progression of worsening heart failure. The present method comprises the step of administering to a human or higher mammal an effective amount of a composition comprising one or more of the PKC-α inhibitors according to the present invention.
  • The present method comprised a method for treating or preventing a disease or medical condition selected from diabetes, numerous forms of cancer, microalbinuria, endothelial dysfunction, cerebrovascular disease, stroke, coronary heart disease, cardiovascular disease and sequela (e.g. arrhythmia, sudden death, increased infarct size, congestive heart failure, angina), myocardial ischemic states, hypertension, lipid disorders, ischemia-reperfusion injury, atherosclerosis, peripheral artery/vascular disease, microvascular complications of diabetes (neuropathy, nephropathy, retinopathy), restenosis, renal disease, blood coagulation disorders, inflammatory diseases, cardiac hypertrophy, dilated cardiomyopathy, ischemic injury and suboptimal mitogen stimulation said method comprised of the steps of administering to a patient in need thereof a therapeutic amount of a PKC-α inhibitor as disclosed herein.
  • The present invention also relates to the use of the 2-arylamino-4-(heterocyclic)-amino-pyrimidines or salts thereof, according to the present invention in the manufacture of a medicament for the treatment of heart disease wherein inhibition of PKC-α provides a benefit.
    • Procedures Assessment of PKC-α Inhibitory Activity
  • Measurement of PKCα enzyme activity is performed using full-length human PKCα enzyme (Upstate Biotechnology) at a final concentration of 0.12 μg/ml in a kinase assay buffer (0.09 mg/ml bovine serum albumin (BSA), 210 μM ethylenediaminetetraacetic acid (EDTA), 360 μM CaCl2, 1 mM Tris-HCl, pH=7.5, 0.5 mM MgCl2, 0.015 mg/ml phosphatidylserine and 0.015 mg/ml diacylglycerol). The reaction is initiated by addition of adenosine triphosphate (ATP; final concentration 45 μM) and a peptide substrate consisting of amino acids 28-43 (Ala-Ala-Lys-Ile-Gln-Ala-Ser-Phe-Arg-Gly-His-Met-Ala-Arg-Lys-Lys) of neurogranin (Promega; final concentration 22 μM). After a 30 minute incubation at 24° C. the reaction is terminated by adding; 5 μL of the reaction mixture into 50 μL of MALDI matrix solution (5 mg/ml α-cyano-4-hydroxy-cinnamic acid in 50% Acetonitrile/H2O, 0.1% TFA, 5 mM ammonium phosphate). Two microliters of the stopped reaction mixture is transferred onto a MALDI-TOF mass spectrometer target plate.
  • All spectra are collected on an Applied Biosystems 4700 Proteomics Analyzer MALDI-TOF MS equipped with a Nd:YAG laser (355 nm, 3 ns pulse width, 200 Hz repetition rate) in negative ion reflector mode. The system is operated with 4700 Explorer software, version 3.0. Automated acquisition parameters are adjusted to capture and average only those individual spectra within defined success criteria. Specifically, signal intensities for the substrate peptide are set to a minimum threshold of 3000 counts and a maximum intensity of 65,000 counts. This ensured that neither null spectra nor saturated spectra are averaged into the final readout. Between 1000 and 1500 laser shots are averaged for each sample. Data are collected in triplicate from 3 successive days to capture the maximum variability related to preparation of enzyme reaction, transfer of samples to MALDI target plates, data collection, and data extraction.
  • The isotope cluster areas for each peptide substrate and product peaks are extracted into a Microsoft Excel worksheet from the 10×10 array of spectral data simultaneously using the automated analysis function provided within the 4700 Explore software. The isotope cluster area is defined by the software algorithm based on the molecular weight and the general elemental composition of the peptides. The percent conversion (% C) of substrate to product is calculated as the cluster area of the product (P) divided by the sum of the cluster areas of the substrate (S) and the product multiplied by 100 as represented by the following equation. % ⁢   ⁢ C = P P + S × 100.
  • For dose-dependent inhibition studies, the inhibition is plotted as a % Maximal Activity (% MA). Equation one is a measure of the ratio of product to substrate then solving for the % C. However, to measure inhibition of the enzyme activity, one must measure the degree to which that activity (% C) is curtailed. Thus the dose-dependant inhibition data is plotted as % MA where the maximal activity is the % C measured in control reactions with no inhibitor as represented by the following equation: % ⁢   ⁢ MA = % ⁢   ⁢ C ⁢   ⁢ with ⁢   ⁢ inhibitor % ⁢   ⁢ C ⁢   ⁢ with ⁢   ⁢ no ⁢   ⁢ inhibitor × 100.
    • Evaluation of PKCα Inhibitors in Cardiomyocytes
  • Determination of PKC(X activity in cells is determined using murine HL-1 atrial cardiac muscle cells. On day 1, HL-1 cells are plated at 18,000 cells/well in a 96-well tissue culture plate Cells are cultured in 0.1 ml Claycomb growth medium (without norepinephrine) supplemented with 10% fetal bovine serum, 200 mM glutamine and 1% antibiotic/antimycotic. On day 2, cells are washed 1× with 100 μl of phosphate buffered saline (PBS) and the medium is replaced with 100 μl serum free Claycomb medium supplemented with 200 mM glutamine. For compound testing, the medium is removed and replaced with serum free Claycomb medium supplemented with 200 mM glutamine containing different concentrations of compound at a final volume of 50 μl. Compounds are dissolved in 100% dimethylsulfoxide (DMSO) and final DMSO concentrations are maintained at 0.5%. Plates are then incubated for 30 minutes at 37° C. in a 5% CO2 incubator. The medium is then removed and the plates are rinsed 1× with ice-cold 100 μl PBS. The PBS is removed and replaced with 10 μl of ice-cold lysis buffer consisting of B-PERII detergent (Pierce) diluted 1:1 in distilled water and including a final concentration of 0.3% β-mercaptoethanol, 50 μg/ml phenylmethylsulfonylfluoride (PMSF) 10 mM benzamidine, 10 nM okadaic acid, 20 μg/ml leupeptin and 20 μg/ml soybean trypsin inhibitor. The plates are gently mixed for 10-20 minutes at 4° C. Next, 90 μl of coactivation buffer, consisting of 0.1 mg/ml BSA, 250 μM EDTA, 400 μM CaCl2, is added to each well. Twenty-five microliters of the cell lysate/coactivation buffer solution is removed from each well and the enzyme activity measured by addition of 25 μl of substrate solution, consisting of 0.1 mg/ml bovine serum albumin, 235 μM EDTA, 400 μM CaCl2, 1 mM Tris-HCl, pH=7.5, 0.5 mM MgCl2, 0.015 mg/ml phosphatidylserine and 0.015 mg/ml diacylglycerol, 20 μM ATP and 2 μM of an octapeptide fragment of the EGF receptor (Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu). After a 30 minute incubation at 24° C. the reaction is terminated by adding 5 μL of the reaction mixture into 50 μL of MALDI matrix solution (5 mg/ml α-cyano-4-hydroxycinnamic acid in 50% Acetonitrile/H2O, 0.1% TFA, 5 mM ammonium phosphate). Two microliters of the stopped reaction mixture is transferred onto a MALDI-TOF mass spectrometer target plate. Dose-dependent inhibition is measured by mass spectrometry as % maximal activity as described above for the isolated PKCα inhibition assays.
    • In Vivo Evaluation of PKCα Inhibitors in the Anesthetized Rat
  • Selected PKCα inhibitors are evaluated in rats with acute heart failure (HF) after myocardial infarction (MI) for effects on cardiac contractility and hemodynamics. Male, Sprague-Dawley rats are anesthetized with isoflurane, intubated, placed on ventilators and maintained at a surgical plane of anesthesia during the course of the experiment. The animals are instrumented, for the measurement of left ventricular function (+dP/dt, LVDP), arterial blood pressure, and the ECG is monitored for the incidence of arrhythmias. A thoracotomy is performed at the fourth intercostal space to visualize the heart, the pericardium is opened and a suture is placed around the left anterior descending (LAD) coronary artery approximately 3-4 mm from its origin. When hemodynamic values are stabilized, the LAD is permanently ligated to induce a myocardial infarction. Severe arrhythmia are treated with the administration of lidocaine. Typically, cardiac function stabilized approximately 40-60 min after ligation and baseline hemodynamic values are measured. N2-(3-chlorophenyl)-N4-(3-(dimethylamino)propyl)pyrimidine-2,4-diamine, 100 and 300 nmol/kg/min for 10 min each dose, and hemodynamic parameters are measured after each dose. The effects of treatment are normalized to pre-treatment baseline values and expressed as a percentage. Statistical significance (p<0.05) is evaluated using one-way ANOVA and Dunnett's multiple comparison test.
    • In Vivo Evaluation of PKCα Inhibitors in the Anesthetized Rat
  • Selected PKCα inhibitors are evaluated in rats with myocardial infarction (MI) for effects on cardiac contractility and hemodynamics.
  • Male, Sprague-Dawley or Lewis rats weighing between 225-500 gm are anesthetized with isoflurane and an MI is induced as follows. A thoracotomy is performed at the fourth intercostal space to visualize the heart, the pericardium is opened and a suture is placed around the left anterior descending (LAD) coronary artery approximately 3-4 mm from its origin. When hemodynamic values are stabilized, the LAD is permanently ligated to induce a myocardial infarction. Severe arrhythmias are treated with the administration of lidocaine. Typically, cardiac function stabilized approximately 40-60 min after ligation and baseline hemodynamic values are measured.
  • The effects of inhibitors on cardiac contractility and hemodynamics are evaluated in MI rats as follows. The animals are anesthetized with isoflurane. A femoral artery is isolated and cannulated for the measurement of systemic blood pressure. A jugular vein is isolated and cannulated for the intravenous infusion of inhibitor. The right carotid artery is isolated and a Millar conductance catheter is inserted to the left ventricle (LV) of the heart. The LV systolic pressure, end-diastolic pressure, +dP/dtmax, −dP/dtmin, and heart rate are derived from the LV pressure waveform. Mean arterial blood pressure is derived from the systemic blood pressure waveform. Data are recorded continuously and derived using computerized data acquisition software (Notocord or Powerlab).
  • After a period of stabilization, PKC-α inhibitors are infused at the following infusion doses in MI rats: 10, 30, 100, 300 and 1000 nmol/kg/min. The infusion of each dose is allowed to run for at least five minutes. At the end of the test infusions, 5.0 μg/kg/min of dobutamine is infused. The effects of treatment are normalized to pretreatment baseline values and expressed as a percentage. Statistical significance (p<0.05) is evaluated using a one-way ANOVA and Dunnett's multiple comparison test.
  • Table VI provides non-limiting examples of PKC-α IC50 values for representative compounds of the present invention.
    TABLE VI
    PKC-α
    Compound IC50 (nM)
    N2-(3-Chlorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine 2
    N2-(3-Chlorophenyl)-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine- 5
    2,4-diamine
    1-{3-[2-(3-Chlorophenylamino)-pyrimidin-4-ylamino]-propyl}-pyrrolidin-2- 710
    one
    N2-[3-Trifluoromethyl-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine- 0.5
    2,4-diamine
    N4-(3-Pyrrolidin-1-yl-propyl)-N2-[3-methylphenyl]-pyrimidine-2,4-diamine 40
    N4-(3-Pyrrolidin-1-yl-propyl)-N2-[3-methoxyphenyl]-pyrimidine-2,4- 16
    diamine
    N2-(3-Chlorophenyl)-N4-[2-(1-methylpyrrolidin-2-yl)-ethyl]-pyrimidine-2,4- 0.4
    diamine
    N2-(3-Chlorophenyl)-N4-morpholin-2-ylmethyl-pyrimidine-2,4-diamine 23
    N2-(3-Chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine 3
    N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-4-ylmethyl)-pyrimidine-2,4- 30
    diamine
    N2-(3-Chlorophenyl)-N4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-pyrimidine- 4
    2,4-diamine
    N2-(4-(Benzyloxy)-3-chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)- 40
    pyrimidine-2,4-diamine
    N2-(3-Nitrophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine 1
    N2-(3-Nitrophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine 2
    N2-(3-Bromophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine 1
    N2-(3-Isopropylphenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4- 80
    diamine
    N2-Biphenyl-3-yl-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine 3
    N2-(3,5-Bis-trifluoromethyl-phenyl)-N4-(3-morpholin-4-yl-propyl)- 21
    pyrimidine-2,4-diamine
    N2-[3-(Pyridin-3-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4- 28
    diamine
    N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}- 23
    benzenesulfonamide
    N2-[3-(N,N-dimethylamino)-phenyl]-N4-(3-morpholin-4-yl-propyl)- 53
    pyrimidine-2,4-diamine
    N2-(3-Fluorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine 64
    N2-(3-Nitro-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4- 182
    diamine
    3-[4-(3-Morpholin-4-ylpropylamino)-pyrimidin-2-ylamino]-N-(pyridin-3- 52
    ylmethyl)-benzenesulfonamide
    N2-[3-(1H-Indol-2-ylmethyl)-phenyl]-N4-(3-morpholin-4-yl-propyl)- 18
    pyrimidine-2,4-diamine
    {3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}- 465
    methanol
    N2-(3-(Benzo[d]thiazol-2-yl)-phenyl)-N4-(3-morpholin-4-yl-propyl)- 40
    pyrimidine-2,4-diamine
    3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]- 14
    benzenesulfonamide
    N-(3-Chlorophenyl)-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2- 12
    ylamino]-benzamide
    N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}- 25
    benzamide
    N-Isopropyl-3-[4-(3-Pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]- 344
    benzamide
    N2-(3-Phenoxyphenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4- 50
    diamine
    N2-(3-Chlorophenyl)-N4-piperidin-4-ylmethyl- 37
    pyrimidine-2,4-diamine
    N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-3-ylmethyl)- 4
    pyrimidine-2,4-diamine
    N2-(3-Chlorophenyl)-N4-piperidin-3-ylmethyl- 25
    pyrimidine-2,4-diamine
    N2-(3-Chlorophenyl)-N4—[(3S)-1-methylpyrrolidin-3-ylmethyl]- 13
    pyrimidine-2,4-diamine
    N2-(3-Chlorophenyl)-N4—[(3R)-1-methylpyrrolidin-3-ylmethyl]- 7
    pyrimidine-2,4-diamine
    N2-[3-(4-Methyl-piperazine-1-sulfonyl)phenyl]-N4-(3-morpholin-4- 83
    ylpropyl)-pyrimidine-2,4-diamine
    N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}- 112
    nicotinamide
    N2-[3-(1H-Indol-4-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine- 12
    2,4-diamine
  • While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims (41)

1. A compound having the formula:
Figure US20070293494A1-20071220-C00043
wherein R is a substituted or unsubstituted heterocyclic unit containing from 3 to 7 atoms;
L is a linking group having the formula:

—[C(R4aR4b)]n—
each R4a and R4b is independently chosen from:
i) hydrogen; or
ii) C1-C4 linear, branched, or cyclic alkyl;
the index n is from 0 to 4; and
R1 is phenyl having the formula:
Figure US20070293494A1-20071220-C00044
R5 is hydrogen or one or more independently chosen substitutes for hydrogen.
2. A compound according to claim 1 wherein R is a unit having the formula:
Figure US20070293494A1-20071220-C00045
R2 and R3 are taken together to form a ring containing from 3 to 7 atoms optionally substituted with one or more substituents.
3. A compound according to claim 2 wherein R is chosen from pyrrolidin-1-yl, pyrrolin-1-yl, imidazolidin-1-yl, imidazolin-1-yl, pyrazolidin-1-yl, pyrazolin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, morpholin-4-yl, 4-acetylpiperazin-1-yl, and 4-methanesulfonyl-piperazin-1-yl.
4. A compound according to claim 3 wherein R is pyrrolidin-1-yl or morpholin-4-yl.
5. A compound according to claim 1 wherein R is a unit having the formula:
Figure US20070293494A1-20071220-C00046
R2 and R3 are taken together to form a ring containing from 3 to 7 atoms optionally substituted with one or more substituents; R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
6. A compound according to claim 5 wherein R is chosen from pyrrolidin-2-yl, N-methyl-pyrrolidin-2-yl, N-methylpyrrolidin-2-on-5-yl, pyrrolin-2-yl, imidazolidin-2-yl, imidazolin-2-yl, pyrazolidin-2-yl, pyrazolin-2-yl, piperidin-2-yl, N-methyl-piperidin-2-yl, piperazin-2-yl, 1-methylpiperazin-2-yl, 4-methylpiperazin-2-yl, 1,4-dimethylpiperazin-2-yl, morpholin-3-yl, and N-methylmorpholin-3-yl.
7. A compound according to claim 1 wherein R is a unit having the formula:
Figure US20070293494A1-20071220-C00047
wherein R2 and R3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
8. A compound according to claim 7 wherein R is chosen from piperidin-3-yl, pyrrolidin-3-yl, and morpholin-2-yl.
9. A compound according to claim 7 wherein R1 is chosen from N-methyl-pyrrolidin-3-yl, N-methylpiperidin-3-yl, N-(2-propyl)-piperidin-3-yl and N-methylmorpholin-3-yl.
10. A compound according to claim 1 wherein R is a unit having the formula:
Figure US20070293494A1-20071220-C00048
wherein R2 and R3 are taken together to form a heterocycle having from 3 to 7 atoms optionally substituted with one or more substituents; R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
11. A compound according to claim 10 wherein R is chosen from piperidin-4-yl, N-methyl-piperidin-4-yl, 2,2,6,6-tetramethyl-piperidin-4-yl, N-methyl-2,2,6,6-tetramethyl-piperidin-4-yl, 8-azabicyclo[3.2.1]oct-3-yl or N-methyl-8-azabicyclo[3.2.1]oct-3-yl.
12. A compound according to claim 1 wherein L is a unit chosen from —CH2CH2—, —CH2CH2CH22—, and —CH2CH2CH2CH2—.
13. A compound according to claim 1 wherein R5 represent one of more independently chosen substitutions for hydrogen, R5 having the formula:

-(L1)y-R6
R6 is a unit chosen from:
i) hydrogen;
ii) halogen;
iii) nitro;
iv) hydroxy;
v) amino, mono- or di-substituted (C1-C4 linear or branched alkyl)amino;
vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
viii) substituted or unsubstituted phenyl;
ix) substituted or unsubstituted C2-C5 heterocyclic;
x) substituted or unsubstituted C3-C8 heteroaryl;
xi) cyano; or
xii) CHmX3-m wherein X is halogen and m is from 0 to 2;
L1 is a linking unit chosen from:
i) —[C(R7aR7b)]j—;
ii) —[C(R7aR7b)]jO[C(R8aR8b)]k—;
iii) —[C(R7aR7b)]jNR9SO2[C(R8aR8b)]k—;
iv) —[C(R7aR7b)]jSO2NR9[C(R8aR8b)]k—;
v) —[C(R7aR7b)]NR9C(O)[C(R8aR8b)]k—;
vi) —[C(R7aR7b)]jC(O)NR9[C(R8aR8b)]k—; or
vii) —[C(R7aR7b)]jSO2[C(R8aR8b)]k—;
R7a, R7b, R8a, R8b, and R9 are each independently hydrogen, methyl, or ethyl; the indices j and k are each independently from 0 to 3; the index y is 0 or 1.
14. A compound according to claim 13 wherein R1 is chosen from 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 3,4-difluorophenyl, 3-trifluoromethylphenyl, 3-trifluoromethyl-4-chlorophenyl, 3-methoxyphenyl, 3-methylphenyl, 3-ethylphenyl, or 3-isopropylphenyl.
15. A compound according to claim 13 wherein R1 is chosen from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-trichlorophenyl, or 2,4,6-trichlorophenyl.
16. A compound according to claim 13 wherein R1 is chosen from 2-methylphenyl, 4-methylphenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethyl-phenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethyl-phenyl, 2,3,6-trimethylphenyl, 2,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, or 2,4,6-triethylphenyl.
17. A compound according to claim 13 wherein R1 is chosen from 2-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6-trimethoxy-phenyl, 2,4,5-trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 2,5-dihydroxyphenyl, 2,6-dihydroxyphenyl, 3,4-dihydroxy-phenyl, 2,3,4-trihydroxyphenyl, 2,3,5-trihydroxy-phenyl, 2,3,6-trihydroxyphenyl, 2,4,5-trihydroxyphenyl, or 2,4,6-trihydroxyphenyl.
18. A compound according to claim 13 wherein L1 has the formula:

—[CH2]j—
the index j is 0, 1, or 2; and
R6 is chosen from phenyl, piperidin-1-yl, pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.
19. A compound according to claim 18 wherein R1 is chosen from 3-(pyridin-2-yl)phenyl, 3-(pyridin-3-yl)phenyl, 3-(pyridin-4-yl)phenyl, 3-(pyridin-2-yl)phenyl, biphenyl-3-yl, or 3-(piperidin-1-ylmethyl)phenyl.
20. A compound according to claim 13 wherein L1 has the formula:

—O[CH2]k—
the index k is 1 or 2; and
R6 is chosen from phenyl, piperidin-1-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.
21. A compound according to claim 13 wherein L1 has the formula:

—SO2NH[CH2]k—
the index k is 0, 1, or 2; and
R6 is chosen from:
i) hydrogen;
ii) substituted or unsubstituted C1-C4 linear or branched alkyl;
iii) substituted or unsubstituted phenyl; and
iv) substituted or unsubstituted C3-C9 heteroaryl.
22. A compound according to claim 21 wherein R1 is chosen from benzene-sulfonamide, N-methyl-benzenesulfonamide, N-ethyl-benzenesulfonamide, N-(n-propyl)-benzenesulfonamide, N-(iso-propyl)-benzenesulfonamide, N-(n-butyl)-benzenesulfonamide, N-(sec-butyl)-benzenesulfonamide, N-(iso-butyl)-benzene-sulfonamide, and N-(tert-butyl)-benzenesulfonamide.
23. A compound according to claim 21 wherein R1 is chosen from N-phenyl-benzene-sulfonamide, N-(pyrimidin-2-yl)-benzenesulfonamide, N-(pyrimidin-4-yl)-benzenesulfonamide, N-(pyrimidin-5-yl)-benzenesulfonamide, N-(pyridin-2-yl)-benzenesulfonamide, N-(pyridin-3-yl)-benzenesulfonamide, and N-(pyridin-4-yl)-benzenesulfonamide.
24. A compound according to claim 13 wherein L1 has the formula:

—NHC(O)—;
R5 is chosen from:
i) hydrogen;
ii) substituted or unsubstituted C1-C4 linear or branched alkyl;
iii) substituted or unsubstituted phenyl; or
iv) substituted or unsubstituted C3-C9 heteroaryl.
25. A compound according to claim 24 wherein R5 is chosen from phenyl, piperidin-1-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.
26. A compound having the formula:
wherein R5 has the formula:
Figure US20070293494A1-20071220-C00049
R6 is a unit chosen from:
i) hydrogen;
ii) halogen;
iii) nitro;
iv) hydroxy;
v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino;
vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
viii) substituted or unsubstituted phenyl;
ix) substituted or unsubstituted C2-C5 heterocyclic; and
x) substituted or unsubstituted C3-C9 heteroaryl;
xi) cyano; or
xii) CHmX3-m wherein X is halogen and m is from 0 to 2;
L1 is a linking unit chosen from:
i) [CH2]j—;
ii) —O[CH2]k—;
iii) —SO2NH—;
iv) —NHC(O)—; or
v) —C(O)NH—;
the index j is 0, 1 or 2 the index k is 0 or 1.
27. A compound having the formula:
Figure US20070293494A1-20071220-C00050
wherein R is a unit having the formula:
Figure US20070293494A1-20071220-C00051
R2 and R3 are taken together to form a ring containing from 3 to 7 atoms optionally substituted with one or more substituents;
R5 has the formula:

-(L1)y-R6
R6 is a unit chosen from:
i) hydrogen;
ii) halogen;
iii) nitro;
iv) hydroxy;
v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino;
vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
viii) substituted or unsubstituted phenyl;
ix) substituted or unsubstituted C2-C5 heterocyclic;
x) substituted or unsubstituted C3-C9 heteroaryl;
xi) cyano; or
xii) CHmX3-m wherein X is halogen and m is from 0 to 2;
L1 is a linking unit chosen from:
i) —[CH2]j—;
ii) —O[CH2]k—;
iii) —SO2NH—;
iv) —NHC(O)—; or
v) —C(O)NH—;
the index j is 0, 1 or 2, the index k is 0 or 1.
28. A compound having the formula:
Figure US20070293494A1-20071220-C00052
wherein R is a unit having the formula:
Figure US20070293494A1-20071220-C00053
R2 and R3 are taken together to form a ring containing from 3 to 7 atoms optionally substituted with one or more substituents;
R5 has the formula:

-(L1)y-R6
R6 is a unit chosen from:
i) hydrogen;
ii) halogen;
iii) nitro;
iv) hydroxy;
v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino;
vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
viii) substituted or unsubstituted phenyl;
ix) substituted or unsubstituted C2-C5 heterocyclic; and
x) substituted or unsubstituted C3-C9 heteroaryl;
xi) cyano; or
xii) CHmX3-m wherein X is halogen and m is from 0 to 2;
L1 is a linking unit chosen from:
i) —[CH2]j—;
ii) —O[CH2]k—;
iii) —SO2NH—;
iv) —NHC(O)—; or
v) —C(O)NH—;
the index j is 0, 1 or 2, the index k is 0 or 1.
29. A compound having the formula:
Figure US20070293494A1-20071220-C00054
wherein R is a heterocyclic unit chosen from:
i)
Figure US20070293494A1-20071220-C00055
ii)
iii)
Figure US20070293494A1-20071220-C00056
R2 and R3 are taken together to form a ring containing from 3 to 7 atoms optionally substituted with one or more substituents;
R5 has the formula:

-(L1)y-R6
R6 is a unit chosen from:
i) hydrogen;
ii) halogen;
iii) nitro;
iv) hydroxy;
v) amino or mono- or di-substituted (C1-C4 linear or branched alkyl)amino;
vi) substituted or unsubstituted C1-C4 linear or branched alkyl;
vii) substituted or unsubstituted C1-C4 linear or branched alkoxy;
viii) substituted or unsubstituted phenyl;
ix) substituted or unsubstituted C2-C5 heterocyclic;
x) substituted or unsubstituted C3-C9 heteroaryl;
xi) cyano; or
xii) CHmX3-m wherein X is halogen and m is from 0 to 2;
L1 is a linking unit chosen from:
i) —[CH2]j—;
ii) —O[CH2]r;
iii) —SO2NH—;
iv) —NHC(O)—; or
v) —C(O)NH—;
the index j is 0, 1 or 2, the index k is 0 or 1;
R10 is methyl, ethyl, 1-propyl, 2-propyl, or phenyl.
30. A compound chosen from:
N2-(3-Chlorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Nitrophenyl)-N4-(3-morpholin-4-ylpropyl)-pyrimidine-2,4-diamine;
N2-(3-Bromophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Aminophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-methanol;
N2-(3-Phenoxyphenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine;
N2-(4-(Benzyloxy)-3-chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Nitrophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-Methoxyphenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-Trifluoromethyl-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Isopropylphenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3,5-Bis-trifluoromethyl-phenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-3-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-4-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-Biphenyl-3-yl-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-benzene-sulfonamide;
N2-[3-(1H-Imidazol-1-ylmethyl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2, 4-diamine;
3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-N-(pyridin-3-ylmethyl)-benzenesulfonamide;
3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-benzenesulfonamide;
N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-benzamide;
N-Isopropyl-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide;
N2-[3-(4-Methyl-piperazine-1-sulfonyl)phenyl]-N4-(3-morpholin-4-ylpropyl)-pyrimidine-2, 4-diamine;
N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-nicotinamide;
N2-(3-Chlorophenyl)-N4-piperidin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-2-ylmethyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-piperidin-3-ylmethyl-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-3-ylmethyl)-pyrimidine-2,4-diamine:
N2-(3-Chlorophenyl)-N4-(1-methylpiperidin-4-ylmethyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-[2-(1-methylpyrrolidin-2-yl)-ethyl]-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-morpholin-2-ylmethyl-pyrimidine-2,4-diamine; and
N2-(3-Chlorophenyl)-N4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-pyrimidine-2,4-diamine;
N2-(3-Chloro-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
N-Benzyl-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide;
3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-N-phenyl-benzenesulfonamide;
3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-N-(2-pyridin-3-yl-ethyl)-benzenesulfonamide;
N2-(3-Chloro-phenyl)-N4-piperidin-4-ylmethyl-pyrimidine-2,4-diamine;
N4-(3-Morpholin-4-yl-propyl)-N2-(3-pyridin-4-yl-phenyl)-pyrimidine-2,4-diamine;
N2-(3-Chloro-phenyl)-N4-(1-methyl-pyrrolidin-3-ylmethyl)-pyrimidine-2,4-diamine;
N2-(3-Chloro-phenyl)-N4-(1-isopropyl-piperidin-3-ylmethyl)-pyrimidine-2,4-diamine;
N-{3-[4-(3-Morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-isonicotinamide;
N2-[3-(Morpholine-4-sulfonyl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
1-(4-{3-[2-(3-Chloro-phenylamino)-pyrimidin-4-ylamino]-propyl}-piperazin-1-yl)-ethanone;
N2-[3-(1H-Indol-6-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chloro-phenyl)-N4-[3-(4-methanesulfonyl-piperazin-1-yl)-propyl]-pyrimidine-2,4-diamine;
N4-(3-Morpholin-4-yl-propyl)-N2-(3-trifluoromethoxy-phenyl)-pyrimidine-2,4-diamine;
N4-(3-Morpholin-4-yl-propyl)-N2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-pyrimidine-2,4-diamine;
4-Dimethylamino-N-{3-[4-(3-morpholin-4-yl-propylamino)-pyrimidin-2-ylamino]-phenyl}-benzamide;
N-(3-Chloro-phenyl)-3-[4-(3-pyrrolidin-1-yl-propylamino)-pyrimidin-2-ylamino]-benzamide.
31. A compound chosen from
N2-(3-Chlorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Chlorophenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Fluorophenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine
N2-(3-Methylphenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methylphenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Methoxyphenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Trifluoromethylphenyl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Trifluoromethylphenyl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Trifluoromethylphenyl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Trifluoromethylphenyl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Trifluoromethylphenyl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3-Trifluoromethylphenyl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine; and
N2-(3-Trifluoromethylphenyl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine.
32. A compound chosen from:
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1-Indol-3-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]1-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-pyrazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-indol-2-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-2-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine;
N2-[3-(Pyridin-4-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-2-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine;
N2-[3-(1H-Indol-3-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine; and
N2-[3-(Benzo[d]thiazol-2-yl)-phenyl]-N4-[3-(4-methylpiperazin-1-yl)-propyl]-pyrimidine-2,4-diamine.
33. A compound chosen from:
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine,
N2-(3′-Nitro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Chloro-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N-(3′-Fluoro-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Fluoro-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methyl-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Methoxy-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrrolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrrolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-imidazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-imidazolin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-piperidin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-[(-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-piperazin-1-yl-propyl)-pyrimidine-2,4-diamine;
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-pyrazolidin-1-yl-propyl)-pyrimidine-2,4-diamine; and
N2-(3′-Dimethylamino-biphenyl-3-yl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine.
34. A composition comprising:
A) a compound according to claim 1; and
B) the balance carriers and excipients.
35. A method for improving cardiac contraction/relaxation parameters in heart failure patients comprising administering to a human suffering from acute heart failure a composition comprising a compound according to claim 1.
36. A method for treating or preventing a disease or medical condition selected from diabetes, numerous forms of cancer, microalbinuria, endothelial dysfunction, cerebrovascular disease, stroke, coronary heart disease, cardiovascular disease and sequela (e.g. arrhythmia, sudden death, increased infarct size, congestive heart failure, angina), myocardial ischemic states, hypertension, lipid disorders, ischemia-reperfusion injury, atherosclerosis, peripheral artery/vascular disease, microvascular complications of diabetes (neuropathy, nephropathy, retinopathy), restenosis, renal disease, blood coagulation disorders, inflammatory diseases, cardiac hypertrophy, dilated cardiomyopathy, ischemic injury and suboptimal mitogen stimulation said method comprised of the steps of administering to a patient in need thereof a therapeutic amount of a compound according to claim 1.
37. A method for treating acute heart failure comprising administering to a human an effective amount of a composition comprising one or more of the PKC-α inhibitors according to claim 1.
38. A method for chronic heart failure comprising administering to a human an effective amount of a composition comprising one or more of the PKC-α inhibitors according to claim 1.
39. A method of treating or preventing acute or chronic heart failure said method comprised of the step of administering to a patient in need thereof a pharmaceutically acceptable amount of a compound according to claim 1 or a therapeutically acceptable salt thereof in combination with a drug selected that acts on the renin-angiotensin-aldosterone system, a diuretic digoxin or β-adrenergic receptor blockers, natriuretic peptides and inotropic agents.
40. The method of claim 37 wherein the drug used in combination with a compound according to claim 1 is a renin-angiotensin-aldosterone system selected from an ACEI, ARB, or aldosterone inhibitor.
41. The use of a compound according to claim 1 in the manufacture of a medicament.
US11/762,394 2006-06-15 2007-06-13 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines Abandoned US20070293494A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/762,394 US20070293494A1 (en) 2006-06-15 2007-06-13 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
US12/465,704 US8354407B2 (en) 2006-06-15 2009-05-14 2-anilino-4-(heterocyclic)amino-pyrimidines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81395606P 2006-06-15 2006-06-15
US11/762,394 US20070293494A1 (en) 2006-06-15 2007-06-13 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/465,704 Continuation US8354407B2 (en) 2006-06-15 2009-05-14 2-anilino-4-(heterocyclic)amino-pyrimidines

Publications (1)

Publication Number Publication Date
US20070293494A1 true US20070293494A1 (en) 2007-12-20

Family

ID=38608732

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/762,394 Abandoned US20070293494A1 (en) 2006-06-15 2007-06-13 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
US12/465,704 Active 2028-12-01 US8354407B2 (en) 2006-06-15 2009-05-14 2-anilino-4-(heterocyclic)amino-pyrimidines

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/465,704 Active 2028-12-01 US8354407B2 (en) 2006-06-15 2009-05-14 2-anilino-4-(heterocyclic)amino-pyrimidines

Country Status (16)

Country Link
US (2) US20070293494A1 (en)
EP (1) EP2054392A2 (en)
JP (1) JP2009540013A (en)
KR (1) KR20090019011A (en)
CN (1) CN101506175A (en)
AR (1) AR061380A1 (en)
AU (1) AU2007257650A1 (en)
BR (1) BRPI0713696A2 (en)
CA (1) CA2653777A1 (en)
CL (1) CL2007001749A1 (en)
IL (1) IL195864A0 (en)
MX (1) MX2008016004A (en)
RU (1) RU2008152195A (en)
TW (1) TW200815424A (en)
WO (1) WO2007146981A2 (en)
ZA (1) ZA200809941B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293525A1 (en) * 2006-06-15 2007-12-20 Djung Jane F 2-anilino-4-aminoalkyleneaminopyrimidines
US20100113445A1 (en) * 2007-03-20 2010-05-06 Smithkline Beecham Corporation Chemical Compounds
US20100130486A1 (en) * 2007-07-17 2010-05-27 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US20100179164A1 (en) * 2009-01-14 2010-07-15 Hui Li 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
US20100179165A1 (en) * 2009-01-14 2010-07-15 Tarikere Gururaja Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
WO2016060963A1 (en) * 2014-10-14 2016-04-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US9732070B2 (en) 2009-12-01 2017-08-15 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2021014365A1 (en) 2019-07-22 2021-01-28 Lupin Limited Macrocyclic compounds as sting agonists and methods and uses thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555982T3 (en) 2009-01-15 2016-01-12 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
AR076024A1 (en) * 2009-04-03 2011-05-11 Schering Corp DERIVATIVES OF BRIDGED BICYCLIC HETEROCICLES AND METHODS OF USE OF THE SAME
AU2011205485B2 (en) * 2010-01-13 2014-09-25 Glaxosmithkline Llc Compounds and methods
BR112014015723A8 (en) * 2011-12-23 2017-07-04 Cellzome Ltd pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN102746255A (en) * 2012-07-24 2012-10-24 安徽中医学院 Compound having anti-tumor activity, and preparation method and application thereof
KR102334260B1 (en) * 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 and alk2 inhibitors and methods for their use
BR112016017444A2 (en) * 2014-01-29 2017-10-10 Inst Nat Sante Rech Med molecule and method
AR107672A1 (en) * 2016-02-22 2018-05-23 Hoffmann La Roche PROCESS FOR THE MANUFACTURE OF DERIVATIVES OF 3-PIPERAZIN-1-IL-PROPILAMINE
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
MX2021013662A (en) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof.
BR112021022504A2 (en) 2019-05-10 2022-04-12 Deciphera Pharmaceuticals Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of using them
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2437683A (en) * 1948-03-16 Pyrimedine compounds and method of
US2443305A (en) * 1948-06-15 Pyrimidine derivatives
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US6518286B1 (en) * 1999-03-26 2003-02-11 Astrazeneca Ab Compounds
US20040186118A1 (en) * 2002-11-28 2004-09-23 Judi Bryant Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US20050090493A1 (en) * 1998-08-29 2005-04-28 Astrazeneca Ab 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US20050209231A1 (en) * 2004-01-16 2005-09-22 Xu Wu Compositions and methods for inducing cardiomyogenesis
US7122542B2 (en) * 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20070293525A1 (en) * 2006-06-15 2007-12-20 Djung Jane F 2-anilino-4-aminoalkyleneaminopyrimidines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB592928A (en) 1943-06-11 1947-10-03 Francis Henry Swinden Curd New pyrimidine compounds
DE833651C (en) 1943-11-02 1952-03-10 Ici Ltd Process for the preparation of new pyrimidine pellets
GB587550A (en) 1944-09-25 1947-04-29 Francis Henry Swinden Curd New pyrimidine compounds
US3445467A (en) 1964-05-25 1969-05-20 Ciba Geigy Corp Biphenyl diphenylalkane and diphenylether compounds,amino - substituted on the phenyl rings
FR2244520B1 (en) 1973-07-06 1977-02-04 Ugine Kuhlmann
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
PT945443E (en) 1998-03-27 2003-06-30 Janssen Pharmaceutica Nv HIV INHIBITOR PYRIMIDINE DERIVATIVES
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
EP1257546A1 (en) * 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1392662B1 (en) * 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP1453516A2 (en) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG Novel tri-substituted pyrimidines, method for production and use thereof as medicament
DK1438053T3 (en) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidine derivatives, drug containing these compounds, their use and methods for their preparation
NZ531853A (en) * 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR039540A1 (en) 2002-05-13 2005-02-23 Tibotec Pharm Ltd MICROBICIDE COMPOUNDS WITH PIRIMIDINE OR TRIAZINE CONTENT
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co Nitrogen-containing heterocyclic compounds and medicinal use thereof
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
WO2005003103A2 (en) 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
EP1663242B1 (en) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
MXPA06012613A (en) * 2004-05-07 2007-01-31 Amgen Inc Protein kinase modulators and method of use.
ATE519759T1 (en) * 2004-12-30 2011-08-15 Exelixis Inc PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHODS OF APPLICATION
DE102005016634A1 (en) 2005-04-12 2006-10-19 Merck Patent Gmbh Novel aza heterocycles as kinase inhibitors
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007147125A2 (en) 2006-06-15 2007-12-21 Serenex, Inc. Tetracycline package formulations
TW200808705A (en) 2006-06-15 2008-02-16 Sanofi Aventis Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics
AR061485A1 (en) 2006-06-15 2008-08-27 Serenex Inc STABILIZED TETRACICLINE COMPOSITIONS
CL2009000600A1 (en) * 2008-03-20 2010-05-07 Bayer Cropscience Ag Use of diaminopyrimidine compounds as phytosanitary agents; diaminopyrimidine compounds; its preparation procedure; agent that contains them; procedure for the preparation of said agent; and method for combating pests of animals and / or harmful plant pathogenic fungi.
CN102089278A (en) * 2008-06-11 2011-06-08 Irm责任有限公司 Compounds and compositions useful for the treatment of malaria
EP2350048A2 (en) * 2008-10-16 2011-08-03 Schering Corporation Azine derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8410126B2 (en) 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2437683A (en) * 1948-03-16 Pyrimedine compounds and method of
US2443305A (en) * 1948-06-15 Pyrimidine derivatives
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US20050090493A1 (en) * 1998-08-29 2005-04-28 Astrazeneca Ab 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity
US6518286B1 (en) * 1999-03-26 2003-02-11 Astrazeneca Ab Compounds
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US20040186118A1 (en) * 2002-11-28 2004-09-23 Judi Bryant Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7122542B2 (en) * 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20050209231A1 (en) * 2004-01-16 2005-09-22 Xu Wu Compositions and methods for inducing cardiomyogenesis
US20070293525A1 (en) * 2006-06-15 2007-12-20 Djung Jane F 2-anilino-4-aminoalkyleneaminopyrimidines

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293525A1 (en) * 2006-06-15 2007-12-20 Djung Jane F 2-anilino-4-aminoalkyleneaminopyrimidines
US8158641B2 (en) 2006-06-15 2012-04-17 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
US20100113445A1 (en) * 2007-03-20 2010-05-06 Smithkline Beecham Corporation Chemical Compounds
US20100130486A1 (en) * 2007-07-17 2010-05-27 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US8993585B2 (en) 2007-07-17 2015-03-31 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
CN102317265A (en) * 2009-01-14 2012-01-11 里格尔药品股份有限公司 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
WO2010083241A3 (en) * 2009-01-14 2010-12-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
US20100179165A1 (en) * 2009-01-14 2010-07-15 Tarikere Gururaja Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
US8334297B2 (en) * 2009-01-14 2012-12-18 Rigel Pharmaceuticals Inc. 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
US8575165B2 (en) 2009-01-14 2013-11-05 Rigel Pharmaceuticals, Inc. Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
US20100179164A1 (en) * 2009-01-14 2010-07-15 Hui Li 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
US9732070B2 (en) 2009-12-01 2017-08-15 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
WO2016060963A1 (en) * 2014-10-14 2016-04-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2021014365A1 (en) 2019-07-22 2021-01-28 Lupin Limited Macrocyclic compounds as sting agonists and methods and uses thereof

Also Published As

Publication number Publication date
IL195864A0 (en) 2009-09-01
WO2007146981A2 (en) 2007-12-21
MX2008016004A (en) 2009-01-16
KR20090019011A (en) 2009-02-24
RU2008152195A (en) 2010-07-20
CN101506175A (en) 2009-08-12
CL2007001749A1 (en) 2008-01-25
CA2653777A1 (en) 2007-12-21
TW200815424A (en) 2008-04-01
EP2054392A2 (en) 2009-05-06
US20090227586A1 (en) 2009-09-10
AU2007257650A1 (en) 2007-12-21
ZA200809941B (en) 2009-07-29
AR061380A1 (en) 2008-08-20
JP2009540013A (en) 2009-11-19
US8354407B2 (en) 2013-01-15
BRPI0713696A2 (en) 2012-11-06
WO2007146981A3 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
US8354407B2 (en) 2-anilino-4-(heterocyclic)amino-pyrimidines
US8158641B2 (en) 2-anilino-4-aminoalkyleneaminopyrimidines
US9150519B2 (en) 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
US20190337940A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
US7122544B2 (en) Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
JP5638394B2 (en) Pyrimidine derivatives for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatoses
JP6048406B2 (en) Novel compounds, pharmaceutical compositions and uses thereof
US20090131436A1 (en) Pyrimidine Derivatives
US20100105674A1 (en) Chemical Compounds
US20060025433A1 (en) Pyrimidine derivatives useful as inhibitors of PKC-theta
US10676464B2 (en) 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20150239875A1 (en) Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
KR102472103B1 (en) The novel adamantane derivatives as inhibitors of focal adhesion kinase

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION